{
  "meta": {
    "id": "test1",
    "title": "Biochemistry E&D (Mission NEET PG) - 09-10-2023 - 2023-10-09",
    "category": "NEET PG PYQ"
  },
  "questions": [
    {
      "text": "While examining mRNA samples from both healthy and affected tissues, a scientist identified an mRNA unique to the diseased tissue. The sequence found in this specific mRNA is AGUCUCA. What would be the sequence of the DNA strand that served as the template during transcription of this mRNA?",
      "options": [
        {
          "label": "A",
          "text": "TCAGAGT",
          "correct": false
        },
        {
          "label": "B",
          "text": "AGUCTGA",
          "correct": false
        },
        {
          "label": "C",
          "text": "ATCGATC",
          "correct": false
        },
        {
          "label": "D",
          "text": "TGAGACT",
          "correct": true
        }
      ],
      "correct_answer": "D. TGAGACT",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. D) TGAGACT</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation</li><li>\u2022 To determine the template DNA strand sequence from the given mRNA sequence , we follow these steps:</li><li>\u2022 template DNA strand</li><li>\u2022 mRNA sequence</li><li>\u2022 mRNA Sequence : The given sequence is AGUCUCA . mRNA is complementary to the DNA template strand and replaces thymine (T) with uracil (U). The direction of mRNA is 5\u2019 \u2192 3\u2019 , unless otherwise stated. Step 1: Create the Non-Template (Coding) DNA Strand : The coding DNA strand (non-template strand) has the same sequence as the mRNA but U is replaced with T . mRNA: 5\u2019-AGUCUCA-3\u2019 Coding DNA strand: 5\u2019-AGTCTCA-3\u2019 Step 2: Determine the Template DNA Strand : The template DNA strand is complementary to the coding strand, and it is read in the 3\u2019 \u2192 5\u2019 direction . Coding strand: 5\u2019-AGTCTCA-3\u2019 Template strand (complementary): 3\u2019-TCAGAGT-5\u2019 Step 3: Adjust for Directionality : When writing the template strand in the standard 5\u2019 \u2192 3\u2019 direction , we reverse it: Template strand: 5\u2019-TGAGACT-3\u2019</li><li>\u2022 mRNA Sequence : The given sequence is AGUCUCA . mRNA is complementary to the DNA template strand and replaces thymine (T) with uracil (U). The direction of mRNA is 5\u2019 \u2192 3\u2019 , unless otherwise stated.</li><li>\u2022 mRNA Sequence</li><li>\u2022 AGUCUCA</li><li>\u2022 mRNA is complementary to the DNA template strand and replaces thymine (T) with uracil (U). The direction of mRNA is 5\u2019 \u2192 3\u2019 , unless otherwise stated.</li><li>\u2022 mRNA is complementary to the DNA template strand and replaces thymine (T) with uracil (U).</li><li>\u2022 DNA template strand</li><li>\u2022 The direction of mRNA is 5\u2019 \u2192 3\u2019 , unless otherwise stated.</li><li>\u2022 5\u2019 \u2192 3\u2019</li><li>\u2022 Step 1: Create the Non-Template (Coding) DNA Strand : The coding DNA strand (non-template strand) has the same sequence as the mRNA but U is replaced with T . mRNA: 5\u2019-AGUCUCA-3\u2019 Coding DNA strand: 5\u2019-AGTCTCA-3\u2019</li><li>\u2022 Step 1: Create the Non-Template (Coding) DNA Strand</li><li>\u2022 coding DNA strand</li><li>\u2022 U is replaced with T</li><li>\u2022 mRNA: 5\u2019-AGUCUCA-3\u2019 Coding DNA strand: 5\u2019-AGTCTCA-3\u2019</li><li>\u2022 mRNA: 5\u2019-AGUCUCA-3\u2019</li><li>\u2022 5\u2019-AGUCUCA-3\u2019</li><li>\u2022 Coding DNA strand: 5\u2019-AGTCTCA-3\u2019</li><li>\u2022 5\u2019-AGTCTCA-3\u2019</li><li>\u2022 Step 2: Determine the Template DNA Strand : The template DNA strand is complementary to the coding strand, and it is read in the 3\u2019 \u2192 5\u2019 direction . Coding strand: 5\u2019-AGTCTCA-3\u2019 Template strand (complementary): 3\u2019-TCAGAGT-5\u2019</li><li>\u2022 Step 2: Determine the Template DNA Strand</li><li>\u2022 template DNA strand</li><li>\u2022 complementary</li><li>\u2022 3\u2019 \u2192 5\u2019 direction</li><li>\u2022 Coding strand: 5\u2019-AGTCTCA-3\u2019 Template strand (complementary): 3\u2019-TCAGAGT-5\u2019</li><li>\u2022 Coding strand: 5\u2019-AGTCTCA-3\u2019</li><li>\u2022 5\u2019-AGTCTCA-3\u2019</li><li>\u2022 Template strand (complementary): 3\u2019-TCAGAGT-5\u2019</li><li>\u2022 3\u2019-TCAGAGT-5\u2019</li><li>\u2022 Step 3: Adjust for Directionality : When writing the template strand in the standard 5\u2019 \u2192 3\u2019 direction , we reverse it: Template strand: 5\u2019-TGAGACT-3\u2019</li><li>\u2022 Step 3: Adjust for Directionality</li><li>\u2022 5\u2019 \u2192 3\u2019 direction</li><li>\u2022 Template strand: 5\u2019-TGAGACT-3\u2019</li><li>\u2022 Template strand: 5\u2019-TGAGACT-3\u2019</li><li>\u2022 5\u2019-TGAGACT-3\u2019</li><li>\u2022 Thus, the correct answer is D. TGAGACT .</li><li>\u2022 D. TGAGACT</li><li>\u2022 Other Options:</li><li>\u2022 Other Options:</li><li>\u2022 Option A. TCAGAGT: This sequence is complementary to the mRNA but written in the 3\u2019 \u2192 5\u2019 direction . It must be reversed to match the 5\u2019 \u2192 3\u2019 standard.</li><li>\u2022 Option A. TCAGAGT:</li><li>\u2022 3\u2019 \u2192 5\u2019 direction</li><li>\u2022 Option B. AGUCTGA: This contains a U , which is found in RNA, not DNA.</li><li>\u2022 Option B. AGUCTGA:</li><li>\u2022 U</li><li>\u2022 Option C. ATCGATC: This sequence does not align with the mRNA or its complementary template strand.</li><li>\u2022 Option C. ATCGATC:</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 The template DNA strand is complementary to the mRNA sequence, and when written in the 5\u2019 \u2192 3\u2019 direction , it matches the correct answer TGAGACT . Always proceed step by step:</li><li>\u27a4 template DNA strand</li><li>\u27a4 5\u2019 \u2192 3\u2019 direction</li><li>\u27a4 TGAGACT</li><li>\u27a4 Convert mRNA to coding strand (replace U with T). Find the complementary template strand. Reverse for the 5\u2019 \u2192 3\u2019 orientation.</li><li>\u27a4 Convert mRNA to coding strand (replace U with T).</li><li>\u27a4 Find the complementary template strand.</li><li>\u27a4 Reverse for the 5\u2019 \u2192 3\u2019 orientation.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "ac09e37f",
      "audio": ""
    },
    {
      "text": "A 3-year-old child presents with hepatosplenomegaly, bone pain, and pancytopenia. On histological examination of the bone marrow, characteristic wrinkled tissue paper appearance is noted and shown. This inherited disorder will cause accumulation of which of following lipids in this child?",
      "options": [
        {
          "label": "A",
          "text": "Ceramides",
          "correct": false
        },
        {
          "label": "B",
          "text": "Sphingomyelins",
          "correct": false
        },
        {
          "label": "C",
          "text": "Glucocerebrosides",
          "correct": true
        },
        {
          "label": "D",
          "text": "Galactocerebrosides",
          "correct": false
        }
      ],
      "correct_answer": "C. Glucocerebrosides",
      "question_images": [
        "https://cerebellum-web-static.s3.amazonaws.com/media/public/Screenshot%202024-12-18%20131846.jpg"
      ],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. C) Glucocerebrosides</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation</li><li>\u2022 The child\u2019s presentation, combined with the \"wrinkled tissue paper appearance\" of cells on histology, is highly suggestive of Gaucher's disease . Gaucher's disease is a lysosomal storage disorder caused by a deficiency of the enzyme \u03b2-glucocerebrosidase (\u03b2-glucosylceramidase) . This enzyme defect leads to the accumulation of glucocerebrosides in macrophages, forming Gaucher cells with the characteristic wrinkled appearance.</li><li>\u2022 \"wrinkled tissue paper appearance\"</li><li>\u2022 Gaucher's disease</li><li>\u2022 \u03b2-glucocerebrosidase (\u03b2-glucosylceramidase)</li><li>\u2022 glucocerebrosides</li><li>\u2022 Gaucher cells</li><li>\u2022 Key features of Gaucher's disease:</li><li>\u2022 Hepatosplenomegaly \u2013 Due to accumulation of glucocerebrosides in liver and spleen. Bone pain and skeletal abnormalities \u2013 Caused by infiltration of bone marrow. Pancytopenia \u2013 Due to replacement of bone marrow by Gaucher cells, leading to anemia, leukopenia, and thrombocytopenia. No cherry-red spots or neurodegeneration in non-neuronopathic forms.</li><li>\u2022 Hepatosplenomegaly \u2013 Due to accumulation of glucocerebrosides in liver and spleen.</li><li>\u2022 Hepatosplenomegaly</li><li>\u2022 Bone pain and skeletal abnormalities \u2013 Caused by infiltration of bone marrow.</li><li>\u2022 Bone pain and skeletal abnormalities</li><li>\u2022 Pancytopenia \u2013 Due to replacement of bone marrow by Gaucher cells, leading to anemia, leukopenia, and thrombocytopenia.</li><li>\u2022 Pancytopenia</li><li>\u2022 No cherry-red spots or neurodegeneration in non-neuronopathic forms.</li><li>\u2022 No cherry-red spots or neurodegeneration</li><li>\u2022 Histology of bone marrow reveals Gaucher cells \u2013 enlarged macrophages with a wrinkled tissue paper appearance , as seen in the provided image.</li><li>\u2022 Gaucher cells</li><li>\u2022 wrinkled tissue paper appearance</li><li>\u2022 Other Options:</li><li>\u2022 Other Options:</li><li>\u2022 Option A. Ceramides: Ceramides are precursors for sphingolipids and are not the primary substrate accumulating in Gaucher's disease.</li><li>\u2022 Option A. Ceramides:</li><li>\u2022 Option B. Sphingomyelins: Accumulation of sphingomyelin occurs in Niemann-Pick disease due to sphingomyelinase deficiency, which presents with hepatosplenomegaly, cherry-red spots, and neurodegeneration.</li><li>\u2022 Option B. Sphingomyelins:</li><li>\u2022 Niemann-Pick disease</li><li>\u2022 Option D. Galactocerebrosides: Galactocerebrosides accumulate in Krabbe disease , a lysosomal storage disorder characterized by neurodegeneration but without hepatosplenomegaly.</li><li>\u2022 Option D. Galactocerebrosides:</li><li>\u2022 Krabbe disease</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 Gaucher's disease is caused by a deficiency of \u03b2-glucocerebrosidase , leading to accumulation of glucocerebrosides in macrophages. The presence of hepatosplenomegaly, bone pain, pancytopenia, and \"wrinkled tissue paper appearance\" on histology confirms the diagnosis.</li><li>\u27a4 Gaucher's disease</li><li>\u27a4 \u03b2-glucocerebrosidase</li><li>\u27a4 glucocerebrosides</li><li>\u27a4 \"wrinkled tissue paper appearance\"</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "35e66914",
      "audio": ""
    },
    {
      "text": "Best method to detect the given structure of protein is:",
      "options": [
        {
          "label": "A",
          "text": "Mass spectrometry",
          "correct": false
        },
        {
          "label": "B",
          "text": "Edman\u2019s technique",
          "correct": false
        },
        {
          "label": "C",
          "text": "X-ray crystallography",
          "correct": true
        },
        {
          "label": "D",
          "text": "NMR spectrometry",
          "correct": false
        }
      ],
      "correct_answer": "C. X-ray crystallography",
      "question_images": [
        "https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2023/10/30/picture1_uxTHq4G.jpg"
      ],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. C) X-ray crystallography</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 The image provided depicts an alpha-helix , which is a secondary structure of a protein. To determine the structure of proteins at the atomic level, X-ray Crystallography used:</li><li>\u2022 alpha-helix</li><li>\u2022 secondary structure</li><li>\u2022 X-ray Crystallography used:</li><li>\u2022 It is the gold standard for determining secondary, tertiary, and quaternary structures of proteins. X-ray crystallography works by analyzing the diffraction pattern of X-rays when they pass through a crystallized protein. This method provides high-resolution 3D structures of proteins, making it the best choice for identifying structures like the alpha-helix shown in the diagram.</li><li>\u2022 It is the gold standard for determining secondary, tertiary, and quaternary structures of proteins. X-ray crystallography works by analyzing the diffraction pattern of X-rays when they pass through a crystallized protein. This method provides high-resolution 3D structures of proteins, making it the best choice for identifying structures like the alpha-helix shown in the diagram.</li><li>\u2022 secondary, tertiary, and quaternary structures</li><li>\u2022 X-ray crystallography works by analyzing the diffraction pattern of X-rays when they pass through a crystallized protein. This method provides high-resolution 3D structures of proteins, making it the best choice for identifying structures like the alpha-helix shown in the diagram.</li><li>\u2022 X-ray crystallography works by analyzing the diffraction pattern of X-rays when they pass through a crystallized protein.</li><li>\u2022 This method provides high-resolution 3D structures of proteins, making it the best choice for identifying structures like the alpha-helix shown in the diagram.</li><li>\u2022 alpha-helix</li><li>\u2022 Other Options:</li><li>\u2022 Other Options:</li><li>\u2022 Option A. Mass spectrometry: Useful for analyzing the primary structure of a protein, but it cannot detect secondary or higher-order structures like the alpha-helix.</li><li>\u2022 Option A. Mass spectrometry:</li><li>\u2022 primary structure</li><li>\u2022 Option B. Edman\u2019s technique: This method determines the amino acid sequence (primary structure) of proteins but does not reveal secondary or tertiary structures.</li><li>\u2022 Option B. Edman\u2019s technique:</li><li>\u2022 amino acid sequence</li><li>\u2022 Option D. NMR spectrometry: NMR is used to study proteins in solution, especially non-crystallizable proteins, and can analyze secondary, tertiary, and quaternary structures . However, for crystallizable proteins like this one, X-ray crystallography is preferred due to its higher resolution.</li><li>\u2022 Option D. NMR spectrometry:</li><li>\u2022 secondary, tertiary, and quaternary structures</li><li>\u2022 X-ray crystallography</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 The best method to detect the secondary structure of proteins, such as the alpha-helix , is X-ray crystallography .</li><li>\u27a4 best method to detect the secondary structure of proteins, such as the alpha-helix</li><li>\u27a4 X-ray crystallography</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "e40cc6d0",
      "audio": ""
    },
    {
      "text": "A young man goes to a clinic and tells the doctor that he feels unwell after eating dairy products, leading to gas, bloating, and diarrhea. When he stops eating dairy, these problems go away. To manage his symptoms, he could benefit from a supplement containing which of the following enzyme?",
      "options": [
        {
          "label": "A",
          "text": "\u03b1 - amylase",
          "correct": false
        },
        {
          "label": "B",
          "text": "\u03b1 - Galactosidase",
          "correct": false
        },
        {
          "label": "C",
          "text": "\u03b2 - Galactosidase",
          "correct": true
        },
        {
          "label": "D",
          "text": "\u03b2 - Galactocerebrosidase",
          "correct": false
        }
      ],
      "correct_answer": "C. \u03b2 - Galactosidase",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. C) \u03b2 \u2013 Galactosidase</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 The symptoms described in the question (gas, bloating, and diarrhea after eating dairy products) are classic signs of lactose intolerance . In lactose intolerance:</li><li>\u2022 lactose intolerance</li><li>\u2022 Lactose , a disaccharide present in dairy products, cannot be digested properly due to a deficiency of the enzyme lactase . Lactase is an enzyme that breaks down lactose into its two monosaccharide components: glucose and galactose . Lactase is also called \u03b2-galactosidase because it breaks the beta-glycosidic bond between glucose and galactose in lactose.</li><li>\u2022 Lactose , a disaccharide present in dairy products, cannot be digested properly due to a deficiency of the enzyme lactase .</li><li>\u2022 Lactose</li><li>\u2022 lactase</li><li>\u2022 Lactase is an enzyme that breaks down lactose into its two monosaccharide components: glucose and galactose .</li><li>\u2022 glucose</li><li>\u2022 galactose</li><li>\u2022 Lactase is also called \u03b2-galactosidase because it breaks the beta-glycosidic bond between glucose and galactose in lactose.</li><li>\u2022 \u03b2-galactosidase</li><li>\u2022 beta-glycosidic bond</li><li>\u2022 When lactose remains undigested in the intestines, it undergoes fermentation by gut bacteria, producing gas (hydrogen and methane), leading to bloating and diarrhea .</li><li>\u2022 gas</li><li>\u2022 bloating</li><li>\u2022 diarrhea</li><li>\u2022 Treatment:</li><li>\u2022 Treatment:</li><li>\u2022 To manage symptoms, lactase (\u03b2-galactosidase) supplements can be given to aid the digestion of lactose.</li><li>\u2022 Other Options:</li><li>\u2022 Other Options:</li><li>\u2022 Option A. \u03b1 - amylase: \u03b1-amylase is an enzyme that breaks down starch (polysaccharides) into maltose and glucose. It does not act on lactose, so it is not useful for lactose intolerance.</li><li>\u2022 Option A. \u03b1 - amylase:</li><li>\u2022 Option B. \u03b1 - Galactosidase: \u03b1-galactosidase breaks down complex sugars found in certain vegetables and legumes (like raffinose and stachyose), but it does not act on lactose.</li><li>\u2022 Option B. \u03b1 - Galactosidase:</li><li>\u2022 Option D. \u03b2 - Galactocerebrosidase: This enzyme is involved in the breakdown of galactocerebrosides , which are components of myelin. A deficiency of this enzyme leads to Krabbe disease , a lysosomal storage disorder. It has no role in lactose digestion.</li><li>\u2022 Option D. \u03b2 - Galactocerebrosidase:</li><li>\u2022 galactocerebrosides</li><li>\u2022 Krabbe disease</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 Lactose intolerance occurs due to lactase deficiency. The enzyme \u03b2-galactosidase (lactase) breaks down lactose into glucose and galactose and can be given as a supplement to manage symptoms.</li><li>\u27a4 Lactose intolerance</li><li>\u27a4 \u03b2-galactosidase (lactase)</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "8d5479ee",
      "audio": ""
    },
    {
      "text": "A section of intestinal brush border membrane is shown in picture. Identify the glucose transporters present at marked points X and Y:",
      "options": [
        {
          "label": "A",
          "text": "X-SGLT-2, Y-GLUT-2",
          "correct": false
        },
        {
          "label": "B",
          "text": "X-GLUT-3, Y-SGLT-1",
          "correct": false
        },
        {
          "label": "C",
          "text": "X-SGLT-1, Y-GLUT-2",
          "correct": true
        },
        {
          "label": "D",
          "text": "X-GLUT-2, Y-SGLT-2",
          "correct": false
        }
      ],
      "correct_answer": "C. X-SGLT-1, Y-GLUT-2",
      "question_images": [
        "https://cerebellum-web-static.s3.amazonaws.com/media/public/Screenshot%202024-12-18%20131253.jpg"
      ],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. C) X-SGLT-1, Y-GLUT-2</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 In the intestinal brush border membrane, glucose absorption occurs through a coordinated action of transporters located at specific sites:</li><li>\u2022 glucose absorption</li><li>\u2022 X (Apical membrane): SGLT-1</li><li>\u2022 X (Apical membrane): SGLT-1</li><li>\u2022 The Sodium-Glucose Linked Transporter 1 (SGLT-1) is located on the apical membrane (facing the intestinal lumen). SGLT-1 facilitates the secondary active transport of glucose and galactose into the epithelial cells. It utilizes the sodium gradient created by the Na\u207a/K\u207a ATPase pump.</li><li>\u2022 The Sodium-Glucose Linked Transporter 1 (SGLT-1) is located on the apical membrane (facing the intestinal lumen).</li><li>\u2022 Sodium-Glucose Linked Transporter 1 (SGLT-1)</li><li>\u2022 apical membrane</li><li>\u2022 SGLT-1 facilitates the secondary active transport of glucose and galactose into the epithelial cells. It utilizes the sodium gradient created by the Na\u207a/K\u207a ATPase pump.</li><li>\u2022 secondary active transport</li><li>\u2022 sodium gradient</li><li>\u2022 Y (Basolateral membrane): GLUT-2</li><li>\u2022 Y (Basolateral membrane): GLUT-2</li><li>\u2022 The GLUT-2 transporter is located on the basolateral membrane (facing the interstitial fluid and blood). GLUT-2 mediates the facilitated diffusion of glucose and galactose from the epithelial cells into the bloodstream.</li><li>\u2022 The GLUT-2 transporter is located on the basolateral membrane (facing the interstitial fluid and blood).</li><li>\u2022 GLUT-2</li><li>\u2022 basolateral membrane</li><li>\u2022 GLUT-2 mediates the facilitated diffusion of glucose and galactose from the epithelial cells into the bloodstream.</li><li>\u2022 facilitated diffusion</li><li>\u2022 Other Options:</li><li>\u2022 Other Options:</li><li>\u2022 Option A. X-SGLT-2, Y-GLUT-2: SGLT-2 is found in the kidney proximal tubules , not in the intestines.</li><li>\u2022 Option A. X-SGLT-2, Y-GLUT-2:</li><li>\u2022 kidney proximal tubules</li><li>\u2022 Option B. X-GLUT-3, Y-SGLT-1: GLUT-3 is primarily involved in glucose transport in the brain and neurons , not in the intestines.</li><li>\u2022 Option B. X-GLUT-3, Y-SGLT-1:</li><li>\u2022 brain and neurons</li><li>\u2022 Option D. X-GLUT-2, Y-SGLT-2: GLUT-2 is present on the basolateral side , but SGLT-2 is kidney-specific and not found in the intestinal brush border.</li><li>\u2022 Option D. X-GLUT-2, Y-SGLT-2:</li><li>\u2022 basolateral side</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 In the intestinal brush border:</li><li>\u27a4 SGLT-1 on the apical membrane absorbs glucose and galactose via sodium-dependent active transport. GLUT-2 on the basolateral membrane facilitates glucose diffusion into the blood.</li><li>\u27a4 SGLT-1 on the apical membrane absorbs glucose and galactose via sodium-dependent active transport.</li><li>\u27a4 SGLT-1</li><li>\u27a4 apical membrane</li><li>\u27a4 GLUT-2 on the basolateral membrane facilitates glucose diffusion into the blood.</li><li>\u27a4 GLUT-2</li><li>\u27a4 basolateral membrane</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "0978f688",
      "audio": ""
    },
    {
      "text": "A newborn girl, full-term at birth, was taken to a pediatrician due to her inability to grow and gain weight. After checking her six-month history, it was noted that she had ongoing acidosis, which wasn't fixed by thiamine. Upon physical inspection, she had a small head, weak muscle tone, and low muscle bulk. Her blood test showed high levels of pyruvate. Which of the following statements about her condition is not true?",
      "options": [
        {
          "label": "A",
          "text": "Acetyl CoA levels decrease.",
          "correct": false
        },
        {
          "label": "B",
          "text": "Pyruvate and Alanine levels increase.",
          "correct": false
        },
        {
          "label": "C",
          "text": "Lactate levels increase in the blood.",
          "correct": false
        },
        {
          "label": "D",
          "text": "Giving Vitamin B6 will help in her treatment.",
          "correct": true
        }
      ],
      "correct_answer": "D. Giving Vitamin B6 will help in her treatment.",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. D) Giving Vitamin B6 will help in her treatment.</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Vitamin B6 is not involved in the PDH complex. It is primarily required for transamination reactions (like pyruvate to alanine), but it does not correct the underlying PDH deficiency.</li><li>\u2022 Vitamin B6</li><li>\u2022 The clinical presentation of this newborn strongly suggests a deficiency in the Pyruvate Dehydrogenase (PDH) complex , a condition that results in impaired conversion of pyruvate to acetyl-CoA. This causes pyruvate accumulation, leading to increased levels of lactate and alanine .</li><li>\u2022 Pyruvate Dehydrogenase (PDH) complex</li><li>\u2022 lactate</li><li>\u2022 alanine</li><li>\u2022 Other Options:</li><li>\u2022 Other Options:</li><li>\u2022 Option A. Acetyl CoA levels decrease: True. The PDH complex catalyzes the conversion of pyruvate to acetyl-CoA in the link reaction. In PDH deficiency, this conversion is impaired, leading to decreased acetyl-CoA levels.</li><li>\u2022 Option A. Acetyl CoA levels decrease:</li><li>\u2022 pyruvate to acetyl-CoA</li><li>\u2022 Option B. Pyruvate and Alanine levels increase: True. Pyruvate accumulates because it cannot enter the PDH pathway. Pyruvate is then diverted to form alanine via transamination (catalyzed by alanine transaminase). This results in increased blood levels of both pyruvate and alanine.</li><li>\u2022 Option B. Pyruvate and Alanine levels increase:</li><li>\u2022 Pyruvate accumulates</li><li>\u2022 alanine</li><li>\u2022 Option C. Lactate levels increase in the blood: True. When pyruvate cannot enter the PDH complex, it is instead converted to lactate via lactate dehydrogenase. This leads to lactic acidosis , which explains the ongoing acidosis in the patient.</li><li>\u2022 Option C. Lactate levels increase in the blood:</li><li>\u2022 lactate</li><li>\u2022 lactic acidosis</li><li>\u2022 The Pyruvate Dehydrogenase Complex requires the following cofactors:</li><li>\u2022 The Pyruvate Dehydrogenase Complex requires the following cofactors:</li><li>\u2022 Vitamin B1 (Thiamine) Vitamin B2 (FAD) Vitamin B3 (NAD\u207a) Vitamin B5 (Coenzyme A) Lipoic acid</li><li>\u2022 Vitamin B1 (Thiamine) Vitamin B2 (FAD) Vitamin B3 (NAD\u207a) Vitamin B5 (Coenzyme A) Lipoic acid</li><li>\u2022 Vitamin B2 (FAD) Vitamin B3 (NAD\u207a) Vitamin B5 (Coenzyme A) Lipoic acid</li><li>\u2022 Vitamin B2 (FAD) Vitamin B3 (NAD\u207a) Vitamin B5 (Coenzyme A) Lipoic acid</li><li>\u2022 Vitamin B3 (NAD\u207a) Vitamin B5 (Coenzyme A) Lipoic acid</li><li>\u2022 Vitamin B3 (NAD\u207a)</li><li>\u2022 Vitamin B5 (Coenzyme A)</li><li>\u2022 Lipoic acid</li><li>\u2022 Additional Notes:</li><li>\u2022 Additional Notes:</li><li>\u2022 PDH deficiency is an X-linked disorder and is one of the causes of congenital lactic acidosis . Symptoms include poor growth, developmental delay, weak muscle tone, and lactic acidosis. Thiamine (Vitamin B1) supplementation may help in some cases, but it was already noted to have failed in this patient.</li><li>\u2022 PDH deficiency is an X-linked disorder and is one of the causes of congenital lactic acidosis .</li><li>\u2022 X-linked disorder</li><li>\u2022 congenital lactic acidosis</li><li>\u2022 Symptoms include poor growth, developmental delay, weak muscle tone, and lactic acidosis.</li><li>\u2022 Thiamine (Vitamin B1) supplementation may help in some cases, but it was already noted to have failed in this patient.</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 In Pyruvate Dehydrogenase Complex deficiency , acetyl-CoA decreases, while pyruvate, lactate, and alanine levels increase. Vitamin B6 is not part of the PDH complex, so it does not help in treatment.</li><li>\u27a4 Pyruvate Dehydrogenase Complex deficiency</li><li>\u27a4 Vitamin B6</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "8995c780",
      "audio": ""
    },
    {
      "text": "The molecule marked by blue question mark can be all the following EXCEPT:",
      "options": [
        {
          "label": "A",
          "text": "Pyruvate",
          "correct": false
        },
        {
          "label": "B",
          "text": "Lactate",
          "correct": false
        },
        {
          "label": "C",
          "text": "Alanine",
          "correct": false
        },
        {
          "label": "D",
          "text": "Glycerol",
          "correct": true
        }
      ],
      "correct_answer": "D. Glycerol",
      "question_images": [
        "https://cerebellum-web-static.s3.amazonaws.com/media/public/Screenshot%202024-12-18%20131348.jpg"
      ],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. D) Glycerol</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation</li><li>\u2022 The image represents the metabolic exchanges between the liver and muscle during processes like gluconeogenesis and glycolysis.</li><li>\u2022 liver</li><li>\u2022 muscle</li><li>\u2022 Pyruvate , Lactate , and Alanine are intermediates that participate in metabolic cycles like: Cori Cycle : Lactate produced in the muscles from anaerobic glycolysis is transported to the liver, where it is converted back to glucose. Cahill Cycle : Alanine is produced in the muscles from the transamination of pyruvate. It travels to the liver, where it is converted back into glucose. Pyruvate : Directly involved as an intermediate in glycolysis and gluconeogenesis. Glycerol , however, is different: Glycerol comes from the breakdown of triglycerides (lipolysis) in adipose tissue. It enters the liver for gluconeogenesis but is not produced by muscle cells as part of glucose metabolism.</li><li>\u2022 Pyruvate , Lactate , and Alanine are intermediates that participate in metabolic cycles like: Cori Cycle : Lactate produced in the muscles from anaerobic glycolysis is transported to the liver, where it is converted back to glucose. Cahill Cycle : Alanine is produced in the muscles from the transamination of pyruvate. It travels to the liver, where it is converted back into glucose. Pyruvate : Directly involved as an intermediate in glycolysis and gluconeogenesis.</li><li>\u2022 Pyruvate</li><li>\u2022 Lactate</li><li>\u2022 Alanine</li><li>\u2022 Cori Cycle : Lactate produced in the muscles from anaerobic glycolysis is transported to the liver, where it is converted back to glucose. Cahill Cycle : Alanine is produced in the muscles from the transamination of pyruvate. It travels to the liver, where it is converted back into glucose. Pyruvate : Directly involved as an intermediate in glycolysis and gluconeogenesis.</li><li>\u2022 Cori Cycle : Lactate produced in the muscles from anaerobic glycolysis is transported to the liver, where it is converted back to glucose.</li><li>\u2022 Cori Cycle</li><li>\u2022 Cahill Cycle : Alanine is produced in the muscles from the transamination of pyruvate. It travels to the liver, where it is converted back into glucose.</li><li>\u2022 Cahill Cycle</li><li>\u2022 Pyruvate : Directly involved as an intermediate in glycolysis and gluconeogenesis.</li><li>\u2022 Pyruvate</li><li>\u2022 Glycerol , however, is different: Glycerol comes from the breakdown of triglycerides (lipolysis) in adipose tissue. It enters the liver for gluconeogenesis but is not produced by muscle cells as part of glucose metabolism.</li><li>\u2022 Glycerol</li><li>\u2022 Glycerol comes from the breakdown of triglycerides (lipolysis) in adipose tissue. It enters the liver for gluconeogenesis but is not produced by muscle cells as part of glucose metabolism.</li><li>\u2022 Glycerol comes from the breakdown of triglycerides (lipolysis) in adipose tissue.</li><li>\u2022 breakdown of triglycerides</li><li>\u2022 It enters the liver for gluconeogenesis but is not produced by muscle cells as part of glucose metabolism.</li><li>\u2022 is not produced by muscle cells</li><li>\u2022 Since glycerol does not originate from muscle metabolism, it cannot be the molecule marked by the blue question mark in the diagram.</li><li>\u2022 Other Options:</li><li>\u2022 Other Options:</li><li>\u2022 Option A. Pyruvate: Pyruvate is formed in muscle cells during glycolysis and can enter gluconeogenesis in the liver.</li><li>\u2022 Option A. Pyruvate:</li><li>\u2022 Option B. Lactate: Lactate is a product of anaerobic glycolysis in muscles. It travels to the liver via the Cori Cycle to be converted back to glucose.</li><li>\u2022 Option B. Lactate:</li><li>\u2022 Cori Cycle</li><li>\u2022 Option C. Alanine: Alanine is derived from pyruvate through transamination in the muscle and participates in the Cahill Cycle , contributing to gluconeogenesis in the liver.</li><li>\u2022 Option C. Alanine:</li><li>\u2022 Cahill Cycle</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 Glycerol cannot be produced by muscles as part of glucose metabolism. It originates from the breakdown of triglycerides in adipose tissue, not from glucose-related cycles like the Cori or Cahill cycles.</li><li>\u27a4 Glycerol</li><li>\u27a4 breakdown of triglycerides</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "bf14a443",
      "audio": ""
    },
    {
      "text": "A 2-week-old infant is brought to the pediatric clinic with jaundice, poor feeding, and failure to gain weight. The parents report that they have been feeding the baby with regular cow's milk formula since birth. Lab investigations of urine showed positive test for reducing substances but negative for glucose. A diagnosis of an inherited metabolic disorder is suspected. Which enzyme deficiency is most consistent with this infant's presentation?",
      "options": [
        {
          "label": "A",
          "text": "Phenylalanine hydroxylase",
          "correct": false
        },
        {
          "label": "B",
          "text": "Galactose-1-phosphate uridyltransferase",
          "correct": true
        },
        {
          "label": "C",
          "text": "Glucose-6-phosphate dehydrogenase (G6PD)",
          "correct": false
        },
        {
          "label": "D",
          "text": "Uridine diphosphogalactose 4-epimerase",
          "correct": false
        }
      ],
      "correct_answer": "B. Galactose-1-phosphate uridyltransferase",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. B) Galactose-1-phosphate uridyltransferase</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation</li><li>\u2022 The presentation of jaundice, poor feeding, failure to gain weight , and the positive test for reducing substances but negative for glucose indicates classical galactosemia . This condition is caused by a deficiency of galactose-1-phosphate uridyltransferase (GALT) .</li><li>\u2022 jaundice, poor feeding, failure to gain weight</li><li>\u2022 positive test for reducing substances but negative for glucose</li><li>\u2022 classical galactosemia</li><li>\u2022 galactose-1-phosphate uridyltransferase (GALT)</li><li>\u2022 Mechanism of Disease :</li><li>\u2022 Mechanism of Disease</li><li>\u2022 In classical galactosemia, the enzyme galactose-1-phosphate uridyltransferase is deficient. This enzyme normally converts galactose-1-phosphate (derived from lactose in milk) into glucose-1-phosphate. The deficiency leads to accumulation of galactose-1-phosphate and its metabolites, including galactitol , which are toxic to various tissues.</li><li>\u2022 In classical galactosemia, the enzyme galactose-1-phosphate uridyltransferase is deficient. This enzyme normally converts galactose-1-phosphate (derived from lactose in milk) into glucose-1-phosphate. The deficiency leads to accumulation of galactose-1-phosphate and its metabolites, including galactitol , which are toxic to various tissues.</li><li>\u2022 galactose-1-phosphate uridyltransferase</li><li>\u2022 This enzyme normally converts galactose-1-phosphate (derived from lactose in milk) into glucose-1-phosphate. The deficiency leads to accumulation of galactose-1-phosphate and its metabolites, including galactitol , which are toxic to various tissues.</li><li>\u2022 This enzyme normally converts galactose-1-phosphate (derived from lactose in milk) into glucose-1-phosphate.</li><li>\u2022 galactose-1-phosphate</li><li>\u2022 The deficiency leads to accumulation of galactose-1-phosphate and its metabolites, including galactitol , which are toxic to various tissues.</li><li>\u2022 galactose-1-phosphate</li><li>\u2022 galactitol</li><li>\u2022 Key Clinical Features :</li><li>\u2022 Key Clinical Features</li><li>\u2022 Jaundice : Due to liver damage caused by the toxic metabolites. Poor Feeding and Weight Loss : Inability to metabolize galactose disrupts energy production. Urine Positive for Reducing Substances but Negative for Glucose : The reducing substance here is galactose , not glucose. This can be detected using Benedict\u2019s test. Oil Drop Cataract : Accumulation of galactitol in the lens of the eye causes osmotic swelling and cataract formation. Mental Retardation : If untreated, chronic toxicity leads to neurodevelopmental delay.</li><li>\u2022 Jaundice : Due to liver damage caused by the toxic metabolites. Poor Feeding and Weight Loss : Inability to metabolize galactose disrupts energy production. Urine Positive for Reducing Substances but Negative for Glucose : The reducing substance here is galactose , not glucose. This can be detected using Benedict\u2019s test. Oil Drop Cataract : Accumulation of galactitol in the lens of the eye causes osmotic swelling and cataract formation. Mental Retardation : If untreated, chronic toxicity leads to neurodevelopmental delay.</li><li>\u2022 Jaundice</li><li>\u2022 Poor Feeding and Weight Loss : Inability to metabolize galactose disrupts energy production. Urine Positive for Reducing Substances but Negative for Glucose : The reducing substance here is galactose , not glucose. This can be detected using Benedict\u2019s test. Oil Drop Cataract : Accumulation of galactitol in the lens of the eye causes osmotic swelling and cataract formation. Mental Retardation : If untreated, chronic toxicity leads to neurodevelopmental delay.</li><li>\u2022 Poor Feeding and Weight Loss : Inability to metabolize galactose disrupts energy production.</li><li>\u2022 Poor Feeding and Weight Loss</li><li>\u2022 Urine Positive for Reducing Substances but Negative for Glucose : The reducing substance here is galactose , not glucose. This can be detected using Benedict\u2019s test.</li><li>\u2022 Urine Positive for Reducing Substances but Negative for Glucose</li><li>\u2022 galactose</li><li>\u2022 Oil Drop Cataract : Accumulation of galactitol in the lens of the eye causes osmotic swelling and cataract formation.</li><li>\u2022 Oil Drop Cataract</li><li>\u2022 galactitol</li><li>\u2022 Mental Retardation : If untreated, chronic toxicity leads to neurodevelopmental delay.</li><li>\u2022 Mental Retardation</li><li>\u2022 Why Cow\u2019s Milk Formula Matters :</li><li>\u2022 Why Cow\u2019s Milk Formula Matters</li><li>\u2022 Cow\u2019s milk contains lactose (a disaccharide of glucose and galactose). Galactose accumulates in infants with GALT deficiency when they consume lactose-containing milk.</li><li>\u2022 Cow\u2019s milk contains lactose (a disaccharide of glucose and galactose). Galactose accumulates in infants with GALT deficiency when they consume lactose-containing milk.</li><li>\u2022 lactose</li><li>\u2022 Other Options:</li><li>\u2022 Other Options:</li><li>\u2022 Option A. Phenylalanine hydroxylase: Deficiency of phenylalanine hydroxylase causes Phenylketonuria (PKU) . It presents with musty body odor, eczema, and developmental delay but does not involve reducing substances in the urine.</li><li>\u2022 Option A. Phenylalanine hydroxylase:</li><li>\u2022 Phenylketonuria (PKU)</li><li>\u2022 Option C. Glucose-6-phosphate dehydrogenase (G6PD): G6PD deficiency leads to hemolytic anemia triggered by oxidative stress (e.g., infections, drugs). It does not cause jaundice, poor feeding, or positive reducing substances in urine.</li><li>\u2022 Option C. Glucose-6-phosphate dehydrogenase (G6PD):</li><li>\u2022 hemolytic anemia</li><li>\u2022 Option D. Uridine diphosphogalactose 4-epimerase: This causes a less common form of galactosemia, but symptoms are usually milder compared to GALT deficiency.</li><li>\u2022 Option D. Uridine diphosphogalactose 4-epimerase:</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 Classical galactosemia is caused by a deficiency of galactose-1-phosphate uridyltransferase (GALT) . It presents with jaundice, poor feeding, failure to thrive , and urine positive for reducing substances (galactose). Early diagnosis and removal of lactose from the diet are essential to prevent long-term complications.</li><li>\u27a4 Classical galactosemia</li><li>\u27a4 galactose-1-phosphate uridyltransferase (GALT)</li><li>\u27a4 jaundice, poor feeding, failure to thrive</li><li>\u27a4 urine positive for reducing substances</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "8758c2a2",
      "audio": ""
    },
    {
      "text": "A 62-year-old male presents to the emergency department with severe chest pain radiating to the left arm, which began a few hours ago. An ECG indicates signs consistent with an acute myocardial infarction. While waiting for further management, a serum test is ordered, which reveals an abnormal LDH isoenzyme pattern. Which of the following best describes the expected LDH pattern seen in acute myocardial infarction?",
      "options": [
        {
          "label": "A",
          "text": "LDH-3 greater than LDH-2",
          "correct": false
        },
        {
          "label": "B",
          "text": "LDH-2 greater than LDH-3",
          "correct": false
        },
        {
          "label": "C",
          "text": "LDH-1 greater than LDH-2",
          "correct": true
        },
        {
          "label": "D",
          "text": "LDH-4 greater than LDH-1",
          "correct": false
        }
      ],
      "correct_answer": "C. LDH-1 greater than LDH-2",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. C) LDH-1 greater than LDH-2</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation</li><li>\u2022 Lactate Dehydrogenase (LDH) has 5 isoenzymes (LDH-1 to LDH-5), each localized predominantly to specific tissues:</li><li>\u2022 5 isoenzymes</li><li>\u2022 LDH-1 : Heart and red blood cells LDH-2 : Reticuloendothelial system, normally dominant in serum LDH-3 : Lungs, pancreas, and kidney LDH-4 : Liver and skeletal muscle LDH-5 : Liver and skeletal muscle</li><li>\u2022 LDH-1 : Heart and red blood cells</li><li>\u2022 LDH-1</li><li>\u2022 LDH-2 : Reticuloendothelial system, normally dominant in serum</li><li>\u2022 LDH-2</li><li>\u2022 LDH-3 : Lungs, pancreas, and kidney</li><li>\u2022 LDH-3</li><li>\u2022 LDH-4 : Liver and skeletal muscle</li><li>\u2022 LDH-4</li><li>\u2022 LDH-5 : Liver and skeletal muscle</li><li>\u2022 LDH-5</li><li>\u2022 Normal LDH Pattern</li><li>\u2022 Normal LDH Pattern</li><li>\u2022 Under normal conditions, LDH-2 is greater than LDH-1 in serum.</li><li>\u2022 Under normal conditions, LDH-2 is greater than LDH-1 in serum.</li><li>\u2022 LDH-2</li><li>\u2022 greater than LDH-1</li><li>\u2022 Acute Myocardial Infarction (MI)</li><li>\u2022 Acute Myocardial Infarction (MI)</li><li>\u2022 During an MI, cardiac tissue damage releases LDH-1 (heart isoenzyme) into the bloodstream. This causes a \"flipped pattern\" : LDH-1 becomes greater than LDH-2 . This is a key biochemical finding in the diagnosis of myocardial infarction and typically appears 12-24 hours after onset and lasts up to 10 days.</li><li>\u2022 During an MI, cardiac tissue damage releases LDH-1 (heart isoenzyme) into the bloodstream.</li><li>\u2022 cardiac tissue damage</li><li>\u2022 This causes a \"flipped pattern\" : LDH-1 becomes greater than LDH-2 .</li><li>\u2022 \"flipped pattern\"</li><li>\u2022 LDH-1 becomes greater than LDH-2</li><li>\u2022 This is a key biochemical finding in the diagnosis of myocardial infarction and typically appears 12-24 hours after onset and lasts up to 10 days.</li><li>\u2022 12-24 hours after onset</li><li>\u2022 Other Options:</li><li>\u2022 Other Options:</li><li>\u2022 Option A. LDH-3 greater than LDH-2 : LDH-3 is elevated in conditions affecting the lungs (e.g., pulmonary embolism) or pancreas. It is not characteristic of MI.</li><li>\u2022 Option A. LDH-3 greater than LDH-2</li><li>\u2022 lungs</li><li>\u2022 Option B. LDH-2 greater than LDH-3 : This is the normal LDH pattern in healthy individuals.</li><li>\u2022 Option B. LDH-2 greater than LDH-3</li><li>\u2022 normal LDH pattern</li><li>\u2022 Option D. LDH-4 greater than LDH-1: LDH-4 is associated with liver and skeletal muscle damage , not cardiac injury.</li><li>\u2022 Option D. LDH-4 greater than LDH-1:</li><li>\u2022 liver and skeletal muscle damage</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 In acute myocardial infarction , the LDH isoenzyme pattern shows a \"flip\" where LDH-1 becomes greater than LDH-2 due to cardiac tissue damage. This is a diagnostic marker of myocardial injury.</li><li>\u27a4 acute myocardial infarction</li><li>\u27a4 \"flip\"</li><li>\u27a4 LDH-1 becomes greater than LDH-2</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "1cd903d2",
      "audio": ""
    },
    {
      "text": "A 27-year-old male of presents with recurrent kidney stones since adolescence. Stone analysis reveals calcium oxalate. Blood and urine oxalate levels are raised. Given the early-onset and stone composition, which inherited metabolic disorder is most likely?",
      "options": [
        {
          "label": "A",
          "text": "Cystinosis",
          "correct": false
        },
        {
          "label": "B",
          "text": "Primary hyperoxaluria",
          "correct": true
        },
        {
          "label": "C",
          "text": "Alkaptonuria",
          "correct": false
        },
        {
          "label": "D",
          "text": "Glycinuria",
          "correct": false
        }
      ],
      "correct_answer": "B. Primary hyperoxaluria",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. B) Primary hyperoxaluria</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation</li><li>\u2022 The presentation of recurrent calcium oxalate kidney stones with increased blood and urine oxalate levels is characteristic of Primary Hyperoxaluria , a rare inherited metabolic disorder.</li><li>\u2022 calcium oxalate kidney stones</li><li>\u2022 increased blood and urine oxalate levels</li><li>\u2022 Primary Hyperoxaluria</li><li>\u2022 Primary Hyperoxaluria : Caused by a defect in glyoxylate metabolism leading to overproduction of oxalate , which combines with calcium to form calcium oxalate stones . It is an autosomal recessive disorder caused by deficiencies of specific enzymes, most commonly: Type I : Deficiency of alanine-glyoxylate aminotransferase (AGT) . Type II : Deficiency of glyoxylate reductase/hydroxypyruvate reductase (GRHPR) . The excess oxalate is excreted in the urine, leading to stone formation and potential kidney damage. Key Features : Early-Onset : Symptoms typically start in childhood or adolescence with recurrent kidney stones. Elevated Blood and Urine Oxalate : The hallmark finding. Calcium Oxalate Stones : Frequent and recurrent stone formation, often resistant to dietary interventions. Progression : If untreated, oxalate crystals can deposit in tissues (systemic oxalosis), leading to renal failure.</li><li>\u2022 Primary Hyperoxaluria : Caused by a defect in glyoxylate metabolism leading to overproduction of oxalate , which combines with calcium to form calcium oxalate stones . It is an autosomal recessive disorder caused by deficiencies of specific enzymes, most commonly: Type I : Deficiency of alanine-glyoxylate aminotransferase (AGT) . Type II : Deficiency of glyoxylate reductase/hydroxypyruvate reductase (GRHPR) . The excess oxalate is excreted in the urine, leading to stone formation and potential kidney damage.</li><li>\u2022 Primary Hyperoxaluria</li><li>\u2022 Caused by a defect in glyoxylate metabolism leading to overproduction of oxalate , which combines with calcium to form calcium oxalate stones . It is an autosomal recessive disorder caused by deficiencies of specific enzymes, most commonly: Type I : Deficiency of alanine-glyoxylate aminotransferase (AGT) . Type II : Deficiency of glyoxylate reductase/hydroxypyruvate reductase (GRHPR) . The excess oxalate is excreted in the urine, leading to stone formation and potential kidney damage.</li><li>\u2022 Caused by a defect in glyoxylate metabolism leading to overproduction of oxalate , which combines with calcium to form calcium oxalate stones .</li><li>\u2022 glyoxylate metabolism</li><li>\u2022 oxalate</li><li>\u2022 calcium oxalate stones</li><li>\u2022 It is an autosomal recessive disorder caused by deficiencies of specific enzymes, most commonly: Type I : Deficiency of alanine-glyoxylate aminotransferase (AGT) . Type II : Deficiency of glyoxylate reductase/hydroxypyruvate reductase (GRHPR) .</li><li>\u2022 autosomal recessive disorder</li><li>\u2022 Type I : Deficiency of alanine-glyoxylate aminotransferase (AGT) . Type II : Deficiency of glyoxylate reductase/hydroxypyruvate reductase (GRHPR) .</li><li>\u2022 Type I : Deficiency of alanine-glyoxylate aminotransferase (AGT) .</li><li>\u2022 Type I</li><li>\u2022 alanine-glyoxylate aminotransferase (AGT)</li><li>\u2022 Type II : Deficiency of glyoxylate reductase/hydroxypyruvate reductase (GRHPR) .</li><li>\u2022 Type II</li><li>\u2022 glyoxylate reductase/hydroxypyruvate reductase (GRHPR)</li><li>\u2022 The excess oxalate is excreted in the urine, leading to stone formation and potential kidney damage.</li><li>\u2022 Key Features : Early-Onset : Symptoms typically start in childhood or adolescence with recurrent kidney stones. Elevated Blood and Urine Oxalate : The hallmark finding. Calcium Oxalate Stones : Frequent and recurrent stone formation, often resistant to dietary interventions. Progression : If untreated, oxalate crystals can deposit in tissues (systemic oxalosis), leading to renal failure.</li><li>\u2022 Key Features</li><li>\u2022 Early-Onset : Symptoms typically start in childhood or adolescence with recurrent kidney stones. Elevated Blood and Urine Oxalate : The hallmark finding. Calcium Oxalate Stones : Frequent and recurrent stone formation, often resistant to dietary interventions. Progression : If untreated, oxalate crystals can deposit in tissues (systemic oxalosis), leading to renal failure.</li><li>\u2022 Early-Onset : Symptoms typically start in childhood or adolescence with recurrent kidney stones.</li><li>\u2022 Early-Onset</li><li>\u2022 Elevated Blood and Urine Oxalate : The hallmark finding.</li><li>\u2022 Elevated Blood and Urine Oxalate</li><li>\u2022 Calcium Oxalate Stones : Frequent and recurrent stone formation, often resistant to dietary interventions.</li><li>\u2022 Calcium Oxalate Stones</li><li>\u2022 Progression : If untreated, oxalate crystals can deposit in tissues (systemic oxalosis), leading to renal failure.</li><li>\u2022 Progression</li><li>\u2022 Other Options:</li><li>\u2022 Other Options:</li><li>\u2022 Option A. Cystinosis: Cystinosis is characterized by the accumulation of cystine in lysosomes, leading to cystine crystals in tissues. It can cause renal tubular dysfunction (Fanconi syndrome) but does not increase oxalate levels or cause calcium oxalate stones.</li><li>\u2022 Option A. Cystinosis:</li><li>\u2022 cystine</li><li>\u2022 Option C. Alkaptonuria : Alkaptonuria is caused by a deficiency of homogentisate oxidase , leading to accumulation of homogentisic acid. It causes black urine and ochronosis (black pigmentation of connective tissues) but is not associated with calcium oxalate stones.</li><li>\u2022 Option C. Alkaptonuria</li><li>\u2022 homogentisate oxidase</li><li>\u2022 black urine</li><li>\u2022 Option D. Glycinuria: Glycinuria is characterized by a defect in glycine reabsorption in the kidneys, leading to increased glycine in the urine. However, urine oxalate levels remain normal , differentiating it from primary hyperoxaluria.</li><li>\u2022 Option D. Glycinuria:</li><li>\u2022 glycine reabsorption</li><li>\u2022 urine oxalate levels remain normal</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 Primary Hyperoxaluria is an inherited disorder caused by enzyme deficiencies in glyoxylate metabolism, leading to elevated blood and urine oxalate levels and recurrent calcium oxalate kidney stones , typically starting in childhood or adolescence.</li><li>\u27a4 Primary Hyperoxaluria</li><li>\u27a4 blood and urine oxalate levels</li><li>\u27a4 calcium oxalate kidney stones</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "32f5685f",
      "audio": ""
    },
    {
      "text": "A 7-year-old boy is brought to the pediatric clinic with recurrent episodes of a photosensitive rash, intermittent diarrhea, and mood swings. His teacher has also reported difficulties in concentration at school. On examination, the child appears to have some cerebellar signs including coordination problems. Urinalysis shows an elevated excretion of neutral amino acids. Based on the findings, which amino acid deficiency is most characteristic of the child's likely inherited metabolic disorder?",
      "options": [
        {
          "label": "A",
          "text": "Histidine",
          "correct": false
        },
        {
          "label": "B",
          "text": "Glutamine",
          "correct": false
        },
        {
          "label": "C",
          "text": "Tryptophan",
          "correct": true
        },
        {
          "label": "D",
          "text": "Arginine",
          "correct": false
        }
      ],
      "correct_answer": "C. Tryptophan",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. C) Tryptophan</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation</li><li>\u2022 The clinical presentation\u2014 photosensitive rash , diarrhea , CNS symptoms (mood swings, coordination problems) , and elevated excretion of neutral amino acids \u2014is characteristic of Hartnup disease , an autosomal recessive disorder affecting the transport of neutral amino acids, particularly tryptophan , in the kidneys and intestines.</li><li>\u2022 photosensitive rash</li><li>\u2022 diarrhea</li><li>\u2022 CNS symptoms (mood swings, coordination problems)</li><li>\u2022 excretion of neutral amino acids</li><li>\u2022 Hartnup disease</li><li>\u2022 tryptophan</li><li>\u2022 Hartnup Disease : Caused by a defect in the SLC6A19 transporter , which impairs the reabsorption of neutral amino acids (like tryptophan) in the renal tubules and intestines. This leads to tryptophan deficiency and its decreased conversion to niacin (Vitamin B3) . Symptoms Resembling Pellagra : Tryptophan is a precursor for niacin synthesis. Deficiency of niacin causes symptoms known as pellagra , summarized as the \"4 Ds\" : Dermatitis : Photosensitive rash on sun-exposed areas (face, neck, hands). Diarrhea : Gastrointestinal disturbances. Dementia : Cognitive issues, mood swings, and difficulties in concentration. Death : If untreated. Neurological symptoms such as cerebellar ataxia (coordination problems) and mood swings are also common. Biochemical Findings : Elevated Excretion of Neutral Amino Acids : In Hartnup disease, neutral amino acids like tryptophan spill into the urine due to defective reabsorption in the renal tubules. Tryptophan-Niacin Conversion : Approximately 60 mg of tryptophan is required to produce 1 mg of niacin . Therefore, tryptophan deficiency leads to a niacin deficiency , causing pellagra-like symptoms.</li><li>\u2022 Hartnup Disease : Caused by a defect in the SLC6A19 transporter , which impairs the reabsorption of neutral amino acids (like tryptophan) in the renal tubules and intestines. This leads to tryptophan deficiency and its decreased conversion to niacin (Vitamin B3) .</li><li>\u2022 Hartnup Disease</li><li>\u2022 Caused by a defect in the SLC6A19 transporter , which impairs the reabsorption of neutral amino acids (like tryptophan) in the renal tubules and intestines. This leads to tryptophan deficiency and its decreased conversion to niacin (Vitamin B3) .</li><li>\u2022 Caused by a defect in the SLC6A19 transporter , which impairs the reabsorption of neutral amino acids (like tryptophan) in the renal tubules and intestines.</li><li>\u2022 SLC6A19 transporter</li><li>\u2022 neutral amino acids</li><li>\u2022 This leads to tryptophan deficiency and its decreased conversion to niacin (Vitamin B3) .</li><li>\u2022 tryptophan deficiency</li><li>\u2022 niacin (Vitamin B3)</li><li>\u2022 Symptoms Resembling Pellagra : Tryptophan is a precursor for niacin synthesis. Deficiency of niacin causes symptoms known as pellagra , summarized as the \"4 Ds\" : Dermatitis : Photosensitive rash on sun-exposed areas (face, neck, hands). Diarrhea : Gastrointestinal disturbances. Dementia : Cognitive issues, mood swings, and difficulties in concentration. Death : If untreated. Neurological symptoms such as cerebellar ataxia (coordination problems) and mood swings are also common.</li><li>\u2022 Symptoms Resembling Pellagra</li><li>\u2022 Tryptophan is a precursor for niacin synthesis. Deficiency of niacin causes symptoms known as pellagra , summarized as the \"4 Ds\" : Dermatitis : Photosensitive rash on sun-exposed areas (face, neck, hands). Diarrhea : Gastrointestinal disturbances. Dementia : Cognitive issues, mood swings, and difficulties in concentration. Death : If untreated. Neurological symptoms such as cerebellar ataxia (coordination problems) and mood swings are also common.</li><li>\u2022 Tryptophan is a precursor for niacin synthesis. Deficiency of niacin causes symptoms known as pellagra , summarized as the \"4 Ds\" : Dermatitis : Photosensitive rash on sun-exposed areas (face, neck, hands). Diarrhea : Gastrointestinal disturbances. Dementia : Cognitive issues, mood swings, and difficulties in concentration. Death : If untreated.</li><li>\u2022 pellagra</li><li>\u2022 \"4 Ds\"</li><li>\u2022 Dermatitis : Photosensitive rash on sun-exposed areas (face, neck, hands). Diarrhea : Gastrointestinal disturbances. Dementia : Cognitive issues, mood swings, and difficulties in concentration. Death : If untreated.</li><li>\u2022 Dermatitis : Photosensitive rash on sun-exposed areas (face, neck, hands).</li><li>\u2022 Dermatitis</li><li>\u2022 Diarrhea : Gastrointestinal disturbances.</li><li>\u2022 Diarrhea</li><li>\u2022 Dementia : Cognitive issues, mood swings, and difficulties in concentration.</li><li>\u2022 Dementia</li><li>\u2022 Death : If untreated.</li><li>\u2022 Death</li><li>\u2022 Neurological symptoms such as cerebellar ataxia (coordination problems) and mood swings are also common.</li><li>\u2022 cerebellar ataxia</li><li>\u2022 Biochemical Findings : Elevated Excretion of Neutral Amino Acids : In Hartnup disease, neutral amino acids like tryptophan spill into the urine due to defective reabsorption in the renal tubules.</li><li>\u2022 Biochemical Findings</li><li>\u2022 Elevated Excretion of Neutral Amino Acids : In Hartnup disease, neutral amino acids like tryptophan spill into the urine due to defective reabsorption in the renal tubules.</li><li>\u2022 Elevated Excretion of Neutral Amino Acids : In Hartnup disease, neutral amino acids like tryptophan spill into the urine due to defective reabsorption in the renal tubules.</li><li>\u2022 Elevated Excretion of Neutral Amino Acids</li><li>\u2022 tryptophan</li><li>\u2022 Tryptophan-Niacin Conversion : Approximately 60 mg of tryptophan is required to produce 1 mg of niacin . Therefore, tryptophan deficiency leads to a niacin deficiency , causing pellagra-like symptoms.</li><li>\u2022 Tryptophan-Niacin Conversion</li><li>\u2022 Approximately 60 mg of tryptophan is required to produce 1 mg of niacin . Therefore, tryptophan deficiency leads to a niacin deficiency , causing pellagra-like symptoms.</li><li>\u2022 Approximately 60 mg of tryptophan is required to produce 1 mg of niacin . Therefore, tryptophan deficiency leads to a niacin deficiency , causing pellagra-like symptoms.</li><li>\u2022 60 mg of tryptophan</li><li>\u2022 1 mg of niacin</li><li>\u2022 niacin deficiency</li><li>\u2022 Other Options:</li><li>\u2022 Other Options:</li><li>\u2022 Option A. Histidine: Histidine is a neutral amino acid, but its deficiency does not cause pellagra-like symptoms or neurological features.</li><li>\u2022 Option A. Histidine:</li><li>\u2022 Option B. Glutamine: Glutamine is a neutral amino acid, but its deficiency does not cause niacin deficiency or affect neutral amino acid transport.</li><li>\u2022 Option B. Glutamine:</li><li>\u2022 Option D. Arginine: Arginine is a basic amino acid, not a neutral amino acid, and its deficiency causes urea cycle defects , not pellagra-like symptoms.</li><li>\u2022 Option D. Arginine:</li><li>\u2022 urea cycle defects</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 Hartnup disease is caused by defective transport of neutral amino acids , particularly tryptophan , leading to niacin deficiency and pellagra-like symptoms (photosensitive rash, diarrhea, dementia). Elevated urinary excretion of neutral amino acids is a hallmark finding.</li><li>\u27a4 Hartnup disease</li><li>\u27a4 neutral amino acids</li><li>\u27a4 tryptophan</li><li>\u27a4 niacin deficiency</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "7e7b1682",
      "audio": ""
    },
    {
      "text": "Identify the given structure:",
      "options": [
        {
          "label": "A",
          "text": "Cytidine",
          "correct": false
        },
        {
          "label": "B",
          "text": "Cytosine",
          "correct": false
        },
        {
          "label": "C",
          "text": "Adenosine",
          "correct": true
        },
        {
          "label": "D",
          "text": "Adenine nucleotide",
          "correct": false
        }
      ],
      "correct_answer": "C. Adenosine",
      "question_images": [
        "https://cerebellum-web-static.s3.amazonaws.com/media/public/Screenshot%202024-12-18%20131814.jpg"
      ],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. C) Adenosine</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation</li><li>\u2022 Two-Ring Structure :</li><li>\u2022 Two-Ring Structure</li><li>\u2022 The molecule contains a two-ring structure, which is characteristic of purines (adenine and guanine). If there is an amino group (-NH2) at the top of the six-membered ring, the purine is adenine . If no amino group is present at the top but a keto group is seen, the purine would be guanine . In this case, there is an amino group , so the purine base is adenine .</li><li>\u2022 The molecule contains a two-ring structure, which is characteristic of purines (adenine and guanine).</li><li>\u2022 purines</li><li>\u2022 If there is an amino group (-NH2) at the top of the six-membered ring, the purine is adenine .</li><li>\u2022 amino group (-NH2)</li><li>\u2022 adenine</li><li>\u2022 If no amino group is present at the top but a keto group is seen, the purine would be guanine .</li><li>\u2022 guanine</li><li>\u2022 In this case, there is an amino group , so the purine base is adenine .</li><li>\u2022 amino group</li><li>\u2022 adenine</li><li>\u2022 Presence of Sugar :</li><li>\u2022 Presence of Sugar</li><li>\u2022 A sugar molecule (ribose) is attached to the adenine base, forming a nucleoside . Adenine + Ribose = Adenosine (a nucleoside).</li><li>\u2022 A sugar molecule (ribose) is attached to the adenine base, forming a nucleoside .</li><li>\u2022 nucleoside</li><li>\u2022 Adenine + Ribose = Adenosine (a nucleoside).</li><li>\u2022 Adenine + Ribose</li><li>\u2022 Adenosine</li><li>\u2022 No Phosphate Group :</li><li>\u2022 No Phosphate Group</li><li>\u2022 A nucleotide includes a phosphate group attached to the nucleoside. Since the structure lacks a phosphate group, it is a nucleoside , not a nucleotide.</li><li>\u2022 A nucleotide includes a phosphate group attached to the nucleoside.</li><li>\u2022 nucleotide</li><li>\u2022 phosphate group</li><li>\u2022 Since the structure lacks a phosphate group, it is a nucleoside , not a nucleotide.</li><li>\u2022 nucleoside</li><li>\u2022 Other Options :</li><li>\u2022 Other Options :</li><li>\u2022 Option A. Cytidine: Cytidine is a nucleoside of cytosine , a pyrimidine base (single-ring structure). The given molecule has a two-ring purine structure , so it cannot be cytidine.</li><li>\u2022 Option A. Cytidine:</li><li>\u2022 nucleoside</li><li>\u2022 cytosine</li><li>\u2022 two-ring purine structure</li><li>\u2022 Option B. Cytosine: Cytosine is a pyrimidine base (single-ring structure) with an amino group. The given molecule is a purine, not cytosine.</li><li>\u2022 Option B. Cytosine:</li><li>\u2022 pyrimidine base</li><li>\u2022 Option D. Adenine nucleotide: Adenine nucleotide includes adenine + ribose + phosphate . Since there is no phosphate group in the given structure, it cannot be a nucleotide.</li><li>\u2022 Option D. Adenine nucleotide:</li><li>\u2022 adenine + ribose + phosphate</li><li>\u2022 no phosphate group</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 The structure is adenosine , a nucleoside consisting of the purine base adenine attached to ribose sugar .</li><li>\u27a4 adenosine</li><li>\u27a4 nucleoside</li><li>\u27a4 adenine</li><li>\u27a4 ribose sugar</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "24e5a9cf",
      "audio": ""
    },
    {
      "text": "Following a specific point mutation, a lysine residue gets replaced by an aspartic acid residue in a protein. This alteration affects the protein's overall charge. What will happen to the mobility towards anode, of this mutated protein compared to the normal protein on gel electrophoresis?",
      "options": [
        {
          "label": "A",
          "text": "Faster due to decreased overall positive charge.",
          "correct": true
        },
        {
          "label": "B",
          "text": "Slower due to increased overall negative charge.",
          "correct": false
        },
        {
          "label": "C",
          "text": "Dependent on the pH of the gel",
          "correct": false
        },
        {
          "label": "D",
          "text": "Unchanged",
          "correct": false
        }
      ],
      "correct_answer": "A. Faster due to decreased overall positive charge.",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. A) Faster due to decreased overall positive charge.</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation</li><li>\u2022 Lysine is a positively charged amino acid, while aspartic acid carries a negative charge at physiological pH. When lysine is replaced by aspartic acid, the protein's overall charge becomes more negative due to the loss of a positive charge and the addition of a negative charge.</li><li>\u2022 In gel electrophoresis, proteins move towards the anode (positive electrode) because they are negatively charged under standard electrophoresis conditions. The increased overall negative charge caused by the mutation enhances the protein\u2019s movement towards the anode, resulting in faster mobility compared to the normal protein.</li><li>\u2022 anode</li><li>\u2022 faster mobility</li><li>\u2022 Other Options:</li><li>\u2022 Other Options:</li><li>\u2022 Option B. Slower due to increased overall negative charge: This is incorrect because increased negative charge would accelerate the protein's movement towards the positively charged anode, not slow it down.</li><li>\u2022 Option B. Slower due to increased overall negative charge:</li><li>\u2022 accelerate</li><li>\u2022 Option C. Dependent on the pH of the gel: While pH can affect protein charge, the question describes a very specific mutation leading to a clear charge shift. Given this specificity, the answer does not depend on the pH but rather on the increase in negative charge.</li><li>\u2022 Option C. Dependent on the pH of the gel:</li><li>\u2022 Option D. Unchanged: This is incorrect because replacing a positively charged lysine with a negatively charged aspartic acid clearly alters the overall charge, changing the protein\u2019s mobility in gel electrophoresis.</li><li>\u2022 Option D. Unchanged:</li><li>\u2022 clearly alters</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 The replacement of lysine (positive charge) with aspartic acid (negative charge) increases the overall negative charge of the protein, resulting in faster movement towards the anode in gel electrophoresis.</li><li>\u27a4 faster movement towards the anode</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "6d196fd2",
      "audio": ""
    },
    {
      "text": "A 40-year-old patient presents with symptoms of peripheral neuropathy and mild hepatosplenomegaly. On examination, the tonsils appear notably enlarged and have an orange-yellow hue. Laboratory investigations reveal a remarkably low level of high-density lipoprotein (HDL) cholesterol. Which inherited metabolic disorder is most likely responsible for this clinical presentation?",
      "options": [
        {
          "label": "A",
          "text": "Niemann-Pick disease",
          "correct": false
        },
        {
          "label": "B",
          "text": "Tangier disease",
          "correct": true
        },
        {
          "label": "C",
          "text": "Fabry disease",
          "correct": false
        },
        {
          "label": "D",
          "text": "Familial hypercholesterolemia",
          "correct": false
        }
      ],
      "correct_answer": "B. Tangier disease",
      "question_images": [],
      "explanation_images": [
        "https://cerebellum-web-static.s3.amazonaws.com/media/public/Screenshot%202024-12-18%20131911.jpg"
      ],
      "explanation": "<p><strong>Ans. B) Tangier disease</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation</li><li>\u2022 Tangier disease, also known as familial alpha-lipoprotein deficiency , is a rare autosomal recessive disorder caused by mutations in the ABCA1 gene . This gene encodes a transmembrane protein responsible for transferring cellular cholesterol to apolipoprotein A1, which is necessary for the formation of HDL (high-density lipoprotein).</li><li>\u2022 familial alpha-lipoprotein deficiency</li><li>\u2022 ABCA1 gene</li><li>\u2022 HDL</li><li>\u2022 Key Clinical Features:</li><li>\u2022 Key Clinical Features:</li><li>\u2022 Extremely low HDL cholesterol levels \u2013 This is a hallmark of Tangier disease. Orange-yellow tonsils \u2013 Caused by cholesterol accumulation in macrophages of the tonsils, giving them a characteristic appearance. Peripheral neuropathy \u2013 Due to cholesterol buildup in peripheral nerves. Hepatosplenomegaly \u2013 Cholesterol accumulation occurs in the liver and spleen. Cholesterol deposits in other tissues, including lymph nodes and the cornea.</li><li>\u2022 Extremely low HDL cholesterol levels \u2013 This is a hallmark of Tangier disease.</li><li>\u2022 Extremely low HDL cholesterol levels</li><li>\u2022 Orange-yellow tonsils \u2013 Caused by cholesterol accumulation in macrophages of the tonsils, giving them a characteristic appearance.</li><li>\u2022 Orange-yellow tonsils</li><li>\u2022 Peripheral neuropathy \u2013 Due to cholesterol buildup in peripheral nerves.</li><li>\u2022 Peripheral neuropathy</li><li>\u2022 Hepatosplenomegaly \u2013 Cholesterol accumulation occurs in the liver and spleen.</li><li>\u2022 Hepatosplenomegaly</li><li>\u2022 Cholesterol deposits in other tissues, including lymph nodes and the cornea.</li><li>\u2022 Cholesterol deposits</li><li>\u2022 The unique clinical finding of orange-yellow tonsils combined with peripheral neuropathy and low HDL levels makes Tangier disease the most likely diagnosis.</li><li>\u2022 orange-yellow tonsils</li><li>\u2022 Other Options:</li><li>\u2022 Other Options:</li><li>\u2022 Option A. Niemann-Pick disease: Niemann-Pick disease involves a deficiency of sphingomyelinase leading to accumulation of sphingomyelin. While it can present with hepatosplenomegaly and neurological symptoms, it does not cause low HDL or orange-yellow tonsils .</li><li>\u2022 Option A. Niemann-Pick disease:</li><li>\u2022 sphingomyelinase</li><li>\u2022 not cause low HDL or orange-yellow tonsils</li><li>\u2022 Option C. Fabry disease: Fabry disease is caused by a deficiency of \u03b1-galactosidase A , leading to accumulation of globotriaosylceramide. It presents with angiokeratomas, neuropathic pain, and renal failure, but does not cause low HDL or enlarged tonsils .</li><li>\u2022 Option C. Fabry disease:</li><li>\u2022 \u03b1-galactosidase A</li><li>\u2022 does not cause low HDL or enlarged tonsils</li><li>\u2022 Option D. Familial hypercholesterolemia: Familial hypercholesterolemia is characterized by elevated LDL cholesterol due to defects in the LDL receptor or its ligand (ApoB-100). It causes xanthomas and atherosclerosis but does not cause low HDL levels or orange-yellow tonsils .</li><li>\u2022 Option D. Familial hypercholesterolemia:</li><li>\u2022 LDL receptor</li><li>\u2022 not cause low HDL levels or orange-yellow tonsils</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 Tangier disease is caused by mutations in the ABCA1 gene , leading to extremely low HDL levels , cholesterol accumulation, orange-yellow tonsils , peripheral neuropathy, and hepatosplenomegaly.</li><li>\u27a4 ABCA1 gene</li><li>\u27a4 low HDL levels</li><li>\u27a4 orange-yellow tonsils</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "b9efe84e",
      "audio": ""
    },
    {
      "text": "The image depicts a nucleotide. If this nucleotide is added to a developing DNA sequence during a PCR process, what is the expected outcome?",
      "options": [
        {
          "label": "A",
          "text": "Synthesis of DNA stops.",
          "correct": true
        },
        {
          "label": "B",
          "text": "The DNA forms more quickly",
          "correct": false
        },
        {
          "label": "C",
          "text": "The rate of DNA synthesis decreases",
          "correct": false
        },
        {
          "label": "D",
          "text": "A glowing or fluorescent reaction is produced.",
          "correct": false
        }
      ],
      "correct_answer": "A. Synthesis of DNA stops.",
      "question_images": [
        "https://cerebellum-web-static.s3.amazonaws.com/media/public/Screenshot%202024-12-18%20132031.jpg"
      ],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. A) Synthesis of DNA stops.</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation</li><li>\u2022 The structure depicted in the image is a dideoxynucleotide (ddNTP) .</li><li>\u2022 dideoxynucleotide (ddNTP)</li><li>\u2022 Key feature of ddNTPs : Unlike regular deoxynucleotides (dNTPs), ddNTPs lack both the 2\u2019-hydroxyl group (2\u2019-OH) and the 3\u2019-hydroxyl group (3\u2019-OH) on the sugar component. Role of the 3\u2019-OH group in DNA synthesis : During DNA synthesis, the 3\u2019-OH group of the growing DNA strand forms a phosphodiester bond with the incoming nucleotide\u2019s phosphate group. Since ddNTPs lack the 3\u2019-OH group , no further nucleotides can be added after a ddNTP is incorporated, leading to termination of DNA synthesis . Application in PCR : ddNTPs are commonly used in Sanger sequencing to terminate DNA synthesis at specific points. By adding fluorescently abelled ddNTPs, researchers can determine the sequence of the DNA strand.</li><li>\u2022 Key feature of ddNTPs : Unlike regular deoxynucleotides (dNTPs), ddNTPs lack both the 2\u2019-hydroxyl group (2\u2019-OH) and the 3\u2019-hydroxyl group (3\u2019-OH) on the sugar component.</li><li>\u2022 Key feature of ddNTPs</li><li>\u2022 ddNTPs lack both the 2\u2019-hydroxyl group (2\u2019-OH)</li><li>\u2022 3\u2019-hydroxyl group (3\u2019-OH)</li><li>\u2022 Role of the 3\u2019-OH group in DNA synthesis : During DNA synthesis, the 3\u2019-OH group of the growing DNA strand forms a phosphodiester bond with the incoming nucleotide\u2019s phosphate group. Since ddNTPs lack the 3\u2019-OH group , no further nucleotides can be added after a ddNTP is incorporated, leading to termination of DNA synthesis .</li><li>\u2022 Role of the 3\u2019-OH group in DNA synthesis</li><li>\u2022 ddNTPs lack the 3\u2019-OH group</li><li>\u2022 termination of DNA synthesis</li><li>\u2022 Application in PCR : ddNTPs are commonly used in Sanger sequencing to terminate DNA synthesis at specific points. By adding fluorescently abelled ddNTPs, researchers can determine the sequence of the DNA strand.</li><li>\u2022 Application in PCR</li><li>\u2022 Sanger sequencing</li><li>\u2022 Other Options:</li><li>\u2022 Other Options:</li><li>\u2022 Option B. The DNA forms more quickly: Incorrect. ddNTPs halt DNA synthesis rather than accelerating it.</li><li>\u2022 Option B. The DNA forms more quickly:</li><li>\u2022 Option C. The rate of DNA synthesis decreases: Incorrect. The rate does not gradually slow; synthesis stops abruptly after incorporation of ddNTP.</li><li>\u2022 Option C. The rate of DNA synthesis decreases:</li><li>\u2022 stops abruptly</li><li>\u2022 Option D. A glowing or fluorescent reaction is produced: Incorrect in this context. While fluorescent ddNTPs are used in sequencing, the nucleotide shown itself is not necessarily fluorescent unless specified.</li><li>\u2022 Option D. A glowing or fluorescent reaction is produced:</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 Dideoxynucleotides (ddNTPs) lack a 3\u2019-OH group . When added during PCR or sequencing, they terminate DNA synthesis because no further nucleotides can attach. This is the basis of the Sanger sequencing method .</li><li>\u27a4 lack a 3\u2019-OH group</li><li>\u27a4 Sanger sequencing method</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "6e5f188d",
      "audio": ""
    },
    {
      "text": "A postgraduate student aims to establish a genomic library of a human cell line in Escherichia coli cells. To do so, she must slice both the E. coli plasmid DNA and human cell DNA with a restriction enzyme known to always target palindromic DNA sequences. Which among the following DNA sequences is palindromic and could potentially be recognized by this enzyme?",
      "options": [
        {
          "label": "A",
          "text": "AAGAAG",
          "correct": false
        },
        {
          "label": "B",
          "text": "CATCTA",
          "correct": false
        },
        {
          "label": "C",
          "text": "TAGGAT",
          "correct": false
        },
        {
          "label": "D",
          "text": "GTGCAC",
          "correct": true
        }
      ],
      "correct_answer": "D. GTGCAC",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. D) GTGCAC</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation</li><li>\u2022 A palindromic DNA sequence is one in which the sequence of bases on the 5\u2019 to 3\u2019 strand is identical to the sequence on the complementary strand (3\u2019 to 5\u2019) when read in the opposite direction .</li><li>\u2022 palindromic DNA sequence</li><li>\u2022 5\u2019 to 3\u2019 strand</li><li>\u2022 complementary strand (3\u2019 to 5\u2019)</li><li>\u2022 opposite direction</li><li>\u2022 Original strand (5\u2019 \u2192 3\u2019): GTGCAC Complementary strand (3\u2019 \u2192 5\u2019): CACGTG When you read the complementary strand in the 5\u2019 \u2192 3\u2019 direction, it is: GTGCAC . This matches the original sequence, so it is palindromic .</li><li>\u2022 Original strand (5\u2019 \u2192 3\u2019): GTGCAC</li><li>\u2022 GTGCAC</li><li>\u2022 Complementary strand (3\u2019 \u2192 5\u2019): CACGTG When you read the complementary strand in the 5\u2019 \u2192 3\u2019 direction, it is: GTGCAC . This matches the original sequence, so it is palindromic .</li><li>\u2022 CACGTG</li><li>\u2022 5\u2019 \u2192 3\u2019</li><li>\u2022 GTGCAC</li><li>\u2022 palindromic</li><li>\u2022 Other Options:</li><li>\u2022 Other Options:</li><li>\u2022 Option A. AAGAAG: Complementary strand: TTCTTC \u2192 This does not match the original sequence when read in reverse. Not palindromic.</li><li>\u2022 Option A. AAGAAG:</li><li>\u2022 TTCTTC</li><li>\u2022 Not palindromic.</li><li>\u2022 Option B. CATCTA: Complementary strand: GTAGAT \u2192 This does not match the original sequence in reverse. Not palindromic.</li><li>\u2022 Option B. CATCTA:</li><li>\u2022 GTAGAT</li><li>\u2022 Not palindromic.</li><li>\u2022 Option C. TAGGAT: Complementary strand: ATCCTA \u2192 This does not match the original sequence when reversed. Not palindromic.</li><li>\u2022 Option C. TAGGAT:</li><li>\u2022 ATCCTA</li><li>\u2022 Not palindromic.</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 A palindromic DNA sequence reads the same in the 5\u2019 \u2192 3\u2019 direction on one strand and the 5\u2019 \u2192 3\u2019 direction on its complementary strand. The correct sequence here is GTGCAC .</li><li>\u27a4 palindromic DNA sequence</li><li>\u27a4 GTGCAC</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "6fcee12a",
      "audio": ""
    },
    {
      "text": "A 35-year-old woman presents to the clinic with a history of heightened sensitivity to sunlight, resulting in severe skin lesions after minimal sun exposure. She also has a family history of early-onset cancers, especially skin malignancies. Laboratory studies reveal a defect in a pathway that specifically repairs small DNA lesions caused by oxidation or deamination. Which DNA repair mechanism is most likely impaired in this patient?",
      "options": [
        {
          "label": "A",
          "text": "Nucleotide excision repair",
          "correct": true
        },
        {
          "label": "B",
          "text": "Mismatch repair",
          "correct": false
        },
        {
          "label": "C",
          "text": "Base excision repair",
          "correct": false
        },
        {
          "label": "D",
          "text": "Homologous recombination",
          "correct": false
        }
      ],
      "correct_answer": "A. Nucleotide excision repair",
      "question_images": [],
      "explanation_images": [
        "https://cerebellum-web-static.s3.amazonaws.com/media/public/Screenshot%202024-12-18%20132114.jpg"
      ],
      "explanation": "<p><strong>Ans. A) Nucleotide excision repair</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation</li><li>\u2022 The patient\u2019s symptoms of heightened sunlight sensitivity and skin lesions indicate DNA damage caused by UV exposure. However, the question specifies a defect in the repair of small DNA lesions caused by oxidation or deamination . This specific type of DNA damage is repaired by the base excision repair (BER) pathway.</li><li>\u2022 sunlight sensitivity</li><li>\u2022 small DNA lesions caused by oxidation or deamination</li><li>\u2022 base excision repair (BER)</li><li>\u2022 Base Excision Repair (BER):</li><li>\u2022 Base Excision Repair (BER):</li><li>\u2022 BER repairs small, non-helix-distorting lesions in DNA, such as: Oxidative damage (e.g., 8-oxoG) Deamination of cytosine to uracil In this process: DNA glycosylase removes the damaged base, leaving an AP site (apurinic/apyrimidinic site). AP endonuclease cleaves the DNA backbone at the AP site. DNA polymerase fills the gap, and DNA ligase seals the strand.</li><li>\u2022 BER repairs small, non-helix-distorting lesions in DNA, such as: Oxidative damage (e.g., 8-oxoG) Deamination of cytosine to uracil</li><li>\u2022 small, non-helix-distorting lesions</li><li>\u2022 Oxidative damage (e.g., 8-oxoG) Deamination of cytosine to uracil</li><li>\u2022 Oxidative damage (e.g., 8-oxoG)</li><li>\u2022 Oxidative damage</li><li>\u2022 Deamination of cytosine to uracil</li><li>\u2022 Deamination</li><li>\u2022 In this process: DNA glycosylase removes the damaged base, leaving an AP site (apurinic/apyrimidinic site). AP endonuclease cleaves the DNA backbone at the AP site. DNA polymerase fills the gap, and DNA ligase seals the strand.</li><li>\u2022 In this process:</li><li>\u2022 DNA glycosylase removes the damaged base, leaving an AP site (apurinic/apyrimidinic site). AP endonuclease cleaves the DNA backbone at the AP site. DNA polymerase fills the gap, and DNA ligase seals the strand.</li><li>\u2022 DNA glycosylase removes the damaged base, leaving an AP site (apurinic/apyrimidinic site). AP endonuclease cleaves the DNA backbone at the AP site. DNA polymerase fills the gap, and DNA ligase seals the strand.</li><li>\u2022 DNA glycosylase</li><li>\u2022 AP site</li><li>\u2022 AP endonuclease cleaves the DNA backbone at the AP site. DNA polymerase fills the gap, and DNA ligase seals the strand.</li><li>\u2022 AP endonuclease cleaves the DNA backbone at the AP site.</li><li>\u2022 AP endonuclease</li><li>\u2022 DNA polymerase fills the gap, and DNA ligase seals the strand.</li><li>\u2022 DNA polymerase</li><li>\u2022 DNA ligase</li><li>\u2022 Other Options:</li><li>\u2022 Other Options:</li><li>\u2022 Option A. Nucleotide excision repair: Nucleotide excision repair (NER) fixes bulky DNA lesions caused by UV radiation, such as thymine-thymine dimers . Defects in NER lead to xeroderma pigmentosum (XP) , which presents with UV sensitivity and skin malignancies. However, NER does not repair oxidative or deaminated bases .</li><li>\u2022 Option A. Nucleotide excision repair:</li><li>\u2022 bulky DNA lesions</li><li>\u2022 thymine-thymine dimers</li><li>\u2022 xeroderma pigmentosum (XP)</li><li>\u2022 oxidative or deaminated bases</li><li>\u2022 Option B. Mismatch repair: Mismatch repair (MMR) corrects mismatched base pairs during DNA replication. Defects cause Hereditary Nonpolyposis Colorectal Cancer (HNPCC/Lynch syndrome) .</li><li>\u2022 Option B. Mismatch repair:</li><li>\u2022 mismatched base pairs</li><li>\u2022 Hereditary Nonpolyposis Colorectal Cancer (HNPCC/Lynch syndrome)</li><li>\u2022 Option D. Homologous recombination: Homologous recombination (HR) repairs double-stranded DNA breaks and maintains genome stability. Defects in HR cause diseases like BRCA-related breast/ovarian cancer and Fanconi anemia .</li><li>\u2022 Option D. Homologous recombination:</li><li>\u2022 double-stranded DNA breaks</li><li>\u2022 BRCA-related breast/ovarian cancer</li><li>\u2022 Fanconi anemia</li><li>\u2022 Note :</li><li>\u2022 Note</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 Base excision repair (BER) repairs small DNA lesions caused by oxidation or deamination . Defects in this repair pathway can lead to genomic instability and sensitivity to DNA-damaging agents.</li><li>\u27a4 Base excision repair (BER)</li><li>\u27a4 oxidation</li><li>\u27a4 deamination</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "ae152ad6",
      "audio": ""
    },
    {
      "text": "A 58-year-old male presents to the clinic with a triad of symptoms: confusion, ophthalmoplegia, and ataxia. On further questioning, he reports a history of chronic alcohol abuse. Physical examination reveals bilateral nystagmus and a broad-based gait. Given these clinical findings, which vitamin deficiency is most likely responsible for this patient's condition?",
      "options": [
        {
          "label": "A",
          "text": "Vitamin B12",
          "correct": false
        },
        {
          "label": "B",
          "text": "Vitamin C",
          "correct": false
        },
        {
          "label": "C",
          "text": "Vitamin D",
          "correct": false
        },
        {
          "label": "D",
          "text": "Vitamin B1 (thiamine)",
          "correct": true
        }
      ],
      "correct_answer": "D. Vitamin B1 (thiamine)",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. D) Vitamin B1 (thiamine)</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation</li><li>\u2022 The triad of confusion , ophthalmoplegia , and ataxia in a patient with a history of chronic alcohol abuse is highly characteristic of Wernicke's encephalopathy . This condition results from a deficiency of Vitamin B1 (thiamine) .</li><li>\u2022 confusion</li><li>\u2022 ophthalmoplegia</li><li>\u2022 ataxia</li><li>\u2022 chronic alcohol abuse</li><li>\u2022 Wernicke's encephalopathy</li><li>\u2022 Vitamin B1 (thiamine)</li><li>\u2022 Pathophysiology</li><li>\u2022 Pathophysiology</li><li>\u2022 Thiamine (Vitamin B1) is an essential cofactor for enzymes involved in carbohydrate metabolism, particularly: Pyruvate dehydrogenase (converts pyruvate to acetyl-CoA) \u03b1-ketoglutarate dehydrogenase (TCA cycle) Transketolase (pentose phosphate pathway) Chronic alcohol use impairs thiamine absorption, storage, and utilization, leading to thiamine deficiency .</li><li>\u2022 Thiamine (Vitamin B1) is an essential cofactor for enzymes involved in carbohydrate metabolism, particularly: Pyruvate dehydrogenase (converts pyruvate to acetyl-CoA) \u03b1-ketoglutarate dehydrogenase (TCA cycle) Transketolase (pentose phosphate pathway)</li><li>\u2022 Pyruvate dehydrogenase (converts pyruvate to acetyl-CoA) \u03b1-ketoglutarate dehydrogenase (TCA cycle) Transketolase (pentose phosphate pathway)</li><li>\u2022 Pyruvate dehydrogenase (converts pyruvate to acetyl-CoA)</li><li>\u2022 Pyruvate dehydrogenase</li><li>\u2022 \u03b1-ketoglutarate dehydrogenase (TCA cycle)</li><li>\u2022 \u03b1-ketoglutarate dehydrogenase</li><li>\u2022 Transketolase (pentose phosphate pathway)</li><li>\u2022 Transketolase</li><li>\u2022 Chronic alcohol use impairs thiamine absorption, storage, and utilization, leading to thiamine deficiency .</li><li>\u2022 thiamine deficiency</li><li>\u2022 Clinical Features of Wernicke's Encephalopathy:</li><li>\u2022 Clinical Features of Wernicke's Encephalopathy:</li><li>\u2022 Confusion \u2013 Global confusion and disorientation. Ophthalmoplegia \u2013 Paralysis or weakness of eye muscles, often leading to nystagmus . Ataxia \u2013 Unsteady, broad-based gait due to cerebellar involvement.</li><li>\u2022 Confusion \u2013 Global confusion and disorientation.</li><li>\u2022 Confusion</li><li>\u2022 Ophthalmoplegia \u2013 Paralysis or weakness of eye muscles, often leading to nystagmus .</li><li>\u2022 Ophthalmoplegia</li><li>\u2022 nystagmus</li><li>\u2022 Ataxia \u2013 Unsteady, broad-based gait due to cerebellar involvement.</li><li>\u2022 Ataxia</li><li>\u2022 If untreated, Wernicke's encephalopathy can progress to Korsakoff syndrome , which includes irreversible memory loss , confabulation , and psychosis .</li><li>\u2022 Korsakoff syndrome</li><li>\u2022 irreversible memory loss</li><li>\u2022 confabulation</li><li>\u2022 psychosis</li><li>\u2022 Other Options:</li><li>\u2022 Other Options:</li><li>\u2022 Option A. Vitamin B12: Vitamin B12 deficiency causes subacute combined degeneration of the spinal cord, leading to peripheral neuropathy, paresthesia, and ataxia but not ophthalmoplegia or confusion.</li><li>\u2022 Option A. Vitamin B12:</li><li>\u2022 subacute combined degeneration</li><li>\u2022 Option B. Vitamin C: Vitamin C deficiency leads to scurvy , which is characterized by bleeding gums, petechiae, and poor wound healing, not neurological symptoms.</li><li>\u2022 Option B. Vitamin C:</li><li>\u2022 scurvy</li><li>\u2022 Option C. Vitamin D: Vitamin D deficiency causes osteomalacia (in adults) or rickets (in children), leading to bone pain and weakness but not neurological symptoms.</li><li>\u2022 Option C. Vitamin D:</li><li>\u2022 osteomalacia</li><li>\u2022 rickets</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 Wernicke's encephalopathy is caused by Vitamin B1 (thiamine) deficiency , commonly seen in chronic alcoholics. The classic triad includes:</li><li>\u27a4 Wernicke's encephalopathy</li><li>\u27a4 Vitamin B1 (thiamine) deficiency</li><li>\u27a4 Confusion Ophthalmoplegia (e.g., nystagmus) Ataxia</li><li>\u27a4 Confusion</li><li>\u27a4 Confusion</li><li>\u27a4 Ophthalmoplegia (e.g., nystagmus)</li><li>\u27a4 Ophthalmoplegia</li><li>\u27a4 Ataxia</li><li>\u27a4 Ataxia</li><li>\u27a4 Immediate thiamine supplementation is crucial to prevent progression to Korsakoff syndrome.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "1508df52",
      "audio": ""
    },
    {
      "text": "A 6-month-old male infant is brought to the clinic with hypotonia, seizures, and sparse light colored hair. Upon further investigation, laboratory results show abnormal serum levels of a specific mineral, and a copper-transport protein. What is your diagnosis:",
      "options": [
        {
          "label": "A",
          "text": "Menke\u2019s disease",
          "correct": true
        },
        {
          "label": "B",
          "text": "Wilson\u2019s disease",
          "correct": false
        },
        {
          "label": "C",
          "text": "Von gierke\u2019s disease",
          "correct": false
        },
        {
          "label": "D",
          "text": "Wolman\u2019s disease",
          "correct": false
        }
      ],
      "correct_answer": "A. Menke\u2019s disease",
      "question_images": [],
      "explanation_images": [
        "https://cerebellum-web-static.s3.amazonaws.com/media/public/Screenshot%202024-12-18%20132345.jpg"
      ],
      "explanation": "<p><strong>Ans. A) Menke\u2019s disease</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation</li><li>\u2022 Menke\u2019s disease (also called Menkes kinky hair disease ) is a rare X-linked recessive disorder caused by mutations in the ATP7A gene , which is responsible for copper transport. This leads to a copper deficiency in various tissues despite its accumulation in others.</li><li>\u2022 Menke\u2019s disease</li><li>\u2022 Menkes kinky hair disease</li><li>\u2022 X-linked recessive disorder</li><li>\u2022 ATP7A gene</li><li>\u2022 copper deficiency</li><li>\u2022 Key Features of Menke\u2019s Disease:</li><li>\u2022 Key Features of Menke\u2019s Disease:</li><li>\u2022 1. Clinical Presentation :</li><li>\u2022 1. Clinical Presentation</li><li>\u2022 Hypotonia (poor muscle tone) Seizures Sparse, light-colored, and brittle (\"kinky\") hair \u2013 Due to a lack of tyrosinase , which is copper-dependent for melanin production. Developmental delay and growth retardation Failure to thrive</li><li>\u2022 Hypotonia (poor muscle tone)</li><li>\u2022 Hypotonia</li><li>\u2022 Seizures</li><li>\u2022 Seizures</li><li>\u2022 Sparse, light-colored, and brittle (\"kinky\") hair \u2013 Due to a lack of tyrosinase , which is copper-dependent for melanin production.</li><li>\u2022 Sparse, light-colored, and brittle (\"kinky\") hair</li><li>\u2022 tyrosinase</li><li>\u2022 Developmental delay and growth retardation</li><li>\u2022 Developmental delay and growth retardation</li><li>\u2022 Failure to thrive</li><li>\u2022 Failure to thrive</li><li>\u2022 2. Pathophysiology :</li><li>\u2022 2. Pathophysiology</li><li>\u2022 Copper cannot be transported properly from intestinal cells to the bloodstream. This leads to low serum copper levels and low ceruloplasmin (a copper-carrying protein). Copper-dependent enzymes like lysyl oxidase (collagen crosslinking) and tyrosinase (melanin production) are impaired.</li><li>\u2022 Copper cannot be transported properly from intestinal cells to the bloodstream.</li><li>\u2022 This leads to low serum copper levels and low ceruloplasmin (a copper-carrying protein).</li><li>\u2022 low serum copper levels</li><li>\u2022 low ceruloplasmin</li><li>\u2022 Copper-dependent enzymes like lysyl oxidase (collagen crosslinking) and tyrosinase (melanin production) are impaired.</li><li>\u2022 lysyl oxidase</li><li>\u2022 tyrosinase</li><li>\u2022 3. Characteristic Hair :</li><li>\u2022 3. Characteristic Hair</li><li>\u2022 Hair becomes brittle, depigmented, and resembles \"steel wool\" or \"kinky\" strands.</li><li>\u2022 Hair becomes brittle, depigmented, and resembles \"steel wool\" or \"kinky\" strands.</li><li>\u2022 \"steel wool\"</li><li>\u2022 \"kinky\"</li><li>\u2022 Other Options:</li><li>\u2022 Other Options:</li><li>\u2022 Option B. Wilson\u2019s disease:</li><li>\u2022 Option B. Wilson\u2019s disease:</li><li>\u2022 Wilson's disease involves copper accumulation due to ATP7B gene mutations, leading to liver and brain damage. Presents later (childhood/adolescence) with Kayser-Fleischer rings , liver disease, and neurological symptoms. Serum copper and ceruloplasmin are low, but tissue copper (liver/brain) is high.</li><li>\u2022 Wilson's disease involves copper accumulation due to ATP7B gene mutations, leading to liver and brain damage.</li><li>\u2022 copper accumulation</li><li>\u2022 Presents later (childhood/adolescence) with Kayser-Fleischer rings , liver disease, and neurological symptoms.</li><li>\u2022 Kayser-Fleischer rings</li><li>\u2022 Serum copper and ceruloplasmin are low, but tissue copper (liver/brain) is high.</li><li>\u2022 Serum copper and ceruloplasmin are low, but tissue copper (liver/brain) is high.</li><li>\u2022 Option C. Von Gierke\u2019s disease:</li><li>\u2022 Option C. Von Gierke\u2019s disease:</li><li>\u2022 A glycogen storage disorder due to glucose-6-phosphatase deficiency . Presents with hypoglycemia , hepatomegaly, and lactic acidosis, not copper abnormalities or hair changes.</li><li>\u2022 A glycogen storage disorder due to glucose-6-phosphatase deficiency .</li><li>\u2022 glucose-6-phosphatase deficiency</li><li>\u2022 Presents with hypoglycemia , hepatomegaly, and lactic acidosis, not copper abnormalities or hair changes.</li><li>\u2022 hypoglycemia</li><li>\u2022 Option D. Wolman\u2019s disease:</li><li>\u2022 Option D. Wolman\u2019s disease:</li><li>\u2022 A lysosomal storage disorder involving acid lipase deficiency . Presents with hepatosplenomegaly, failure to thrive, and adrenal calcification but not copper-related symptoms or hair abnormalities.</li><li>\u2022 A lysosomal storage disorder involving acid lipase deficiency .</li><li>\u2022 acid lipase deficiency</li><li>\u2022 Presents with hepatosplenomegaly, failure to thrive, and adrenal calcification but not copper-related symptoms or hair abnormalities.</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 Menke\u2019s disease is characterized by:</li><li>\u27a4 Menke\u2019s disease</li><li>\u27a4 Hypotonia , seizures , and growth retardation Sparse, light-colored, \"kinky\" hair Low serum copper and ceruloplasmin</li><li>\u27a4 Hypotonia , seizures , and growth retardation</li><li>\u27a4 Hypotonia</li><li>\u27a4 seizures</li><li>\u27a4 growth retardation</li><li>\u27a4 Sparse, light-colored, \"kinky\" hair</li><li>\u27a4 Sparse, light-colored, \"kinky\" hair</li><li>\u27a4 Low serum copper and ceruloplasmin</li><li>\u27a4 Low serum copper and ceruloplasmin</li><li>\u27a4 Defective copper transport due to mutations in ATP7A .</li><li>\u27a4 copper transport</li><li>\u27a4 ATP7A</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "0a9e343d",
      "audio": ""
    },
    {
      "text": "A teenager suffering from the deficiency of muscle phosphorylase is getting examined by a rubber ball squeezing test while exercising her forearm. Which of following statements will be true for this patient compared to a normal person?",
      "options": [
        {
          "label": "A",
          "text": "Exercise endurance",
          "correct": false
        },
        {
          "label": "B",
          "text": "\u2191 blood glucose in the blood drawn from the exercising forearm vein.",
          "correct": false
        },
        {
          "label": "C",
          "text": "\u2191 blood lactate in the blood drawn from the exercising forearm vein.",
          "correct": false
        },
        {
          "label": "D",
          "text": "Relatively \u2193 blood lactate in the blood drawn from the exercising forearm vein.",
          "correct": true
        }
      ],
      "correct_answer": "D. Relatively \u2193 blood lactate in the blood drawn from the exercising forearm vein.",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. D) Relatively \u2193 blood lactate in the blood drawn from the exercising forearm vein.</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 In a patient with muscle phosphorylase deficiency, also known as McArdle's disease , the breakdown of glycogen in muscles is impaired. Muscle phosphorylase is required to convert glycogen into glucose-1-phosphate, which is then converted into glucose-6-phosphate to enter glycolysis. Under normal conditions, during exercise (anaerobic conditions), glycolysis produces pyruvate, which is converted into lactate and enters the blood. This leads to an increase in blood lactate levels in a normal person.</li><li>\u2022 McArdle's disease</li><li>\u2022 lactate</li><li>\u2022 However, in McArdle's disease:</li><li>\u2022 Glycogen cannot be broken down due to the lack of muscle phosphorylase. This means glucose-6-phosphate is not formed, and glycolysis cannot proceed efficiently. As a result, there is no significant lactate production during exercise. Blood lactate levels, therefore, remain relatively low compared to normal individuals.</li><li>\u2022 Glycogen cannot be broken down due to the lack of muscle phosphorylase.</li><li>\u2022 This means glucose-6-phosphate is not formed, and glycolysis cannot proceed efficiently.</li><li>\u2022 As a result, there is no significant lactate production during exercise.</li><li>\u2022 no significant lactate production</li><li>\u2022 Blood lactate levels, therefore, remain relatively low compared to normal individuals.</li><li>\u2022 Thus, the characteristic feature of McArdle's disease is the absence of a rise in blood lactate during exercise.</li><li>\u2022 characteristic feature of McArdle's disease</li><li>\u2022 Other Options:</li><li>\u2022 Other Options:</li><li>\u2022 Option A. Exercise endurance: Patients with McArdle's disease have poor exercise endurance because they cannot mobilize glycogen for energy production in muscles. This option does not directly describe the blood lactate changes.</li><li>\u2022 Option A. Exercise endurance:</li><li>\u2022 Option B. \u2191 blood glucose in the blood drawn from the exercising forearm vein: Blood glucose is primarily regulated by liver glycogenolysis and gluconeogenesis, not muscle glycogen breakdown. McArdle's disease affects muscle phosphorylase, not liver phosphorylase, so this statement is incorrect.</li><li>\u2022 Option B. \u2191 blood glucose in the blood drawn from the exercising forearm vein:</li><li>\u2022 Option C. \u2191 blood lactate in the blood drawn from the exercising forearm vein: In normal individuals, blood lactate increases during exercise due to glycolysis in muscles. In McArdle's disease, muscle phosphorylase deficiency prevents glycogenolysis and lactate production, so blood lactate does not increase. This option is incorrect.</li><li>\u2022 Option C. \u2191 blood lactate in the blood drawn from the exercising forearm vein:</li><li>\u2022 not</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 The characteristic feature of McArdle's disease (muscle phosphorylase deficiency) is the absence of a rise in blood lactate during exercise due to impaired glycogen breakdown in muscles.</li><li>\u27a4 characteristic feature</li><li>\u27a4 the absence of a rise in blood lactate</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "d78c108d",
      "audio": ""
    },
    {
      "text": "A young boy comes to the clinic with coarse facial features, an enlarged abdomen, a prominent forehead, heart valve thickening, enlarged liver and spleen, and hearing difficulties. Notably, there is no haziness in his corneas. What is the most likely diagnosis?",
      "options": [
        {
          "label": "A",
          "text": "Gaucher's disease",
          "correct": false
        },
        {
          "label": "B",
          "text": "Hunter's syndrome",
          "correct": true
        },
        {
          "label": "C",
          "text": "Hurler\u2019s disease",
          "correct": false
        },
        {
          "label": "D",
          "text": "Niemann-Pick disease",
          "correct": false
        }
      ],
      "correct_answer": "B. Hunter's syndrome",
      "question_images": [],
      "explanation_images": [
        "https://cerebellum-web-static.s3.amazonaws.com/media/public/Screenshot%202024-12-18%20111637.jpg"
      ],
      "explanation": "<p><strong>Ans. B) Hunter's syndrome</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 The clinical presentation described\u2014 coarse facial features , enlarged liver and spleen (hepatosplenomegaly), prominent forehead , heart valve thickening , and hearing difficulties \u2014points toward a mucopolysaccharidosis (MPS) disorder. The key detail that helps differentiate the specific diagnosis is \"no haziness in his corneas\" :</li><li>\u2022 coarse facial features</li><li>\u2022 prominent forehead</li><li>\u2022 heart valve thickening</li><li>\u2022 hearing difficulties</li><li>\u2022 mucopolysaccharidosis (MPS)</li><li>\u2022 \"no haziness in his corneas\"</li><li>\u2022 Hunter's Syndrome (MPS II):</li><li>\u2022 Hunter's Syndrome (MPS II):</li><li>\u2022 Hunter\u2019s syndrome is an X-linked recessive lysosomal storage disorder caused by a deficiency of the enzyme iduronate-2-sulfatase . It leads to the accumulation of glycosaminoglycans (GAGs), including dermatan sulfate and heparan sulfate. Characteristic features include: Coarse facial features Hepatosplenomegaly (enlarged liver and spleen) Heart valve thickening Hearing difficulties No corneal clouding (key differentiating feature from Hurler\u2019s syndrome) Death typically occurs in the second decade of life.</li><li>\u2022 Hunter\u2019s syndrome is an X-linked recessive lysosomal storage disorder caused by a deficiency of the enzyme iduronate-2-sulfatase . It leads to the accumulation of glycosaminoglycans (GAGs), including dermatan sulfate and heparan sulfate. Characteristic features include: Coarse facial features Hepatosplenomegaly (enlarged liver and spleen) Heart valve thickening Hearing difficulties No corneal clouding (key differentiating feature from Hurler\u2019s syndrome) Death typically occurs in the second decade of life.</li><li>\u2022 X-linked recessive</li><li>\u2022 iduronate-2-sulfatase</li><li>\u2022 It leads to the accumulation of glycosaminoglycans (GAGs), including dermatan sulfate and heparan sulfate. Characteristic features include: Coarse facial features Hepatosplenomegaly (enlarged liver and spleen) Heart valve thickening Hearing difficulties No corneal clouding (key differentiating feature from Hurler\u2019s syndrome) Death typically occurs in the second decade of life.</li><li>\u2022 It leads to the accumulation of glycosaminoglycans (GAGs), including dermatan sulfate and heparan sulfate.</li><li>\u2022 Characteristic features include: Coarse facial features Hepatosplenomegaly (enlarged liver and spleen) Heart valve thickening Hearing difficulties No corneal clouding (key differentiating feature from Hurler\u2019s syndrome)</li><li>\u2022 Coarse facial features Hepatosplenomegaly (enlarged liver and spleen) Heart valve thickening Hearing difficulties No corneal clouding (key differentiating feature from Hurler\u2019s syndrome)</li><li>\u2022 Coarse facial features</li><li>\u2022 Hepatosplenomegaly (enlarged liver and spleen)</li><li>\u2022 Heart valve thickening</li><li>\u2022 Hearing difficulties</li><li>\u2022 Hearing difficulties</li><li>\u2022 No corneal clouding (key differentiating feature from Hurler\u2019s syndrome)</li><li>\u2022 No corneal clouding</li><li>\u2022 Death typically occurs in the second decade of life.</li><li>\u2022 second decade</li><li>\u2022 Other Options:</li><li>\u2022 Other Options:</li><li>\u2022 Option A. Gaucher's disease: Caused by a deficiency of beta-glucocerebrosidase , leading to glucocerebroside accumulation. It primarily causes hepatosplenomegaly, bone pain, and neurological symptoms but does not cause coarse facial features or heart valve thickening .</li><li>\u2022 Option A. Gaucher's disease:</li><li>\u2022 beta-glucocerebrosidase</li><li>\u2022 not cause coarse facial features or heart valve thickening</li><li>\u2022 Option C. Hurler\u2019s disease: Hurler\u2019s syndrome shares similar features but is caused by a deficiency of alpha-L-iduronidase . Unlike Hunter\u2019s syndrome, Hurler\u2019s presents with corneal clouding , which is absent in this case.</li><li>\u2022 Option C. Hurler\u2019s disease:</li><li>\u2022 alpha-L-iduronidase</li><li>\u2022 corneal clouding</li><li>\u2022 Option D. Niemann-Pick disease: Caused by a deficiency of sphingomyelinase . It presents with hepatosplenomegaly and neurological symptoms but does not typically include coarse facial features or heart valve thickening.</li><li>\u2022 Option D. Niemann-Pick disease:</li><li>\u2022 sphingomyelinase</li><li>\u2022 Note:</li><li>\u2022 Note:</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 The absence of corneal clouding and the presence of coarse facial features, hepatosplenomegaly, and hearing difficulties point to Hunter's syndrome (MPS II) , an X-linked recessive disorder caused by a deficiency of iduronate-2-sulfatase .</li><li>\u27a4 absence of corneal clouding</li><li>\u27a4 coarse facial features, hepatosplenomegaly, and hearing difficulties</li><li>\u27a4 Hunter's syndrome (MPS II)</li><li>\u27a4 X-linked recessive</li><li>\u27a4 iduronate-2-sulfatase</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "034bca5b",
      "audio": ""
    },
    {
      "text": "A 50-year-old man who drank too much alcohol fell in the street. He was quickly taken to the hospital. What is the first line treatment to be given to this patient in ER?",
      "options": [
        {
          "label": "A",
          "text": "Vitamin B1",
          "correct": true
        },
        {
          "label": "B",
          "text": "Glucose",
          "correct": false
        },
        {
          "label": "C",
          "text": "Fructose",
          "correct": false
        },
        {
          "label": "D",
          "text": "Vitamin B6",
          "correct": false
        }
      ],
      "correct_answer": "A. Vitamin B1",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. A) Vitamin B1</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 In patients with alcohol intoxication , there is a high risk of thiamine (Vitamin B1) deficiency , which can cause or worsen a condition known as Wernicke's encephalopathy . Wernicke\u2019s encephalopathy is an acute neurological emergency characterized by:</li><li>\u2022 alcohol intoxication</li><li>\u2022 thiamine (Vitamin B1) deficiency</li><li>\u2022 Wernicke's encephalopathy</li><li>\u2022 Confusion Ataxia (loss of coordination) Ophthalmoplegia (eye muscle paralysis)</li><li>\u2022 Confusion</li><li>\u2022 Confusion</li><li>\u2022 Ataxia (loss of coordination)</li><li>\u2022 Ataxia</li><li>\u2022 Ophthalmoplegia (eye muscle paralysis)</li><li>\u2022 Ophthalmoplegia</li><li>\u2022 Role of Thiamine (Vitamin B1):</li><li>\u2022 Role of Thiamine (Vitamin B1):</li><li>\u2022 Thiamine is a cofactor for several important enzymes, including pyruvate dehydrogenase , which is required for the conversion of pyruvate to acetyl-CoA in the link reaction of glucose metabolism. In thiamine deficiency, if glucose is administered before thiamine , pyruvate accumulates and is converted to lactate , leading to lactic acidosis and worsening the patient's condition.</li><li>\u2022 Thiamine is a cofactor for several important enzymes, including pyruvate dehydrogenase , which is required for the conversion of pyruvate to acetyl-CoA in the link reaction of glucose metabolism.</li><li>\u2022 pyruvate dehydrogenase</li><li>\u2022 conversion of pyruvate to acetyl-CoA</li><li>\u2022 In thiamine deficiency, if glucose is administered before thiamine , pyruvate accumulates and is converted to lactate , leading to lactic acidosis and worsening the patient's condition.</li><li>\u2022 before thiamine</li><li>\u2022 lactate</li><li>\u2022 lactic acidosis</li><li>\u2022 Treatment Protocol:</li><li>\u2022 Treatment Protocol:</li><li>\u2022 Administer Vitamin B1 (Thiamine) first to prevent Wernicke\u2019s encephalopathy and lactic acidosis. After thiamine, glucose can be administered slowly and gradually to restore energy balance without causing pyruvate accumulation.</li><li>\u2022 Administer Vitamin B1 (Thiamine) first to prevent Wernicke\u2019s encephalopathy and lactic acidosis.</li><li>\u2022 Administer Vitamin B1 (Thiamine) first</li><li>\u2022 After thiamine, glucose can be administered slowly and gradually to restore energy balance without causing pyruvate accumulation.</li><li>\u2022 glucose</li><li>\u2022 Other Options:</li><li>\u2022 Other Options:</li><li>\u2022 Option B. Glucose: Administering glucose before thiamine in a patient with thiamine deficiency can worsen lactic acidosis. Therefore, glucose is given only after thiamine .</li><li>\u2022 Option B. Glucose:</li><li>\u2022 before thiamine</li><li>\u2022 after thiamine</li><li>\u2022 Option C. Fructose: Fructose is not used as a first-line treatment for alcohol intoxication and does not address thiamine deficiency or energy metabolism.</li><li>\u2022 Option C. Fructose:</li><li>\u2022 Option D. Vitamin B6: Vitamin B6 is involved in amino acid metabolism but does not address the acute issue of thiamine deficiency and Wernicke's encephalopathy.</li><li>\u2022 Option D. Vitamin B6:</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 In cases of alcohol intoxication , the first-line treatment is Vitamin B1 (Thiamine) to prevent Wernicke's encephalopathy and lactic acidosis. Glucose administration should always follow thiamine supplementation.</li><li>\u27a4 alcohol intoxication</li><li>\u27a4 Vitamin B1 (Thiamine)</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "7117a8e0",
      "audio": ""
    },
    {
      "text": "ChIP is used for:",
      "options": [
        {
          "label": "A",
          "text": "Protein DNA interactions and histone modifications",
          "correct": true
        },
        {
          "label": "B",
          "text": "Study mutations",
          "correct": false
        },
        {
          "label": "C",
          "text": "Amplify DNA",
          "correct": false
        },
        {
          "label": "D",
          "text": "Movement of proteins",
          "correct": false
        }
      ],
      "correct_answer": "A. Protein DNA interactions and histone modifications",
      "question_images": [],
      "explanation_images": [
        "https://cerebellum-web-static.s3.amazonaws.com/media/public/Screenshot%202024-12-18%20131326.jpg"
      ],
      "explanation": "<p><strong>Ans. A) Protein DNA interactions and histone modifications</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation</li><li>\u2022 ChIP, or Chromatin Immunoprecipitation , is a technique used to investigate protein-DNA interactions and to study histone modifications.</li><li>\u2022 Chromatin Immunoprecipitation</li><li>\u2022 ChIP works by selectively isolating proteins bound to DNA using antibodies that recognize the target proteins (antigens). In the process: Enzymes cleave the DNA at specific points to break it into smaller fragments. An antigen-antibody reaction occurs where antibodies bind to proteins attached to DNA. This protein-DNA complex is then precipitated, allowing researchers to analyze the specific DNA regions associated with proteins. It is particularly useful for identifying histone modifications or transcription factors bound to specific regions of the genome.</li><li>\u2022 ChIP works by selectively isolating proteins bound to DNA using antibodies that recognize the target proteins (antigens).</li><li>\u2022 antibodies</li><li>\u2022 In the process: Enzymes cleave the DNA at specific points to break it into smaller fragments. An antigen-antibody reaction occurs where antibodies bind to proteins attached to DNA. This protein-DNA complex is then precipitated, allowing researchers to analyze the specific DNA regions associated with proteins.</li><li>\u2022 Enzymes cleave the DNA at specific points to break it into smaller fragments. An antigen-antibody reaction occurs where antibodies bind to proteins attached to DNA. This protein-DNA complex is then precipitated, allowing researchers to analyze the specific DNA regions associated with proteins.</li><li>\u2022 Enzymes cleave the DNA at specific points to break it into smaller fragments.</li><li>\u2022 An antigen-antibody reaction occurs where antibodies bind to proteins attached to DNA.</li><li>\u2022 antigen-antibody reaction</li><li>\u2022 This protein-DNA complex is then precipitated, allowing researchers to analyze the specific DNA regions associated with proteins.</li><li>\u2022 specific DNA regions</li><li>\u2022 It is particularly useful for identifying histone modifications or transcription factors bound to specific regions of the genome.</li><li>\u2022 ChIP can also be followed by other methods like sequencing (ChIP-Seq) or microarray analysis (ChIP-on-chip) to identify and map protein-DNA interactions on a genome-wide scale.</li><li>\u2022 Other Options:</li><li>\u2022 Other Options:</li><li>\u2022 Option B. Study mutations: While ChIP-on-chip (a microarray-based approach) can detect comparative changes, ChIP itself is not primarily used for studying mutations. Techniques like sequencing or PCR are better suited for detecting mutations.</li><li>\u2022 Option B. Study mutations:</li><li>\u2022 ChIP</li><li>\u2022 Option C. Amplify DNA: DNA amplification is primarily done using Polymerase Chain Reaction (PCR) , not ChIP. ChIP isolates protein-DNA complexes but does not amplify DNA on its own.</li><li>\u2022 Option C. Amplify DNA:</li><li>\u2022 Polymerase Chain Reaction (PCR)</li><li>\u2022 Option D. Movement of proteins: The movement or localization of proteins within cells is studied using techniques like immunofluorescence or Western blotting , not ChIP.</li><li>\u2022 Option D. Movement of proteins:</li><li>\u2022 immunofluorescence</li><li>\u2022 Western blotting</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 ChIP (Chromatin Immunoprecipitation) is a technique used to study protein-DNA interactions and histone modifications by isolating specific protein-DNA complexes using antibodies.</li><li>\u27a4 ChIP (Chromatin Immunoprecipitation)</li><li>\u27a4 protein-DNA interactions</li><li>\u27a4 histone modifications</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "a717250f",
      "audio": ""
    },
    {
      "text": "A 3-year-old boy presents to the outpatient clinic with a swollen abdomen and failure to thrive. On examination, his liver is palpable 4 cm below the right costal margin, and he has a doll-like face with chubby cheeks. Laboratory investigations reveal fasting hypoglycemia, lactic acidosis, and hyperuricemia. A liver biopsy demonstrates increased glycogen storage with normal structure. Which enzyme deficiency is most likely responsible for this patient's clinical presentation?",
      "options": [
        {
          "label": "A",
          "text": "Glucokinase",
          "correct": false
        },
        {
          "label": "B",
          "text": "Muscle glycogen phosphorylase",
          "correct": false
        },
        {
          "label": "C",
          "text": "Glucose-6-phosphatase",
          "correct": true
        },
        {
          "label": "D",
          "text": "Phosphofructokinase",
          "correct": false
        }
      ],
      "correct_answer": "C. Glucose-6-phosphatase",
      "question_images": [],
      "explanation_images": [
        "https://cerebellum-web-static.s3.amazonaws.com/media/public/Screenshot%202024-12-18%20131427.jpg"
      ],
      "explanation": "<p><strong>Ans. C) Glucose-6-phosphatase</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation</li><li>\u2022 The clinical presentation of this patient is characteristic of Von Gierke Disease (Glycogen Storage Disease Type I) , caused by a deficiency of the enzyme glucose-6-phosphatase .</li><li>\u2022 Von Gierke Disease (Glycogen Storage Disease Type I)</li><li>\u2022 glucose-6-phosphatase</li><li>\u2022 Key Features of Von Gierke Disease : Fasting hypoglycemia : Glucose-6-phosphatase catalyzes the final step in gluconeogenesis and glycogenolysis (conversion of glucose-6-phosphate to glucose). Without this enzyme, the liver cannot release glucose into the bloodstream during fasting, leading to severe hypoglycemia. Lactic acidosis : Accumulation of glucose-6-phosphate diverts metabolism toward glycolysis, producing pyruvate and subsequently lactic acid. Hyperuricemia : Excess glucose-6-phosphate increases purine metabolism, leading to uric acid buildup. Hepatomegaly : Glycogen accumulates in the liver because it cannot be broken down and released as free glucose. The structure of glycogen remains normal. Doll-like face with chubby cheeks : Due to increased fat synthesis and deposition from the excess glucose-6-phosphate. Biochemical Mechanism : Enzyme Deficiency : Glucose-6-phosphatase deficiency prevents the conversion of glucose-6-phosphate to glucose. Pathway Blockage : Gluconeogenesis and glycogenolysis both fail to release glucose into the blood.</li><li>\u2022 Key Features of Von Gierke Disease : Fasting hypoglycemia : Glucose-6-phosphatase catalyzes the final step in gluconeogenesis and glycogenolysis (conversion of glucose-6-phosphate to glucose). Without this enzyme, the liver cannot release glucose into the bloodstream during fasting, leading to severe hypoglycemia. Lactic acidosis : Accumulation of glucose-6-phosphate diverts metabolism toward glycolysis, producing pyruvate and subsequently lactic acid. Hyperuricemia : Excess glucose-6-phosphate increases purine metabolism, leading to uric acid buildup. Hepatomegaly : Glycogen accumulates in the liver because it cannot be broken down and released as free glucose. The structure of glycogen remains normal. Doll-like face with chubby cheeks : Due to increased fat synthesis and deposition from the excess glucose-6-phosphate.</li><li>\u2022 Key Features of Von Gierke Disease</li><li>\u2022 Fasting hypoglycemia : Glucose-6-phosphatase catalyzes the final step in gluconeogenesis and glycogenolysis (conversion of glucose-6-phosphate to glucose). Without this enzyme, the liver cannot release glucose into the bloodstream during fasting, leading to severe hypoglycemia. Lactic acidosis : Accumulation of glucose-6-phosphate diverts metabolism toward glycolysis, producing pyruvate and subsequently lactic acid. Hyperuricemia : Excess glucose-6-phosphate increases purine metabolism, leading to uric acid buildup. Hepatomegaly : Glycogen accumulates in the liver because it cannot be broken down and released as free glucose. The structure of glycogen remains normal. Doll-like face with chubby cheeks : Due to increased fat synthesis and deposition from the excess glucose-6-phosphate.</li><li>\u2022 Fasting hypoglycemia : Glucose-6-phosphatase catalyzes the final step in gluconeogenesis and glycogenolysis (conversion of glucose-6-phosphate to glucose). Without this enzyme, the liver cannot release glucose into the bloodstream during fasting, leading to severe hypoglycemia.</li><li>\u2022 Fasting hypoglycemia</li><li>\u2022 Lactic acidosis : Accumulation of glucose-6-phosphate diverts metabolism toward glycolysis, producing pyruvate and subsequently lactic acid.</li><li>\u2022 Lactic acidosis</li><li>\u2022 Hyperuricemia : Excess glucose-6-phosphate increases purine metabolism, leading to uric acid buildup.</li><li>\u2022 Hyperuricemia</li><li>\u2022 Hepatomegaly : Glycogen accumulates in the liver because it cannot be broken down and released as free glucose. The structure of glycogen remains normal.</li><li>\u2022 Hepatomegaly</li><li>\u2022 Doll-like face with chubby cheeks : Due to increased fat synthesis and deposition from the excess glucose-6-phosphate.</li><li>\u2022 Doll-like face with chubby cheeks</li><li>\u2022 Biochemical Mechanism : Enzyme Deficiency : Glucose-6-phosphatase deficiency prevents the conversion of glucose-6-phosphate to glucose. Pathway Blockage : Gluconeogenesis and glycogenolysis both fail to release glucose into the blood.</li><li>\u2022 Biochemical Mechanism</li><li>\u2022 Enzyme Deficiency : Glucose-6-phosphatase deficiency prevents the conversion of glucose-6-phosphate to glucose. Pathway Blockage : Gluconeogenesis and glycogenolysis both fail to release glucose into the blood.</li><li>\u2022 Enzyme Deficiency : Glucose-6-phosphatase deficiency prevents the conversion of glucose-6-phosphate to glucose.</li><li>\u2022 Enzyme Deficiency</li><li>\u2022 Pathway Blockage : Gluconeogenesis and glycogenolysis both fail to release glucose into the blood.</li><li>\u2022 Pathway Blockage</li><li>\u2022 Other Options:</li><li>\u2022 Other Options:</li><li>\u2022 Option A. Glucokinase: Glucokinase is involved in glucose sensing and glycolysis. Deficiency would affect glucose metabolism in the liver but would not cause glycogen accumulation or the severe fasting hypoglycemia seen here.</li><li>\u2022 Option A. Glucokinase:</li><li>\u2022 Option B. Muscle glycogen phosphorylase: Deficiency of muscle glycogen phosphorylase causes McArdle Disease (GSD Type V) , characterized by muscle weakness, cramps, and myoglobinuria during exercise. It does not affect the liver or cause fasting hypoglycemia.</li><li>\u2022 Option B. Muscle glycogen phosphorylase:</li><li>\u2022 McArdle Disease (GSD Type V)</li><li>\u2022 Option D. Phosphofructokinase: Phosphofructokinase deficiency causes Tarui Disease (GSD Type VII) , leading to muscle weakness and hemolysis. It does not cause hepatomegaly, lactic acidosis, or fasting hypoglycemia.</li><li>\u2022 Option D. Phosphofructokinase:</li><li>\u2022 Tarui Disease (GSD Type VII)</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 Von Gierke Disease (GSD Type I) is caused by a deficiency of glucose-6-phosphatase , leading to severe fasting hypoglycemia, lactic acidosis, hepatomegaly , and a characteristic doll-like face with chubby cheeks.</li><li>\u27a4 Von Gierke Disease (GSD Type I)</li><li>\u27a4 glucose-6-phosphatase</li><li>\u27a4 severe fasting hypoglycemia, lactic acidosis, hepatomegaly</li><li>\u27a4 doll-like face</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "8b1cc19a",
      "audio": ""
    },
    {
      "text": "Two children with genetic issues related to fructose processing saw the same doctor. One child\u2019s parents were told to limit fructose in the diet due to health concerns. However, the second child's parents were told their kid wouldn't likely have any problems, even though both kids had fructose in their blood and urine. Based on this, what enzyme conversion is deficient in the second child?",
      "options": [
        {
          "label": "A",
          "text": "Conversion of fructose into fructose-1-phosphate",
          "correct": true
        },
        {
          "label": "B",
          "text": "Changing of fructose-1-phosphate into glyceraldehyde",
          "correct": false
        },
        {
          "label": "C",
          "text": "Changing of fructose-1-phosphate into dihydroxyacetone-phosphate",
          "correct": false
        },
        {
          "label": "D",
          "text": "Conversion of glyceraldehyde into glyceraldehyde-3-phosphate",
          "correct": false
        }
      ],
      "correct_answer": "A. Conversion of fructose into fructose-1-phosphate",
      "question_images": [],
      "explanation_images": [
        "https://cerebellum-web-static.s3.amazonaws.com/media/public/Screenshot%202024-12-18%20124400.jpg"
      ],
      "explanation": "<p><strong>Ans. A) Conversion of fructose into fructose-1-phosphate</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation</li><li>\u2022 The second child\u2019s condition, where fructose appears in blood and urine but does not cause any health issues, is consistent with Essential Fructosuria . This condition is caused by a deficiency of the enzyme fructokinase .</li><li>\u2022 Essential Fructosuria</li><li>\u2022 fructokinase</li><li>\u2022 Fructokinase Role in Metabolism :</li><li>\u2022 Fructokinase Role in Metabolism</li><li>\u2022 Fructokinase catalyzes the conversion of fructose into fructose-1-phosphate . In its absence, fructose cannot be phosphorylated and remains in the bloodstream, where it is filtered by the kidneys and excreted in the urine.</li><li>\u2022 Fructokinase catalyzes the conversion of fructose into fructose-1-phosphate .</li><li>\u2022 fructose into fructose-1-phosphate</li><li>\u2022 In its absence, fructose cannot be phosphorylated and remains in the bloodstream, where it is filtered by the kidneys and excreted in the urine.</li><li>\u2022 Key Features of Essential Fructosuria :</li><li>\u2022 Key Features of Essential Fructosuria</li><li>\u2022 Benign Condition : It is an asymptomatic condition because fructose does not accumulate in toxic forms in the body. Fructose in Blood and Urine : Fructose appears in the blood (fructosemia) and urine (fructosuria) but causes no clinical symptoms. No Dietary Restrictions Needed : Unlike hereditary fructose intolerance (HFI), patients with essential fructosuria do not require dietary modifications.</li><li>\u2022 Benign Condition : It is an asymptomatic condition because fructose does not accumulate in toxic forms in the body.</li><li>\u2022 Benign Condition</li><li>\u2022 Fructose in Blood and Urine : Fructose appears in the blood (fructosemia) and urine (fructosuria) but causes no clinical symptoms.</li><li>\u2022 Fructose in Blood and Urine</li><li>\u2022 No Dietary Restrictions Needed : Unlike hereditary fructose intolerance (HFI), patients with essential fructosuria do not require dietary modifications.</li><li>\u2022 No Dietary Restrictions Needed</li><li>\u2022 Comparison with Hereditary Fructose Intolerance (HFI) :</li><li>\u2022 Comparison with Hereditary Fructose Intolerance (HFI)</li><li>\u2022 HFI is caused by a deficiency of aldolase B , which breaks down fructose-1-phosphate into glyceraldehyde and dihydroxyacetone-phosphate (DHAP). HFI leads to the accumulation of fructose-1-phosphate , which is toxic and causes symptoms such as jaundice, hepatomegaly, vomiting, and hypoglycemia when fructose is ingested. The first child likely has HFI (aldolase B deficiency) and requires dietary restrictions. The second child has Essential Fructosuria (fructokinase deficiency), which is benign and does not require treatment.</li><li>\u2022 HFI is caused by a deficiency of aldolase B , which breaks down fructose-1-phosphate into glyceraldehyde and dihydroxyacetone-phosphate (DHAP).</li><li>\u2022 aldolase B</li><li>\u2022 fructose-1-phosphate</li><li>\u2022 glyceraldehyde</li><li>\u2022 dihydroxyacetone-phosphate</li><li>\u2022 HFI leads to the accumulation of fructose-1-phosphate , which is toxic and causes symptoms such as jaundice, hepatomegaly, vomiting, and hypoglycemia when fructose is ingested. The first child likely has HFI (aldolase B deficiency) and requires dietary restrictions. The second child has Essential Fructosuria (fructokinase deficiency), which is benign and does not require treatment.</li><li>\u2022 fructose-1-phosphate</li><li>\u2022 The first child likely has HFI (aldolase B deficiency) and requires dietary restrictions. The second child has Essential Fructosuria (fructokinase deficiency), which is benign and does not require treatment.</li><li>\u2022 The first child likely has HFI (aldolase B deficiency) and requires dietary restrictions.</li><li>\u2022 first child</li><li>\u2022 HFI</li><li>\u2022 The second child has Essential Fructosuria (fructokinase deficiency), which is benign and does not require treatment.</li><li>\u2022 second child</li><li>\u2022 Essential Fructosuria</li><li>\u2022 Other Options:</li><li>\u2022 Other Options:</li><li>\u2022 Option B. Changing of fructose-1-phosphate into glyceraldehyde: This step is catalyzed by aldolase B and is defective in hereditary fructose intolerance , not in essential fructosuria.</li><li>\u2022 Option B. Changing of fructose-1-phosphate into glyceraldehyde:</li><li>\u2022 aldolase B</li><li>\u2022 hereditary fructose intolerance</li><li>\u2022 Option C. Changing of fructose-1-phosphate into dihydroxyacetone-phosphate: Also part of aldolase B function, affected in HFI.</li><li>\u2022 Option C. Changing of fructose-1-phosphate into dihydroxyacetone-phosphate:</li><li>\u2022 Option D. Conversion of glyceraldehyde into glyceraldehyde-3-phosphate: This step involves triose kinase and is not related to fructokinase deficiency or benign fructosuria.</li><li>\u2022 Option D. Conversion of glyceraldehyde into glyceraldehyde-3-phosphate:</li><li>\u2022 triose kinase</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 Essential Fructosuria is caused by a deficiency of fructokinase , leading to the inability to convert fructose into fructose-1-phosphate. It is a benign condition with no symptoms other than fructose excretion in urine.</li><li>\u27a4 Essential Fructosuria</li><li>\u27a4 fructokinase</li><li>\u27a4 benign condition</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "47f5c84b",
      "audio": ""
    },
    {
      "text": "A 5-day-old neonate is brought to the pediatric outpatient department with poor feeding, irritability, and lethargy. The parents mention a distinctive sweet odor emanating from the baby's urine. A metabolic disorder is suspected. Which of the following enzyme deficiencies is most consistent with this neonate's presentation?",
      "options": [
        {
          "label": "A",
          "text": "Phenylalanine hydroxylase",
          "correct": false
        },
        {
          "label": "B",
          "text": "Branched-chain \u03b1-ketoacid dehydrogenase complex.",
          "correct": true
        },
        {
          "label": "C",
          "text": "Glucose-6-phosphate dehydrogenase",
          "correct": false
        },
        {
          "label": "D",
          "text": "Uridine diphosphogalactose 4-epimerase",
          "correct": false
        }
      ],
      "correct_answer": "B. Branched-chain \u03b1-ketoacid dehydrogenase complex.",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. B) Branched-chain \u03b1-ketoacid dehydrogenase complex.</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation</li><li>\u2022 The clinical presentation described here is characteristic of Maple Syrup Urine Disease (MSUD) , a rare inherited metabolic disorder caused by a deficiency of the branched-chain \u03b1-ketoacid dehydrogenase complex (BCKDC) .</li><li>\u2022 Maple Syrup Urine Disease (MSUD)</li><li>\u2022 branched-chain \u03b1-ketoacid dehydrogenase complex (BCKDC)</li><li>\u2022 Key Clinical Features of MSUD : Distinctive Sweet Odor : The urine smells like maple syrup or burnt sugar, due to the accumulation of branched-chain amino acids (BCAAs) and their keto acids. Poor Feeding, Irritability, and Lethargy : Symptoms result from the accumulation of neurotoxic metabolites. Age of Onset : Symptoms typically appear within the first few days of life . Metabolic Crisis : If untreated, it can lead to seizures, developmental delay, and even death. Biochemical Basis of MSUD : The branched-chain \u03b1-ketoacid dehydrogenase complex (BCKDC) is required for the oxidative decarboxylation of the keto acids derived from the catabolism of branched-chain amino acids: Leucine Isoleucine Valine Deficiency of this enzyme leads to the accumulation of these amino acids and their keto acids in the blood, urine, and tissues, causing toxicity. Vitamin B1 Requirement : The BCKDC requires Thiamine (Vitamin B1) as a cofactor for its activity. In some milder cases, thiamine supplementation can help improve enzyme function.</li><li>\u2022 Key Clinical Features of MSUD : Distinctive Sweet Odor : The urine smells like maple syrup or burnt sugar, due to the accumulation of branched-chain amino acids (BCAAs) and their keto acids. Poor Feeding, Irritability, and Lethargy : Symptoms result from the accumulation of neurotoxic metabolites. Age of Onset : Symptoms typically appear within the first few days of life . Metabolic Crisis : If untreated, it can lead to seizures, developmental delay, and even death.</li><li>\u2022 Key Clinical Features of MSUD</li><li>\u2022 Distinctive Sweet Odor : The urine smells like maple syrup or burnt sugar, due to the accumulation of branched-chain amino acids (BCAAs) and their keto acids. Poor Feeding, Irritability, and Lethargy : Symptoms result from the accumulation of neurotoxic metabolites. Age of Onset : Symptoms typically appear within the first few days of life . Metabolic Crisis : If untreated, it can lead to seizures, developmental delay, and even death.</li><li>\u2022 Distinctive Sweet Odor : The urine smells like maple syrup or burnt sugar, due to the accumulation of branched-chain amino acids (BCAAs) and their keto acids.</li><li>\u2022 Distinctive Sweet Odor</li><li>\u2022 maple syrup</li><li>\u2022 branched-chain amino acids (BCAAs)</li><li>\u2022 Poor Feeding, Irritability, and Lethargy : Symptoms result from the accumulation of neurotoxic metabolites.</li><li>\u2022 Poor Feeding, Irritability, and Lethargy</li><li>\u2022 Age of Onset : Symptoms typically appear within the first few days of life .</li><li>\u2022 Age of Onset</li><li>\u2022 few days of life</li><li>\u2022 Metabolic Crisis : If untreated, it can lead to seizures, developmental delay, and even death.</li><li>\u2022 Metabolic Crisis</li><li>\u2022 Biochemical Basis of MSUD : The branched-chain \u03b1-ketoacid dehydrogenase complex (BCKDC) is required for the oxidative decarboxylation of the keto acids derived from the catabolism of branched-chain amino acids: Leucine Isoleucine Valine Deficiency of this enzyme leads to the accumulation of these amino acids and their keto acids in the blood, urine, and tissues, causing toxicity.</li><li>\u2022 Biochemical Basis of MSUD</li><li>\u2022 The branched-chain \u03b1-ketoacid dehydrogenase complex (BCKDC) is required for the oxidative decarboxylation of the keto acids derived from the catabolism of branched-chain amino acids: Leucine Isoleucine Valine Deficiency of this enzyme leads to the accumulation of these amino acids and their keto acids in the blood, urine, and tissues, causing toxicity.</li><li>\u2022 The branched-chain \u03b1-ketoacid dehydrogenase complex (BCKDC) is required for the oxidative decarboxylation of the keto acids derived from the catabolism of branched-chain amino acids: Leucine Isoleucine Valine</li><li>\u2022 branched-chain \u03b1-ketoacid dehydrogenase complex (BCKDC)</li><li>\u2022 oxidative decarboxylation</li><li>\u2022 Leucine Isoleucine Valine</li><li>\u2022 Leucine</li><li>\u2022 Leucine</li><li>\u2022 Isoleucine</li><li>\u2022 Isoleucine</li><li>\u2022 Valine</li><li>\u2022 Valine</li><li>\u2022 Deficiency of this enzyme leads to the accumulation of these amino acids and their keto acids in the blood, urine, and tissues, causing toxicity.</li><li>\u2022 Vitamin B1 Requirement : The BCKDC requires Thiamine (Vitamin B1) as a cofactor for its activity. In some milder cases, thiamine supplementation can help improve enzyme function.</li><li>\u2022 Vitamin B1 Requirement</li><li>\u2022 The BCKDC requires Thiamine (Vitamin B1) as a cofactor for its activity. In some milder cases, thiamine supplementation can help improve enzyme function.</li><li>\u2022 The BCKDC requires Thiamine (Vitamin B1) as a cofactor for its activity. In some milder cases, thiamine supplementation can help improve enzyme function.</li><li>\u2022 Thiamine (Vitamin B1)</li><li>\u2022 Other Options:</li><li>\u2022 Other Options:</li><li>\u2022 Option A. Phenylalanine hydroxylase: Deficiency of this enzyme causes Phenylketonuria (PKU) , characterized by a musty or mousy odor of urine, not a sweet odor.</li><li>\u2022 Option A. Phenylalanine hydroxylase:</li><li>\u2022 Phenylketonuria (PKU)</li><li>\u2022 musty or mousy odor</li><li>\u2022 Option C. Glucose-6-phosphate dehydrogenase : G6PD deficiency leads to hemolytic anemia triggered by oxidative stress (e.g., infections, drugs), not urine odor changes.</li><li>\u2022 Option C. Glucose-6-phosphate dehydrogenase</li><li>\u2022 hemolytic anemia</li><li>\u2022 Option D. Uridine diphosphogalactose 4-epimerase : Deficiency of this enzyme causes a rare form of galactosemia , presenting with jaundice, cataracts, and hepatomegaly, not sweet-smelling urine.</li><li>\u2022 Option D. Uridine diphosphogalactose 4-epimerase</li><li>\u2022 galactosemia</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 Maple Syrup Urine Disease (MSUD) is caused by a deficiency of the branched-chain \u03b1-ketoacid dehydrogenase complex , leading to the accumulation of branched-chain amino acids and their keto acids. The hallmark feature is a sweet maple syrup odor in the urine .</li><li>\u27a4 Maple Syrup Urine Disease (MSUD)</li><li>\u27a4 branched-chain \u03b1-ketoacid dehydrogenase complex</li><li>\u27a4 sweet maple syrup odor in the urine</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "16c08b6f",
      "audio": ""
    },
    {
      "text": "A 40-year-old male presents to the orthopedic clinic with complaints of chronic joint pain, especially in his knees and hips. On examination, his ear cartilage displays a bluish-black discoloration. Additionally, the patient has a history of recurrent kidney stones and mentions a progressive stiffening of his spine. Based on these clinical findings, which symptom is most characteristic of the likely inherited metabolic disorder?",
      "options": [
        {
          "label": "A",
          "text": "Hepatosplenomegaly",
          "correct": false
        },
        {
          "label": "B",
          "text": "Darkening of urine upon standing",
          "correct": true
        },
        {
          "label": "C",
          "text": "Lens dislocation",
          "correct": false
        },
        {
          "label": "D",
          "text": "Hypoglycemic episodes",
          "correct": false
        }
      ],
      "correct_answer": "B. Darkening of urine upon standing",
      "question_images": [],
      "explanation_images": [
        "https://cerebellum-web-static.s3.amazonaws.com/media/public/Screenshot%202024-12-18%20131725.jpg"
      ],
      "explanation": "<p><strong>Ans. B) Darkening of urine upon standing</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation</li><li>\u2022 The clinical findings described here\u2014 bluish-black discoloration of ear cartilage (ochronosis), chronic joint pain, progressive spinal stiffening, and recurrent kidney stones\u2014are characteristic of Alkaptonuria , an inherited metabolic disorder.</li><li>\u2022 bluish-black discoloration of ear cartilage</li><li>\u2022 Alkaptonuria</li><li>\u2022 Biochemical Basis of Alkaptonuria :</li><li>\u2022 Biochemical Basis of Alkaptonuria</li><li>\u2022 Alkaptonuria is caused by a deficiency of the enzyme homogentisate dioxygenase . This enzyme is involved in the breakdown of tyrosine and phenylalanine . Deficiency leads to accumulation of homogentisic acid (HGA) , which is excreted in urine and deposited in tissues.</li><li>\u2022 Alkaptonuria is caused by a deficiency of the enzyme homogentisate dioxygenase . This enzyme is involved in the breakdown of tyrosine and phenylalanine . Deficiency leads to accumulation of homogentisic acid (HGA) , which is excreted in urine and deposited in tissues.</li><li>\u2022 homogentisate dioxygenase</li><li>\u2022 This enzyme is involved in the breakdown of tyrosine and phenylalanine . Deficiency leads to accumulation of homogentisic acid (HGA) , which is excreted in urine and deposited in tissues.</li><li>\u2022 This enzyme is involved in the breakdown of tyrosine and phenylalanine .</li><li>\u2022 tyrosine</li><li>\u2022 phenylalanine</li><li>\u2022 Deficiency leads to accumulation of homogentisic acid (HGA) , which is excreted in urine and deposited in tissues.</li><li>\u2022 homogentisic acid (HGA)</li><li>\u2022 Key Features of Alkaptonuria :</li><li>\u2022 Key Features of Alkaptonuria</li><li>\u2022 Darkening of Urine : Homogentisic acid is oxidized upon standing, causing the urine to turn black \u2014a pathognomonic feature of alkaptonuria. Ochronosis : Deposition of homogentisic acid in connective tissues leads to bluish-black discoloration of cartilage, sclera, and skin. Chronic Joint Pain : Long-term deposition of homogentisic acid in joints causes degenerative arthritis , particularly in the spine , hips, and knees. Recurrent Kidney Stones : HGA can crystallize in the urine, contributing to kidney stone formation.</li><li>\u2022 Darkening of Urine : Homogentisic acid is oxidized upon standing, causing the urine to turn black \u2014a pathognomonic feature of alkaptonuria.</li><li>\u2022 Darkening of Urine</li><li>\u2022 black</li><li>\u2022 Ochronosis : Deposition of homogentisic acid in connective tissues leads to bluish-black discoloration of cartilage, sclera, and skin.</li><li>\u2022 Ochronosis</li><li>\u2022 bluish-black discoloration</li><li>\u2022 Chronic Joint Pain : Long-term deposition of homogentisic acid in joints causes degenerative arthritis , particularly in the spine , hips, and knees.</li><li>\u2022 Chronic Joint Pain</li><li>\u2022 degenerative arthritis</li><li>\u2022 spine</li><li>\u2022 Recurrent Kidney Stones : HGA can crystallize in the urine, contributing to kidney stone formation.</li><li>\u2022 Recurrent Kidney Stones : HGA can crystallize in the urine, contributing to kidney stone formation.</li><li>\u2022 Recurrent Kidney Stones</li><li>\u2022 Other Options:</li><li>\u2022 Other Options:</li><li>\u2022 Option A. Hepatosplenomegaly: Hepatosplenomegaly is associated with lysosomal storage disorders such as Gaucher disease or Niemann-Pick disease , not alkaptonuria.</li><li>\u2022 Option A. Hepatosplenomegaly:</li><li>\u2022 Gaucher disease</li><li>\u2022 Niemann-Pick disease</li><li>\u2022 Option C. Lens Dislocation: Lens dislocation (ectopia lentis) is characteristic of homocystinuria , not alkaptonuria.</li><li>\u2022 Option C. Lens Dislocation:</li><li>\u2022 homocystinuria</li><li>\u2022 Option D. Hypoglycemic Episodes: Hypoglycemia is seen in disorders such as glycogen storage diseases or gluconeogenesis defects , not in alkaptonuria.</li><li>\u2022 Option D. Hypoglycemic Episodes:</li><li>\u2022 glycogen storage diseases</li><li>\u2022 gluconeogenesis defects</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 Alkaptonuria is caused by a deficiency of homogentisate dioxygenase , leading to the accumulation of homogentisic acid . The darkening of urine upon standing is the most characteristic symptom of this condition. Other features include ochronosis (bluish-black discoloration of cartilage) and chronic degenerative arthritis.</li><li>\u27a4 Alkaptonuria</li><li>\u27a4 homogentisate dioxygenase</li><li>\u27a4 homogentisic acid</li><li>\u27a4 darkening of urine upon standing</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "49f47704",
      "audio": ""
    },
    {
      "text": "A 3-year-old boy is brought to the hospital with episodes of irritability, vomiting, and rapid breathing. The mother mentions that the symptoms seemed to worsen after high-protein meals. Laboratory findings indicate elevated ammonia levels in the blood. Citrulline cannot be found in plasma amino acid analysis, however his urinary orotic acid level is elevated. Given the clinical picture and the boy's age, an inherited metabolic disorder is suspected. Which enzyme reaction is most likely affected in this patient's condition? Conversion of ornithine to citrulline Conversion of citrulline to argininosuccinate Conversion of carbamoyl phosphate to citrulline Conversion of arginine to ornithine",
      "options": [
        {
          "label": "A",
          "text": "A",
          "correct": false
        },
        {
          "label": "B",
          "text": "B only",
          "correct": false
        },
        {
          "label": "C",
          "text": "B and C both",
          "correct": true
        },
        {
          "label": "D",
          "text": "All",
          "correct": false
        }
      ],
      "correct_answer": "C. B and C both",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. C) \u00a0B and C both</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation</li><li>\u2022 The urea cycle involves the stepwise conversion of nitrogenous waste (ammonia) into urea for excretion. The clinical presentation of this patient\u2014 hyperammonemia , absence of citrulline in plasma, and elevated orotic acid in urine \u2014suggests a defect in Ornithine Transcarbamoylase (OTC) activity, the enzyme responsible for converting carbamoyl phosphate and ornithine into citrulline .</li><li>\u2022 urea</li><li>\u2022 hyperammonemia</li><li>\u2022 citrulline</li><li>\u2022 elevated orotic acid in urine</li><li>\u2022 Ornithine Transcarbamoylase (OTC)</li><li>\u2022 carbamoyl phosphate</li><li>\u2022 ornithine</li><li>\u2022 citrulline</li><li>\u2022 Option B. Conversion of citrulline to argininosuccinate:</li><li>\u2022 Option B. Conversion of citrulline to argininosuccinate:</li><li>\u2022 The downstream step in the urea cycle involves converting citrulline to argininosuccinate using the enzyme argininosuccinate synthetase . While the direct defect here is in OTC , lack of citrulline availability due to upstream enzyme failure means this reaction is also indirectly affected. Without citrulline, argininosuccinate formation cannot occur .</li><li>\u2022 The downstream step in the urea cycle involves converting citrulline to argininosuccinate using the enzyme argininosuccinate synthetase . While the direct defect here is in OTC , lack of citrulline availability due to upstream enzyme failure means this reaction is also indirectly affected. Without citrulline, argininosuccinate formation cannot occur .</li><li>\u2022 downstream step</li><li>\u2022 citrulline</li><li>\u2022 argininosuccinate synthetase</li><li>\u2022 While the direct defect here is in OTC , lack of citrulline availability due to upstream enzyme failure means this reaction is also indirectly affected. Without citrulline, argininosuccinate formation cannot occur .</li><li>\u2022 While the direct defect here is in OTC , lack of citrulline availability due to upstream enzyme failure means this reaction is also indirectly affected.</li><li>\u2022 OTC</li><li>\u2022 citrulline</li><li>\u2022 Without citrulline, argininosuccinate formation cannot occur .</li><li>\u2022 argininosuccinate formation cannot occur</li><li>\u2022 Option C. Conversion of carbamoyl phosphate to citrulline:</li><li>\u2022 Option C. Conversion of carbamoyl phosphate to citrulline:</li><li>\u2022 This is the primary defect in OTC deficiency . OTC catalyzes the reaction between carbamoyl phosphate and ornithine to form citrulline in the mitochondria. Deficiency of OTC prevents this step, leading to absence of citrulline and accumulation of carbamoyl phosphate. Excess carbamoyl phosphate leaks into the cytoplasm and stimulates pyrimidine synthesis , causing elevated urinary orotic acid .</li><li>\u2022 This is the primary defect in OTC deficiency .</li><li>\u2022 primary defect</li><li>\u2022 OTC deficiency</li><li>\u2022 OTC catalyzes the reaction between carbamoyl phosphate and ornithine to form citrulline in the mitochondria.</li><li>\u2022 carbamoyl phosphate and ornithine</li><li>\u2022 citrulline</li><li>\u2022 Deficiency of OTC prevents this step, leading to absence of citrulline and accumulation of carbamoyl phosphate.</li><li>\u2022 absence of citrulline</li><li>\u2022 Excess carbamoyl phosphate leaks into the cytoplasm and stimulates pyrimidine synthesis , causing elevated urinary orotic acid .</li><li>\u2022 pyrimidine synthesis</li><li>\u2022 elevated urinary orotic acid</li><li>\u2022 Other Options :</li><li>\u2022 Other Options</li><li>\u2022 Option A. Conversion of Ornithine to Citrulline:</li><li>\u2022 Option A. Conversion of Ornithine to Citrulline:</li><li>\u2022 This step does occur in the urea cycle and involves the combination of ornithine and carbamoyl phosphate to form citrulline . Enzyme involved : Ornithine transcarbamoylase (OTC) , which is the deficient enzyme in this case.</li><li>\u2022 This step does occur in the urea cycle and involves the combination of ornithine and carbamoyl phosphate to form citrulline .</li><li>\u2022 does occur</li><li>\u2022 ornithine</li><li>\u2022 carbamoyl phosphate</li><li>\u2022 citrulline</li><li>\u2022 Enzyme involved : Ornithine transcarbamoylase (OTC) , which is the deficient enzyme in this case.</li><li>\u2022 Enzyme involved</li><li>\u2022 Ornithine transcarbamoylase (OTC)</li><li>\u2022 Option D: Conversion of Arginine to Ornithine:</li><li>\u2022 Option D: Conversion of Arginine to Ornithine:</li><li>\u2022 This step occurs at the final stage of the urea cycle. Enzyme involved : Arginase catalyzes the conversion of arginine to urea and ornithine . This is not affected in OTC deficiency because the defect occurs upstream at the step where citrulline is synthesized.</li><li>\u2022 This step occurs at the final stage of the urea cycle.</li><li>\u2022 at the final stage</li><li>\u2022 Enzyme involved : Arginase catalyzes the conversion of arginine to urea and ornithine .</li><li>\u2022 Enzyme involved</li><li>\u2022 Arginase</li><li>\u2022 arginine</li><li>\u2022 urea</li><li>\u2022 ornithine</li><li>\u2022 This is not affected in OTC deficiency because the defect occurs upstream at the step where citrulline is synthesized.</li><li>\u2022 not affected</li><li>\u2022 upstream</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 In OTC deficiency :</li><li>\u27a4 OTC deficiency</li><li>\u27a4 Citrulline cannot be produced from carbamoyl phosphate and ornithine (Step C). As a result, the next step involving citrulline (Step B) is also disrupted.</li><li>\u27a4 Citrulline cannot be produced from carbamoyl phosphate and ornithine (Step C).</li><li>\u27a4 Citrulline cannot be produced</li><li>\u27a4 As a result, the next step involving citrulline (Step B) is also disrupted.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "45c40c4a",
      "audio": ""
    },
    {
      "text": "A 6-month-old infant presents with motor weakness, exaggerated startle response, and a cherry-red spot-on macular examination. Lab investigation reveal elevated levels of gangliosides in cells. Which inherited metabolic disorder is most likely responsible for this clinical presentation?",
      "options": [
        {
          "label": "A",
          "text": "Niemann-Pick disease",
          "correct": false
        },
        {
          "label": "B",
          "text": "Tay-Sachs disease",
          "correct": true
        },
        {
          "label": "C",
          "text": "Gaucher's disease",
          "correct": false
        },
        {
          "label": "D",
          "text": "Fabry disease",
          "correct": false
        }
      ],
      "correct_answer": "B. Tay-Sachs disease",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. B) Tay-Sachs disease</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation</li><li>\u2022 Tay-Sachs disease is an inherited metabolic disorder caused by a deficiency of the enzyme hexosaminidase A . This leads to the accumulation of GM2 gangliosides in neurons, causing neurodegeneration.</li><li>\u2022 hexosaminidase A</li><li>\u2022 GM2 gangliosides</li><li>\u2022 Key clinical features of Tay-Sachs disease include:</li><li>\u2022 Tay-Sachs disease</li><li>\u2022 Motor weakness \u2013 Infants lose motor skills as the disease progresses. Exaggerated startle response \u2013 A hyperactive reaction to sound or touch. Cherry-red spot on the macula \u2013 This occurs because the surrounding retinal cells are swollen with ganglioside accumulation, making the normal macula stand out. Absence of hepatosplenomegaly \u2013 Unlike other lysosomal storage disorders, gangliosides do not accumulate in the liver.</li><li>\u2022 Motor weakness \u2013 Infants lose motor skills as the disease progresses.</li><li>\u2022 Motor weakness</li><li>\u2022 Exaggerated startle response \u2013 A hyperactive reaction to sound or touch.</li><li>\u2022 Exaggerated startle response</li><li>\u2022 Cherry-red spot on the macula \u2013 This occurs because the surrounding retinal cells are swollen with ganglioside accumulation, making the normal macula stand out.</li><li>\u2022 Cherry-red spot on the macula</li><li>\u2022 Absence of hepatosplenomegaly \u2013 Unlike other lysosomal storage disorders, gangliosides do not accumulate in the liver.</li><li>\u2022 Absence of hepatosplenomegaly</li><li>\u2022 The presence of elevated gangliosides in cells, combined with the characteristic cherry-red spot and absence of hepatosplenomegaly, confirms Tay-Sachs disease.</li><li>\u2022 Other Options:</li><li>\u2022 Other Options:</li><li>\u2022 Option A. Niemann-Pick disease: Niemann-Pick disease can present with a cherry-red spot, but it is accompanied by hepatosplenomegaly , which is absent in Tay-Sachs disease.</li><li>\u2022 Option A. Niemann-Pick disease:</li><li>\u2022 hepatosplenomegaly</li><li>\u2022 Option C. Gaucher's disease: Gaucher's disease is a lysosomal storage disorder caused by glucocerebrosidase deficiency. It presents with hepatosplenomegaly, bone pain, and anemia but does not involve gangliosides or a cherry-red spot .</li><li>\u2022 Option C. Gaucher's disease:</li><li>\u2022 does not involve gangliosides or a cherry-red spot</li><li>\u2022 Option D. Fabry disease: Fabry disease involves a deficiency of \u03b1-galactosidase A leading to accumulation of globotriaosylceramide. It presents with neuropathic pain, angiokeratomas, and renal failure, not cherry-red spots or ganglioside accumulation.</li><li>\u2022 Option D. Fabry disease:</li><li>\u2022 \u03b1-galactosidase A</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 Tay-Sachs disease is characterized by cherry-red spots on the macula , motor weakness, and exaggerated startle response due to the accumulation of GM2 gangliosides caused by hexosaminidase A deficiency . There is no hepatosplenomegaly in this condition.</li><li>\u27a4 cherry-red spots on the macula</li><li>\u27a4 exaggerated startle response</li><li>\u27a4 GM2 gangliosides</li><li>\u27a4 hexosaminidase A deficiency</li><li>\u27a4 no hepatosplenomegaly</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "ea12f25c",
      "audio": ""
    },
    {
      "text": "A 25-year-old patient presents with recurrent episodes of acute pancreatitis. On physical examination, multiple eruptive xanthomas are noticed on the patient\u2019s back and buttocks. Laboratory findings demonstrate significantly elevated serum triglyceride levels. Which inherited metabolic disorder is consistent with this clinical picture?",
      "options": [
        {
          "label": "A",
          "text": "Familial combined hyperlipidemia",
          "correct": false
        },
        {
          "label": "B",
          "text": "Familial hypercholesterolemia",
          "correct": false
        },
        {
          "label": "C",
          "text": "Type I hyperlipoproteinemia",
          "correct": true
        },
        {
          "label": "D",
          "text": "Type IIb hyperlipoproteinemia",
          "correct": false
        }
      ],
      "correct_answer": "C. Type I hyperlipoproteinemia",
      "question_images": [],
      "explanation_images": [
        "https://cerebellum-web-static.s3.amazonaws.com/media/public/Screenshot%202024-12-18%20131953.jpg"
      ],
      "explanation": "<p><strong>Ans. C) Type I hyperlipoproteinemia</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation</li><li>\u2022 Type I hyperlipoproteinemia , also known as familial hyperchylomicronemia , is a rare autosomal recessive disorder caused by a deficiency of lipoprotein lipase (LPL) or its cofactor Apo C-II .</li><li>\u2022 Type I hyperlipoproteinemia</li><li>\u2022 familial hyperchylomicronemia</li><li>\u2022 lipoprotein lipase (LPL)</li><li>\u2022 Apo C-II</li><li>\u2022 Key findings in Type I hyperlipoproteinemia:</li><li>\u2022 Markedly elevated triglyceride levels \u2013 This occurs due to the accumulation of chylomicrons , which transport triglycerides. Recurrent acute pancreatitis \u2013 High triglyceride levels (>1000 mg/dL) predispose patients to pancreatitis. Eruptive xanthomas \u2013 Small, yellow-red papules that appear on the back, buttocks, and extremities due to chylomicron deposition in the skin. No significant increase in cholesterol \u2013 Unlike other hyperlipidemias, cholesterol levels remain relatively normal.</li><li>\u2022 Markedly elevated triglyceride levels \u2013 This occurs due to the accumulation of chylomicrons , which transport triglycerides.</li><li>\u2022 Markedly elevated triglyceride levels</li><li>\u2022 chylomicrons</li><li>\u2022 Recurrent acute pancreatitis \u2013 High triglyceride levels (>1000 mg/dL) predispose patients to pancreatitis.</li><li>\u2022 Recurrent acute pancreatitis</li><li>\u2022 Eruptive xanthomas \u2013 Small, yellow-red papules that appear on the back, buttocks, and extremities due to chylomicron deposition in the skin.</li><li>\u2022 Eruptive xanthomas</li><li>\u2022 No significant increase in cholesterol \u2013 Unlike other hyperlipidemias, cholesterol levels remain relatively normal.</li><li>\u2022 No significant increase in cholesterol</li><li>\u2022 The combination of recurrent pancreatitis , eruptive xanthomas , and elevated triglycerides points specifically to Type I hyperlipoproteinemia.</li><li>\u2022 recurrent pancreatitis</li><li>\u2022 eruptive xanthomas</li><li>\u2022 elevated triglycerides</li><li>\u2022 Other Options:</li><li>\u2022 Other Options:</li><li>\u2022 Option A. Familial combined hyperlipidemia: This condition is characterized by elevated LDL and VLDL levels, leading to increased triglycerides and cholesterol. It does not present with isolated severe triglyceridemia or eruptive xanthomas.</li><li>\u2022 Option A. Familial combined hyperlipidemia:</li><li>\u2022 LDL and VLDL</li><li>\u2022 Option B. Familial hypercholesterolemia: This is a Type IIa hyperlipoproteinemia caused by LDL receptor defects . It leads to isolated elevated cholesterol levels and features such as tendon xanthomas and early atherosclerosis but does not cause recurrent pancreatitis or eruptive xanthomas.</li><li>\u2022 Option B. Familial hypercholesterolemia:</li><li>\u2022 Type IIa hyperlipoproteinemia</li><li>\u2022 LDL receptor defects</li><li>\u2022 cholesterol levels</li><li>\u2022 Option D. Type IIb hyperlipoproteinemia: This condition results in increased LDL and VLDL levels , causing elevated cholesterol and triglycerides (combined hyperlipidemia). It does not present with eruptive xanthomas or such high triglycerides seen in Type I.</li><li>\u2022 Option D. Type IIb hyperlipoproteinemia:</li><li>\u2022 LDL and VLDL levels</li><li>\u2022 Note:</li><li>\u2022 Note:</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 Type I hyperlipoproteinemia (familial hyperchylomicronemia) is characterized by a deficiency of lipoprotein lipase (LPL) or its cofactor Apo C-II , leading to:</li><li>\u27a4 Type I hyperlipoproteinemia (familial hyperchylomicronemia)</li><li>\u27a4 lipoprotein lipase (LPL)</li><li>\u27a4 Apo C-II</li><li>\u27a4 Severe triglyceride elevation Recurrent acute pancreatitis Eruptive xanthomas</li><li>\u27a4 Severe triglyceride elevation</li><li>\u27a4 triglyceride elevation</li><li>\u27a4 Recurrent acute pancreatitis</li><li>\u27a4 acute pancreatitis</li><li>\u27a4 Eruptive xanthomas</li><li>\u27a4 Eruptive xanthomas</li><li>\u27a4 Normal or minimally elevated cholesterol levels.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "a9b8675a",
      "audio": ""
    },
    {
      "text": "A 2-year-old child presents with failure to thrive, developmental delay, and megaloblastic anemia refractory to folic acid and vitamin B12 supplementation. Urine analysis reveals an increased excretion of orotic acid. Which therapeutic intervention is most effective for this inherited metabolic disorder?",
      "options": [
        {
          "label": "A",
          "text": "Supplementation with biotin",
          "correct": false
        },
        {
          "label": "B",
          "text": "Oral uridine administration",
          "correct": true
        },
        {
          "label": "C",
          "text": "Oral Thymidine administration",
          "correct": false
        },
        {
          "label": "D",
          "text": "Enzyme replacement therapy",
          "correct": false
        }
      ],
      "correct_answer": "B. Oral uridine administration",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. B) Oral uridine administration</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation</li><li>\u2022 The clinical presentation of failure to thrive , developmental delay , megaloblastic anemia refractory to folic acid and vitamin B12 , and increased orotic acid excretion in urine points to orotic aciduria , a rare inherited disorder of pyrimidine synthesis.</li><li>\u2022 failure to thrive</li><li>\u2022 developmental delay</li><li>\u2022 megaloblastic anemia refractory to folic acid and vitamin B12</li><li>\u2022 increased orotic acid excretion in urine</li><li>\u2022 orotic aciduria</li><li>\u2022 Pathophysiology : Orotic aciduria occurs due to a deficiency of the enzyme UMP synthase , which catalyzes the conversion of orotic acid to uridine monophosphate (UMP) in the pyrimidine biosynthesis pathway. As a result, orotic acid accumulates and is excreted in the urine. Pyrimidine deficiency (UMP, CMP, and TMP) leads to impaired DNA and RNA synthesis, causing megaloblastic anemia and developmental delays. Treatment : Oral uridine administration is the most effective therapy. Uridine bypasses the enzymatic block caused by UMP synthase deficiency and provides the required pyrimidines for nucleic acid synthesis. Supplementation with uridine allows for the synthesis of UMP , which can be converted to cytidine (CMP) and thymidine (TMP) as needed.</li><li>\u2022 Pathophysiology : Orotic aciduria occurs due to a deficiency of the enzyme UMP synthase , which catalyzes the conversion of orotic acid to uridine monophosphate (UMP) in the pyrimidine biosynthesis pathway. As a result, orotic acid accumulates and is excreted in the urine. Pyrimidine deficiency (UMP, CMP, and TMP) leads to impaired DNA and RNA synthesis, causing megaloblastic anemia and developmental delays.</li><li>\u2022 Pathophysiology</li><li>\u2022 UMP synthase</li><li>\u2022 orotic acid</li><li>\u2022 uridine monophosphate (UMP)</li><li>\u2022 As a result, orotic acid accumulates and is excreted in the urine. Pyrimidine deficiency (UMP, CMP, and TMP) leads to impaired DNA and RNA synthesis, causing megaloblastic anemia and developmental delays.</li><li>\u2022 As a result, orotic acid accumulates and is excreted in the urine.</li><li>\u2022 orotic acid accumulates</li><li>\u2022 Pyrimidine deficiency (UMP, CMP, and TMP) leads to impaired DNA and RNA synthesis, causing megaloblastic anemia and developmental delays.</li><li>\u2022 Pyrimidine deficiency</li><li>\u2022 Treatment : Oral uridine administration is the most effective therapy. Uridine bypasses the enzymatic block caused by UMP synthase deficiency and provides the required pyrimidines for nucleic acid synthesis. Supplementation with uridine allows for the synthesis of UMP , which can be converted to cytidine (CMP) and thymidine (TMP) as needed.</li><li>\u2022 Treatment</li><li>\u2022 Oral uridine administration</li><li>\u2022 Supplementation with uridine allows for the synthesis of UMP , which can be converted to cytidine (CMP) and thymidine (TMP) as needed.</li><li>\u2022 Supplementation with uridine allows for the synthesis of UMP , which can be converted to cytidine (CMP) and thymidine (TMP) as needed.</li><li>\u2022 UMP</li><li>\u2022 cytidine</li><li>\u2022 thymidine</li><li>\u2022 Other Options:</li><li>\u2022 Other Options:</li><li>\u2022 Option A. Supplementation with biotin: Biotin is used in conditions like multiple carboxylase deficiency but has no role in orotic aciduria.</li><li>\u2022 Option A. Supplementation with biotin:</li><li>\u2022 multiple carboxylase deficiency</li><li>\u2022 Option C. Oral thymidine administration: Thymidine supplementation is not effective because thymidine cannot directly correct the uridine deficiency seen in orotic aciduria.</li><li>\u2022 Option C. Oral thymidine administration:</li><li>\u2022 thymidine</li><li>\u2022 Option D. Enzyme replacement therapy: There is no enzyme replacement therapy available for UMP synthase deficiency.</li><li>\u2022 Option D. Enzyme replacement therapy:</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 Orotic aciduria is treated with oral uridine administration to bypass the UMP synthase deficiency. This allows the production of essential pyrimidines, correcting the anemia and other symptoms.</li><li>\u27a4 Orotic aciduria</li><li>\u27a4 oral uridine administration</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "06df1f46",
      "audio": ""
    },
    {
      "text": "A man in his late 20s is concerned about the potential of passing on a genetic disorder to his offspring. His cousin has a rare genetic disease that affects muscle coordination. Before starting a family, he wishes to determine the risk of his future children inheriting this disorder. Which of the following laboratory tests can help identify if he or his partner carry the gene responsible for this condition?",
      "options": [
        {
          "label": "A",
          "text": "Flow cytometry",
          "correct": false
        },
        {
          "label": "B",
          "text": "Chromatography",
          "correct": false
        },
        {
          "label": "C",
          "text": "PCR and sequencing",
          "correct": true
        },
        {
          "label": "D",
          "text": "Western blotting",
          "correct": false
        }
      ],
      "correct_answer": "C. PCR and sequencing",
      "question_images": [],
      "explanation_images": [
        "https://cerebellum-web-static.s3.amazonaws.com/media/public/Screenshot%202024-12-18%20132229.jpg"
      ],
      "explanation": "<p><strong>Ans. C) PCR and sequencing</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation</li><li>\u2022 To identify if an individual carries a gene mutation associated with a genetic disorder, the most appropriate test is PCR (Polymerase Chain Reaction) and sequencing .</li><li>\u2022 carries a gene mutation</li><li>\u2022 PCR (Polymerase Chain Reaction) and sequencing</li><li>\u2022 PCR (Polymerase Chain Reaction): PCR allows for the amplification of specific regions of DNA where the suspected gene or mutation resides. It targets and amplifies known genetic sequences, enabling detailed analysis. DNA Sequencing: Once the DNA region is amplified, sequencing can determine the exact nucleotide sequence to identify mutations, deletions, or other abnormalities in the gene of interest. It is the gold standard for detecting known genetic mutations in rare or familial disorders.</li><li>\u2022 PCR (Polymerase Chain Reaction): PCR allows for the amplification of specific regions of DNA where the suspected gene or mutation resides. It targets and amplifies known genetic sequences, enabling detailed analysis.</li><li>\u2022 PCR (Polymerase Chain Reaction):</li><li>\u2022 PCR allows for the amplification of specific regions of DNA where the suspected gene or mutation resides. It targets and amplifies known genetic sequences, enabling detailed analysis.</li><li>\u2022 PCR allows for the amplification of specific regions of DNA where the suspected gene or mutation resides.</li><li>\u2022 amplification of specific regions of DNA</li><li>\u2022 It targets and amplifies known genetic sequences, enabling detailed analysis.</li><li>\u2022 DNA Sequencing: Once the DNA region is amplified, sequencing can determine the exact nucleotide sequence to identify mutations, deletions, or other abnormalities in the gene of interest. It is the gold standard for detecting known genetic mutations in rare or familial disorders.</li><li>\u2022 DNA Sequencing:</li><li>\u2022 Once the DNA region is amplified, sequencing can determine the exact nucleotide sequence to identify mutations, deletions, or other abnormalities in the gene of interest. It is the gold standard for detecting known genetic mutations in rare or familial disorders.</li><li>\u2022 Once the DNA region is amplified, sequencing can determine the exact nucleotide sequence to identify mutations, deletions, or other abnormalities in the gene of interest.</li><li>\u2022 exact nucleotide sequence</li><li>\u2022 It is the gold standard for detecting known genetic mutations in rare or familial disorders.</li><li>\u2022 This combination of PCR and sequencing provides the most reliable results for identifying carriers of genetic diseases and determining their risk of passing on the condition to offspring.</li><li>\u2022 genetic diseases</li><li>\u2022 Other Options:</li><li>\u2022 Other Options:</li><li>\u2022 Option A. Flow cytometry: Flow cytometry analyzes cell size, structure, and fluorescence and is used to study immune cells or detect abnormal cells (e.g., leukemias). It does not analyze DNA sequences.</li><li>\u2022 Option A. Flow cytometry:</li><li>\u2022 cell size, structure, and fluorescence</li><li>\u2022 Option B. Chromatography: Chromatography is used to separate molecules, such as amino acids, proteins, or drugs, based on their chemical properties. It is not suitable for genetic testing.</li><li>\u2022 Option B. Chromatography:</li><li>\u2022 Option D. Western blotting: Western blotting detects proteins and their expression levels but cannot identify genetic mutations at the DNA level.</li><li>\u2022 Option D. Western blotting:</li><li>\u2022 proteins</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 When a known genetic disorder is suspected, PCR and DNA sequencing are the most effective laboratory techniques to determine whether an individual carries the gene mutation and assess the risk of inheritance.</li><li>\u27a4 genetic disorder</li><li>\u27a4 PCR and DNA sequencing</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "ba0f530a",
      "audio": ""
    },
    {
      "text": "A 35-year-old male presents to the clinic with alopecia, a scaly red rash around his eyes, nose, and mouth, and symptoms of fatigue and depression. During the dietary history, he reports consuming multiple raw eggs daily as part of his workout regimen. Which vitamin deficiency, likely induced by his dietary habit, is responsible for his symptoms?",
      "options": [
        {
          "label": "A",
          "text": "Vitamin B2 (Riboflavin)",
          "correct": false
        },
        {
          "label": "B",
          "text": "Vitamin B6 (Pyridoxine)",
          "correct": false
        },
        {
          "label": "C",
          "text": "Vitamin B7 (Biotin)",
          "correct": true
        },
        {
          "label": "D",
          "text": "Vitamin E",
          "correct": false
        }
      ],
      "correct_answer": "C. Vitamin B7 (Biotin)",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. C) Vitamin B7 (Biotin)</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation</li><li>\u2022 The patient\u2019s symptoms of alopecia , scaly red rash , fatigue , and depression combined with the dietary history of consuming raw eggs daily point toward a deficiency of Vitamin B7 (Biotin) .</li><li>\u2022 alopecia</li><li>\u2022 scaly red rash</li><li>\u2022 fatigue</li><li>\u2022 depression</li><li>\u2022 raw eggs</li><li>\u2022 Vitamin B7 (Biotin)</li><li>\u2022 Biotin and Raw Eggs:</li><li>\u2022 Biotin and Raw Eggs:</li><li>\u2022 Biotin is a water-soluble vitamin (Vitamin B7) essential for: Carboxylation reactions (e.g., pyruvate carboxylase, acetyl-CoA carboxylase). Fatty acid synthesis and gluconeogenesis. Avidin , a protein present in raw egg whites, binds biotin tightly and prevents its absorption in the intestine. Chronic consumption of large amounts of raw eggs can lead to biotin deficiency .</li><li>\u2022 Biotin is a water-soluble vitamin (Vitamin B7) essential for: Carboxylation reactions (e.g., pyruvate carboxylase, acetyl-CoA carboxylase). Fatty acid synthesis and gluconeogenesis.</li><li>\u2022 Biotin</li><li>\u2022 Carboxylation reactions (e.g., pyruvate carboxylase, acetyl-CoA carboxylase). Fatty acid synthesis and gluconeogenesis.</li><li>\u2022 Carboxylation reactions (e.g., pyruvate carboxylase, acetyl-CoA carboxylase).</li><li>\u2022 Fatty acid synthesis and gluconeogenesis.</li><li>\u2022 Avidin , a protein present in raw egg whites, binds biotin tightly and prevents its absorption in the intestine.</li><li>\u2022 Avidin</li><li>\u2022 binds biotin tightly</li><li>\u2022 Chronic consumption of large amounts of raw eggs can lead to biotin deficiency .</li><li>\u2022 biotin deficiency</li><li>\u2022 Clinical Features of Biotin Deficiency:</li><li>\u2022 Clinical Features of Biotin Deficiency:</li><li>\u2022 Alopecia \u2013 Hair loss. Scaly dermatitis \u2013 Especially around the eyes, nose, and mouth . Fatigue and depression \u2013 Generalized weakness and mood disturbances. Neurological symptoms \u2013 Paresthesia, hallucinations in severe cases.</li><li>\u2022 Alopecia \u2013 Hair loss.</li><li>\u2022 Alopecia</li><li>\u2022 Scaly dermatitis \u2013 Especially around the eyes, nose, and mouth .</li><li>\u2022 Scaly dermatitis</li><li>\u2022 eyes, nose, and mouth</li><li>\u2022 Fatigue and depression \u2013 Generalized weakness and mood disturbances.</li><li>\u2022 Fatigue and depression</li><li>\u2022 Neurological symptoms \u2013 Paresthesia, hallucinations in severe cases.</li><li>\u2022 Neurological symptoms</li><li>\u2022 Other Options:</li><li>\u2022 Other Options:</li><li>\u2022 Option A. Vitamin B2 (Riboflavin): Riboflavin deficiency causes cheilitis , angular stomatitis , and corneal vascularization but not alopecia or biotin-specific symptoms.</li><li>\u2022 Option A. Vitamin B2 (Riboflavin):</li><li>\u2022 cheilitis</li><li>\u2022 angular stomatitis</li><li>\u2022 corneal vascularization</li><li>\u2022 Option B. Vitamin B6 (Pyridoxine): Pyridoxine deficiency leads to sideroblastic anemia , irritability , and peripheral neuropath hy . Rash and alopecia are not prominent features.</li><li>\u2022 Option B. Vitamin B6 (Pyridoxine):</li><li>\u2022 sideroblastic anemia</li><li>\u2022 irritability</li><li>\u2022 peripheral neuropath hy</li><li>\u2022 Option D. Vitamin E: Vitamin E deficiency causes neurological symptoms (e.g., ataxia, peripheral neuropathy) and hemolytic anemia but not dermatitis or alopecia.</li><li>\u2022 Option D. Vitamin E:</li><li>\u2022 neurological symptoms</li><li>\u2022 hemolytic anemia</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 Chronic consumption of raw eggs leads to biotin deficiency because avidin in egg whites binds biotin and prevents its absorption. Biotin deficiency presents with:</li><li>\u27a4 raw eggs</li><li>\u27a4 biotin deficiency</li><li>\u27a4 avidin</li><li>\u27a4 Alopecia Scaly red rash around the eyes, nose, and mouth Fatigue and depression</li><li>\u27a4 Alopecia</li><li>\u27a4 Alopecia</li><li>\u27a4 Scaly red rash around the eyes, nose, and mouth</li><li>\u27a4 Scaly red rash</li><li>\u27a4 Fatigue and depression</li><li>\u27a4 Fatigue and depression</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "3af6501b",
      "audio": ""
    },
    {
      "text": "A 72-year-old male, who has been on warfarin therapy for atrial fibrillation, presents with prolonged bleeding following minor trauma. Blood investigations reveal prolonged prothrombin time (PT). Given his medication history, carboxylation of which of the following affected by both Vitamin K and its inhibitor warfarin, is most likely responsible for his symptoms?",
      "options": [
        {
          "label": "A",
          "text": "Clotting factors I, II, V and VII",
          "correct": false
        },
        {
          "label": "B",
          "text": "Clotting factors II, VII, IX and X",
          "correct": true
        },
        {
          "label": "C",
          "text": "Clotting factors III, V, VIII and XI",
          "correct": false
        },
        {
          "label": "D",
          "text": "Clotting factors IV, VI, IX and XII",
          "correct": false
        }
      ],
      "correct_answer": "B. Clotting factors II, VII, IX and X",
      "question_images": [],
      "explanation_images": [
        "https://cerebellum-web-static.s3.amazonaws.com/media/public/Screenshot%202024-12-18%20133404.jpg"
      ],
      "explanation": "<p><strong>Ans. B) Clotting factors II, VII, IX and X</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation</li><li>\u2022 The clinical presentation of prolonged bleeding and increased prothrombin time (PT) in a patient on warfarin therapy indicates interference in the Vitamin K-dependent carboxylation of specific clotting factors.</li><li>\u2022 prolonged bleeding</li><li>\u2022 increased prothrombin time (PT)</li><li>\u2022 warfarin therapy</li><li>\u2022 Vitamin K-dependent carboxylation</li><li>\u2022 Vitamin K and Gamma Carboxylation</li><li>\u2022 Vitamin K and Gamma Carboxylation</li><li>\u2022 Role of Vitamin K : Vitamin K is required for the gamma-carboxylation of glutamate residues on certain clotting factors. This modification is essential to allow clotting factors to bind calcium ions and become biologically active. Vitamin K-Dependent Factors : The clotting factors II (Prothrombin), VII, IX, and X require Vitamin K for activation. Protein C and Protein S (natural anticoagulants) also require Vitamin K for their activation. Warfarin Mechanism of Action : Warfarin inhibits the enzyme Vitamin K epoxide reductase . This enzyme converts Vitamin K epoxide back to its active reduced form (KH2). Without active Vitamin K, gamma-carboxylation of clotting factors II, VII, IX, and X is impaired, leading to defective clot formation and prolonged bleeding.</li><li>\u2022 Role of Vitamin K : Vitamin K is required for the gamma-carboxylation of glutamate residues on certain clotting factors. This modification is essential to allow clotting factors to bind calcium ions and become biologically active.</li><li>\u2022 Role of Vitamin K</li><li>\u2022 Vitamin K is required for the gamma-carboxylation of glutamate residues on certain clotting factors. This modification is essential to allow clotting factors to bind calcium ions and become biologically active.</li><li>\u2022 Vitamin K is required for the gamma-carboxylation of glutamate residues on certain clotting factors.</li><li>\u2022 gamma-carboxylation</li><li>\u2022 glutamate residues</li><li>\u2022 This modification is essential to allow clotting factors to bind calcium ions and become biologically active.</li><li>\u2022 calcium ions</li><li>\u2022 Vitamin K-Dependent Factors : The clotting factors II (Prothrombin), VII, IX, and X require Vitamin K for activation. Protein C and Protein S (natural anticoagulants) also require Vitamin K for their activation.</li><li>\u2022 Vitamin K-Dependent Factors</li><li>\u2022 The clotting factors II (Prothrombin), VII, IX, and X require Vitamin K for activation. Protein C and Protein S (natural anticoagulants) also require Vitamin K for their activation.</li><li>\u2022 The clotting factors II (Prothrombin), VII, IX, and X require Vitamin K for activation.</li><li>\u2022 clotting factors II (Prothrombin), VII, IX, and X</li><li>\u2022 Protein C and Protein S (natural anticoagulants) also require Vitamin K for their activation.</li><li>\u2022 Warfarin Mechanism of Action : Warfarin inhibits the enzyme Vitamin K epoxide reductase . This enzyme converts Vitamin K epoxide back to its active reduced form (KH2). Without active Vitamin K, gamma-carboxylation of clotting factors II, VII, IX, and X is impaired, leading to defective clot formation and prolonged bleeding.</li><li>\u2022 Warfarin Mechanism of Action</li><li>\u2022 Warfarin inhibits the enzyme Vitamin K epoxide reductase . This enzyme converts Vitamin K epoxide back to its active reduced form (KH2). Without active Vitamin K, gamma-carboxylation of clotting factors II, VII, IX, and X is impaired, leading to defective clot formation and prolonged bleeding.</li><li>\u2022 Warfarin inhibits the enzyme Vitamin K epoxide reductase .</li><li>\u2022 Vitamin K epoxide reductase</li><li>\u2022 This enzyme converts Vitamin K epoxide back to its active reduced form (KH2).</li><li>\u2022 active reduced form</li><li>\u2022 Without active Vitamin K, gamma-carboxylation of clotting factors II, VII, IX, and X is impaired, leading to defective clot formation and prolonged bleeding.</li><li>\u2022 Other Options:</li><li>\u2022 Other Options:</li><li>\u2022 Option A. Clotting factors I, II, V, and VII: Factor I (fibrinogen) and Factor V are not dependent on Vitamin K for activation.</li><li>\u2022 Option A. Clotting factors I, II, V, and VII:</li><li>\u2022 Option C. Clotting factors III, V, VIII, and XI: Factor III (Tissue Factor), Factor V, Factor VIII, and Factor XI do not require Vitamin K.</li><li>\u2022 Option C. Clotting factors III, V, VIII, and XI:</li><li>\u2022 Option D. Clotting factors IV, VI, IX, and XII: Factor IV (calcium) is not a protein, and Factor VI does not exist. Factor IX is Vitamin K-dependent, but the other factors listed are not.</li><li>\u2022 Option D. Clotting factors IV, VI, IX, and XII:</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 Vitamin K is required for the gamma-carboxylation of clotting factors II, VII, IX, and X . Warfarin inhibits Vitamin K epoxide reductase, preventing this carboxylation and leading to prolonged PT and bleeding.</li><li>\u27a4 gamma-carboxylation of clotting factors II, VII, IX, and X</li><li>\u27a4 prolonged PT</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "5b2a032c",
      "audio": ""
    },
    {
      "text": "A 28-year-old woman presents with swollen gums, joint pain, and easy bruising. On examination, her gums appear inflamed and bleed easily. A dietary history reveals minimal intake of fresh fruits and vegetables. She is diagnosed with ascorbic acid deficiency resulting in lack of collagen maturation. Which of the following best explains the defect in collagen seen in her condition? Inability to form disulfide bridges in collagen chains. Impairment in forming hydrogen bonds between collagens helices. Disruption in the hydroxylation of proline and lysine residues in collagen Failure to glycosylate specific residues in collagen.",
      "options": [
        {
          "label": "A",
          "text": "a",
          "correct": false
        },
        {
          "label": "B",
          "text": "b only",
          "correct": false
        },
        {
          "label": "C",
          "text": "b and c both",
          "correct": true
        },
        {
          "label": "D",
          "text": "None",
          "correct": false
        }
      ],
      "correct_answer": "C. b and c both",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. C ) b and c both</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation</li><li>\u2022 Ascorbic acid (Vitamin C) is a cofactor for the enzymes prolyl hydroxylase and lysyl hydroxylase , which catalyze the hydroxylation of proline and lysine residues in collagen. Hydroxylation is a critical step in collagen maturation for the following reasons:</li><li>\u2022 Ascorbic acid (Vitamin C)</li><li>\u2022 prolyl hydroxylase</li><li>\u2022 lysyl hydroxylase</li><li>\u2022 hydroxylation of proline and lysine residues</li><li>\u2022 Stabilization of Collagen Triple Helix : Hydroxylation of proline and lysine residues allows the formation of hydrogen bonds between collagen helices. These bonds stabilize the triple helix structure of collagen, which is essential for its tensile strength. While hydrogen bonds are indeed impaired, the root cause of this impairment is the disruption in hydroxylation of proline and lysine . Defect in Vitamin C Deficiency : In Vitamin C deficiency (as seen in scurvy ), hydroxylation is impaired. This leads to weak, unstable collagen fibers due to a lack of hydrogen bonding, resulting in symptoms like: Swollen, bleeding gums Easy bruising Joint pain Poor wound healing</li><li>\u2022 Stabilization of Collagen Triple Helix : Hydroxylation of proline and lysine residues allows the formation of hydrogen bonds between collagen helices. These bonds stabilize the triple helix structure of collagen, which is essential for its tensile strength. While hydrogen bonds are indeed impaired, the root cause of this impairment is the disruption in hydroxylation of proline and lysine .</li><li>\u2022 Stabilization of Collagen Triple Helix</li><li>\u2022 Hydroxylation of proline and lysine residues allows the formation of hydrogen bonds between collagen helices. These bonds stabilize the triple helix structure of collagen, which is essential for its tensile strength. While hydrogen bonds are indeed impaired, the root cause of this impairment is the disruption in hydroxylation of proline and lysine .</li><li>\u2022 Hydroxylation of proline and lysine residues allows the formation of hydrogen bonds between collagen helices.</li><li>\u2022 hydrogen bonds</li><li>\u2022 These bonds stabilize the triple helix structure of collagen, which is essential for its tensile strength.</li><li>\u2022 While hydrogen bonds are indeed impaired, the root cause of this impairment is the disruption in hydroxylation of proline and lysine .</li><li>\u2022 hydrogen bonds</li><li>\u2022 disruption in hydroxylation of proline and lysine</li><li>\u2022 Defect in Vitamin C Deficiency : In Vitamin C deficiency (as seen in scurvy ), hydroxylation is impaired. This leads to weak, unstable collagen fibers due to a lack of hydrogen bonding, resulting in symptoms like: Swollen, bleeding gums Easy bruising Joint pain Poor wound healing</li><li>\u2022 Defect in Vitamin C Deficiency</li><li>\u2022 In Vitamin C deficiency (as seen in scurvy ), hydroxylation is impaired. This leads to weak, unstable collagen fibers due to a lack of hydrogen bonding, resulting in symptoms like: Swollen, bleeding gums Easy bruising Joint pain Poor wound healing</li><li>\u2022 In Vitamin C deficiency (as seen in scurvy ), hydroxylation is impaired.</li><li>\u2022 scurvy</li><li>\u2022 This leads to weak, unstable collagen fibers due to a lack of hydrogen bonding, resulting in symptoms like: Swollen, bleeding gums Easy bruising Joint pain Poor wound healing</li><li>\u2022 weak, unstable collagen fibers</li><li>\u2022 Swollen, bleeding gums Easy bruising Joint pain Poor wound healing</li><li>\u2022 Swollen, bleeding gums</li><li>\u2022 Swollen, bleeding gums</li><li>\u2022 Easy bruising</li><li>\u2022 Easy bruising</li><li>\u2022 Joint pain</li><li>\u2022 Joint pain</li><li>\u2022 Poor wound healing</li><li>\u2022 Poor wound healing</li><li>\u2022 Other Options:</li><li>\u2022 Other Options:</li><li>\u2022 Option A. Inability to form disulfide bridges in collagen chains : Disulfide bridges occur in the formation of procollagen in the endoplasmic reticulum, but they are not dependent on Vitamin C.</li><li>\u2022 Option A. Inability to form disulfide bridges in collagen chains</li><li>\u2022 procollagen</li><li>\u2022 Option D. Failure to glycosylate specific residues in collagen: Glycosylation of collagen occurs after hydroxylation but does not directly depend on Vitamin C.</li><li>\u2022 Option D. Failure to glycosylate specific residues in collagen:</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 Vitamin C deficiency disrupts the hydroxylation of proline and lysine residues in collagen. This prevents the formation of hydrogen bonds needed to stabilize the collagen triple helix, resulting in symptoms of scurvy such as bleeding gums, joint pain, and poor wound healing.</li><li>\u27a4 hydroxylation of proline and lysine residues</li><li>\u27a4 scurvy</li><li>\u27a4 The most specific explanation is \"disruption in the hydroxylation of proline and lysine residues\" (Option C) .</li><li>\u27a4 \"disruption in the hydroxylation of proline and lysine residues\" (Option C)</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "894c2960",
      "audio": ""
    },
    {
      "text": "A 35-year-old individual who consumed fast food from a street vendor for several days recently comes to a hospital with continuous vomiting over the last three days. Despite not being able to eat or drink much, the patient's blood glucose levels remain stable. Which organ has played the primary role in maintaining this individual's blood glucose level in this duration?",
      "options": [
        {
          "label": "A",
          "text": "Liver",
          "correct": true
        },
        {
          "label": "B",
          "text": "Muscle",
          "correct": false
        },
        {
          "label": "C",
          "text": "Adipose tissue",
          "correct": false
        },
        {
          "label": "D",
          "text": "Kidneys",
          "correct": false
        }
      ],
      "correct_answer": "A. Liver",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. A) Liver</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 When a person is fasting or unable to consume food (such as in cases of prolonged vomiting), the body must maintain blood glucose levels to provide energy to glucose-dependent tissues like the brain and red blood cells. The liver plays the primary role in maintaining blood glucose levels during fasting through two metabolic pathways:</li><li>\u2022 liver</li><li>\u2022 Glycogenolysis (Breakdown of stored glycogen): Initially, the liver breaks down glycogen into glucose. This process provides glucose for approximately 12\u201318 hours after the last meal. Gluconeogenesis (Synthesis of glucose from non-carbohydrate sources): After glycogen stores are depleted, the liver synthesizes glucose from precursors such as amino acids, lactate, and glycerol. Gluconeogenesis becomes the dominant process after about 18 hours of fasting and continues for days to maintain blood glucose levels.</li><li>\u2022 Glycogenolysis (Breakdown of stored glycogen): Initially, the liver breaks down glycogen into glucose. This process provides glucose for approximately 12\u201318 hours after the last meal.</li><li>\u2022 Glycogenolysis</li><li>\u2022 Initially, the liver breaks down glycogen into glucose. This process provides glucose for approximately 12\u201318 hours after the last meal.</li><li>\u2022 Initially, the liver breaks down glycogen into glucose.</li><li>\u2022 This process provides glucose for approximately 12\u201318 hours after the last meal.</li><li>\u2022 12\u201318 hours</li><li>\u2022 Gluconeogenesis (Synthesis of glucose from non-carbohydrate sources): After glycogen stores are depleted, the liver synthesizes glucose from precursors such as amino acids, lactate, and glycerol. Gluconeogenesis becomes the dominant process after about 18 hours of fasting and continues for days to maintain blood glucose levels.</li><li>\u2022 Gluconeogenesis</li><li>\u2022 After glycogen stores are depleted, the liver synthesizes glucose from precursors such as amino acids, lactate, and glycerol. Gluconeogenesis becomes the dominant process after about 18 hours of fasting and continues for days to maintain blood glucose levels.</li><li>\u2022 After glycogen stores are depleted, the liver synthesizes glucose from precursors such as amino acids, lactate, and glycerol.</li><li>\u2022 Gluconeogenesis becomes the dominant process after about 18 hours of fasting and continues for days to maintain blood glucose levels.</li><li>\u2022 18 hours</li><li>\u2022 In this patient, vomiting has lasted for three days , meaning glycogen stores are exhausted, and gluconeogenesis in the liver is now primarily responsible for maintaining blood glucose levels.</li><li>\u2022 three days</li><li>\u2022 Other Options:</li><li>\u2022 Other Options:</li><li>\u2022 Option B. Muscle: Muscles store glycogen, but they lack the enzyme glucose-6-phosphatase , which is required to release free glucose into the blood. Muscle glycogen can only be used locally within the muscle for energy production and does not contribute to blood glucose maintenance.</li><li>\u2022 Option B. Muscle:</li><li>\u2022 glucose-6-phosphatase</li><li>\u2022 Option C. Adipose tissue: Adipose tissue primarily stores energy in the form of triglycerides. During fasting, adipose tissue releases free fatty acids and glycerol into the blood. While glycerol can be used as a substrate for gluconeogenesis, adipose tissue itself does not directly produce glucose.</li><li>\u2022 Option C. Adipose tissue:</li><li>\u2022 free fatty acids</li><li>\u2022 glycerol</li><li>\u2022 Option D. Kidneys: The kidneys play a minor role in gluconeogenesis during prolonged fasting, but this contribution is significantly less than that of the liver. The liver remains the primary organ responsible for glucose production.</li><li>\u2022 Option D. Kidneys:</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 During prolonged fasting (more than 18 hours), the liver maintains blood glucose levels primarily through gluconeogenesis , ensuring adequate energy supply for essential tissues like the brain.</li><li>\u27a4 liver</li><li>\u27a4 gluconeogenesis</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "bd122a66",
      "audio": ""
    },
    {
      "text": "A 56-year-old patient with Type I Diabetes came in reporting frequent urination. Lab tests showed his blood had high levels of compounds that can lead to acidosis if they build up too much. Which of the following conditions favors the production of these compounds in uncontrolled diabetes?",
      "options": [
        {
          "label": "A",
          "text": "Increased plasma free fatty acid",
          "correct": true
        },
        {
          "label": "B",
          "text": "Increase in Insulin/ glucagon ratio.",
          "correct": false
        },
        {
          "label": "C",
          "text": "Decreased acetyl CoA",
          "correct": false
        },
        {
          "label": "D",
          "text": "Increased availability of oxaloacetate",
          "correct": false
        }
      ],
      "correct_answer": "A. Increased plasma free fatty acid",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. A) Increased plasma free fatty acid</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 In uncontrolled Type I Diabetes , there is a lack of insulin, which prevents glucose uptake by tissues. This leads to the body relying heavily on fat breakdown for energy. The breakdown of triglycerides in adipose tissue releases free fatty acids (FFAs) into the bloodstream, which are transported to the liver. The following process occurs:</li><li>\u2022 Type I Diabetes</li><li>\u2022 free fatty acids (FFAs)</li><li>\u2022 Increased plasma free fatty acids: Due to insulin deficiency, hormone-sensitive lipase in adipose tissue becomes active, breaking down triglycerides into free fatty acids. These FFAs travel to the liver and undergo beta-oxidation , generating large amounts of acetyl-CoA . Ketone body production: In diabetes, the excess acetyl-CoA cannot enter the TCA cycle efficiently because oxaloacetate is diverted to gluconeogenesis (a result of increased glucagon and decreased insulin). The excess acetyl-CoA is instead converted into ketone bodies (acetoacetate, beta-hydroxybutyrate, and acetone). These ketone bodies accumulate in the blood and can lead to diabetic ketoacidosis (DKA).</li><li>\u2022 Increased plasma free fatty acids: Due to insulin deficiency, hormone-sensitive lipase in adipose tissue becomes active, breaking down triglycerides into free fatty acids. These FFAs travel to the liver and undergo beta-oxidation , generating large amounts of acetyl-CoA .</li><li>\u2022 Increased plasma free fatty acids:</li><li>\u2022 Due to insulin deficiency, hormone-sensitive lipase in adipose tissue becomes active, breaking down triglycerides into free fatty acids. These FFAs travel to the liver and undergo beta-oxidation , generating large amounts of acetyl-CoA .</li><li>\u2022 Due to insulin deficiency, hormone-sensitive lipase in adipose tissue becomes active, breaking down triglycerides into free fatty acids.</li><li>\u2022 hormone-sensitive lipase</li><li>\u2022 These FFAs travel to the liver and undergo beta-oxidation , generating large amounts of acetyl-CoA .</li><li>\u2022 beta-oxidation</li><li>\u2022 acetyl-CoA</li><li>\u2022 Ketone body production: In diabetes, the excess acetyl-CoA cannot enter the TCA cycle efficiently because oxaloacetate is diverted to gluconeogenesis (a result of increased glucagon and decreased insulin). The excess acetyl-CoA is instead converted into ketone bodies (acetoacetate, beta-hydroxybutyrate, and acetone). These ketone bodies accumulate in the blood and can lead to diabetic ketoacidosis (DKA).</li><li>\u2022 Ketone body production:</li><li>\u2022 In diabetes, the excess acetyl-CoA cannot enter the TCA cycle efficiently because oxaloacetate is diverted to gluconeogenesis (a result of increased glucagon and decreased insulin). The excess acetyl-CoA is instead converted into ketone bodies (acetoacetate, beta-hydroxybutyrate, and acetone). These ketone bodies accumulate in the blood and can lead to diabetic ketoacidosis (DKA).</li><li>\u2022 In diabetes, the excess acetyl-CoA cannot enter the TCA cycle efficiently because oxaloacetate is diverted to gluconeogenesis (a result of increased glucagon and decreased insulin).</li><li>\u2022 excess acetyl-CoA</li><li>\u2022 TCA cycle</li><li>\u2022 gluconeogenesis</li><li>\u2022 The excess acetyl-CoA is instead converted into ketone bodies (acetoacetate, beta-hydroxybutyrate, and acetone).</li><li>\u2022 ketone bodies</li><li>\u2022 These ketone bodies accumulate in the blood and can lead to diabetic ketoacidosis (DKA).</li><li>\u2022 diabetic ketoacidosis</li><li>\u2022 Therefore, the condition that favors ketone body production in uncontrolled diabetes is increased plasma free fatty acids .</li><li>\u2022 increased plasma free fatty acids</li><li>\u2022 Other Options:</li><li>\u2022 Other Options:</li><li>\u2022 Option B. Increase in Insulin/ glucagon ratio: In uncontrolled diabetes, insulin levels are low while glucagon levels are high , which decreases the insulin/glucagon ratio. This promotes lipolysis and ketone body production. Therefore, an increase in this ratio would inhibit ketogenesis, making this option incorrect.</li><li>\u2022 Option B. Increase in Insulin/ glucagon ratio:</li><li>\u2022 low</li><li>\u2022 high</li><li>\u2022 increase</li><li>\u2022 Option C. Decreased acetyl CoA: In diabetes, acetyl-CoA levels are increased due to the breakdown of free fatty acids. This excess acetyl-CoA contributes to ketone body production. Thus, decreased acetyl-CoA is not correct.</li><li>\u2022 Option C. Decreased acetyl CoA:</li><li>\u2022 acetyl-CoA levels are increased</li><li>\u2022 Option D. Increased availability of oxaloacetate: In uncontrolled diabetes, oxaloacetate is diverted for gluconeogenesis, resulting in reduced oxaloacetate availability for the TCA cycle. This prevents acetyl-CoA from entering the cycle and favors ketogenesis. Increased oxaloacetate would inhibit ketogenesis, so this option is incorrect.</li><li>\u2022 Option D. Increased availability of oxaloacetate:</li><li>\u2022 reduced oxaloacetate availability</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 In uncontrolled Type I Diabetes, increased plasma free fatty acids due to insulin deficiency promote the production of ketone bodies through beta-oxidation, leading to diabetic ketoacidosis (DKA) .</li><li>\u27a4 increased plasma free fatty acids</li><li>\u27a4 ketone bodies</li><li>\u27a4 diabetic ketoacidosis (DKA)</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "324357fb",
      "audio": ""
    },
    {
      "text": "A 15-month-old toddler is brought to the clinic due to episodes of discomfort following certain meals. Omitting dairy from the diet had no impact on the symptoms. The child's growth and development markers are on track. No anomalies were detected in a liver biopsy. However, after careful observation, it was noticed that discomfort arises every time the child consumes fruit-based foods or drinks, leading to noticeable bloating and gas. This child most likely would show a deficiency of:",
      "options": [
        {
          "label": "A",
          "text": "SGLT-1",
          "correct": false
        },
        {
          "label": "B",
          "text": "GLUT-5",
          "correct": true
        },
        {
          "label": "C",
          "text": "GLUT-2",
          "correct": false
        },
        {
          "label": "D",
          "text": "All the above",
          "correct": false
        }
      ],
      "correct_answer": "B. GLUT-5",
      "question_images": [],
      "explanation_images": [
        "https://cerebellum-web-static.s3.amazonaws.com/media/public/Screenshot%202024-12-18%20131235.jpg"
      ],
      "explanation": "<p><strong>Ans. B) GLUT-5</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 The key clinical clue in this case is that the child experiences bloating and gas specifically after consuming fruit-based foods or drinks . Fruits and juices contain fructose , a monosaccharide that is absorbed in the intestines by the GLUT-5 transporter .</li><li>\u2022 bloating and gas</li><li>\u2022 fruit-based foods or drinks</li><li>\u2022 fructose</li><li>\u2022 GLUT-5 transporter</li><li>\u2022 GLUT-5:</li><li>\u2022 GLUT-5:</li><li>\u2022 GLUT-5 is a fructose transporter found in the small intestine (apical membrane of enterocytes). It facilitates the absorption of fructose into the intestinal cells. A deficiency or defect in GLUT-5 impairs fructose absorption, causing fructose to remain in the intestines. The undigested fructose undergoes fermentation by gut bacteria, producing gas and leading to bloating, diarrhea, and discomfort .</li><li>\u2022 GLUT-5 is a fructose transporter found in the small intestine (apical membrane of enterocytes). It facilitates the absorption of fructose into the intestinal cells. A deficiency or defect in GLUT-5 impairs fructose absorption, causing fructose to remain in the intestines. The undigested fructose undergoes fermentation by gut bacteria, producing gas and leading to bloating, diarrhea, and discomfort .</li><li>\u2022 fructose transporter</li><li>\u2022 small intestine</li><li>\u2022 It facilitates the absorption of fructose into the intestinal cells. A deficiency or defect in GLUT-5 impairs fructose absorption, causing fructose to remain in the intestines. The undigested fructose undergoes fermentation by gut bacteria, producing gas and leading to bloating, diarrhea, and discomfort .</li><li>\u2022 It facilitates the absorption of fructose into the intestinal cells.</li><li>\u2022 A deficiency or defect in GLUT-5 impairs fructose absorption, causing fructose to remain in the intestines.</li><li>\u2022 The undigested fructose undergoes fermentation by gut bacteria, producing gas and leading to bloating, diarrhea, and discomfort .</li><li>\u2022 fermentation</li><li>\u2022 bloating, diarrhea, and discomfort</li><li>\u2022 Other Options:</li><li>\u2022 Other Options:</li><li>\u2022 Option A. SGLT-1: SGLT-1 is a sodium-glucose transporter responsible for the absorption of glucose and galactose in the small intestine. It does not transport fructose.</li><li>\u2022 Option A. SGLT-1:</li><li>\u2022 glucose</li><li>\u2022 galactose</li><li>\u2022 Option C. GLUT-2: GLUT-2 is involved in the transport of glucose, galactose, and fructose from enterocytes (basolateral membrane) into the bloodstream, but it does not mediate initial fructose absorption into the cells.</li><li>\u2022 Option C. GLUT-2:</li><li>\u2022 initial fructose absorption</li><li>\u2022 Option D. All the above: This is incorrect because only GLUT-5 is specifically responsible for fructose transport, while SGLT-1 and GLUT-2 handle glucose and galactose.</li><li>\u2022 Option D. All the above:</li><li>\u2022 only GLUT-5</li><li>\u2022 Note:</li><li>\u2022 Note:</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 GLUT-5 is the primary transporter for fructose absorption in the small intestine. A deficiency in GLUT-5 can lead to symptoms like bloating, gas, and discomfort after consuming fructose-containing foods and drinks.</li><li>\u27a4 GLUT-5</li><li>\u27a4 fructose absorption</li><li>\u27a4 bloating, gas, and discomfort</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "3a65fb7f",
      "audio": ""
    },
    {
      "text": "Pyruvate from glycolysis can go in different directions based on the type of tissue, cell, and if oxygen is present or not. There's a big enzyme complex that guides pyruvate towards aerobic metabolism. This complex does many things, except:",
      "options": [
        {
          "label": "A",
          "text": "Remove a carbon group from a molecule.",
          "correct": false
        },
        {
          "label": "B",
          "text": "Substrate level phosphorylation",
          "correct": true
        },
        {
          "label": "C",
          "text": "Turn pyruvate into an acetyl group.",
          "correct": false
        },
        {
          "label": "D",
          "text": "Attach the acetyl group to a cofactor.",
          "correct": false
        }
      ],
      "correct_answer": "B. Substrate level phosphorylation",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. B) Substrate level phosphorylation</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 The question refers to the Pyruvate Dehydrogenase Complex (PDC) , a multi-enzyme complex responsible for converting pyruvate (from glycolysis) into acetyl-CoA in the presence of oxygen. This process is known as the link reaction , as it links glycolysis to the TCA (Krebs) cycle.</li><li>\u2022 Pyruvate Dehydrogenase Complex (PDC)</li><li>\u2022 pyruvate</li><li>\u2022 acetyl-CoA</li><li>\u2022 link reaction</li><li>\u2022 The Pyruvate Dehydrogenase Complex does not do: Substrate-level phosphorylation involves the direct transfer of a phosphate group to ADP to form ATP. This process occurs in glycolysis and the TCA cycle but not in the link reaction catalyzed by the PDC. The PDC performs oxidative decarboxylation, which generates NADH but not ATP.</li><li>\u2022 The Pyruvate Dehydrogenase Complex does not do:</li><li>\u2022 not</li><li>\u2022 NADH</li><li>\u2022 Other Options:</li><li>\u2022 Other Options:</li><li>\u2022 The Pyruvate Dehydrogenase Complex does:</li><li>\u2022 The Pyruvate Dehydrogenase Complex does:</li><li>\u2022 Option A. Remove a carbon group from a molecule: This is correct. The PDC catalyzes oxidative decarboxylation , where one carbon is removed from pyruvate as CO\u2082 , converting pyruvate (3 carbons) to an acetyl group (2 carbons).</li><li>\u2022 Option A. Remove a carbon group from a molecule:</li><li>\u2022 oxidative decarboxylation</li><li>\u2022 CO\u2082</li><li>\u2022 Option Turn pyruvate into an acetyl group: This is correct. The decarboxylation step produces an acetyl group .</li><li>\u2022 Option Turn pyruvate into an acetyl group:</li><li>\u2022 acetyl group</li><li>\u2022 Option D. Attach the acetyl group to a cofactor: This is correct. The acetyl group is attached to Coenzyme A (CoA) , forming acetyl-CoA , which enters the TCA cycle.</li><li>\u2022 Option D. Attach the acetyl group to a cofactor:</li><li>\u2022 Coenzyme A (CoA)</li><li>\u2022 acetyl-CoA</li><li>\u2022 Notes:</li><li>\u2022 Notes:</li><li>\u2022 The link reaction is irreversible and requires several cofactors: Thiamine pyrophosphate (Vitamin B1) FAD (Vitamin B2) NAD\u207a (Vitamin B3) Coenzyme A (Vitamin B5) Lipoic acid</li><li>\u2022 The link reaction is irreversible and requires several cofactors: Thiamine pyrophosphate (Vitamin B1) FAD (Vitamin B2) NAD\u207a (Vitamin B3) Coenzyme A (Vitamin B5) Lipoic acid</li><li>\u2022 link reaction</li><li>\u2022 irreversible</li><li>\u2022 Thiamine pyrophosphate (Vitamin B1) FAD (Vitamin B2) NAD\u207a (Vitamin B3) Coenzyme A (Vitamin B5) Lipoic acid</li><li>\u2022 Thiamine pyrophosphate (Vitamin B1)</li><li>\u2022 FAD (Vitamin B2)</li><li>\u2022 NAD\u207a (Vitamin B3)</li><li>\u2022 Coenzyme A (Vitamin B5)</li><li>\u2022 Lipoic acid</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 The Pyruvate Dehydrogenase Complex performs oxidative decarboxylation , converting pyruvate to acetyl-CoA. It does not involve substrate-level phosphorylation .</li><li>\u27a4 Pyruvate Dehydrogenase Complex</li><li>\u27a4 oxidative decarboxylation</li><li>\u27a4 does not involve substrate-level phosphorylation</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "62f7b2a3",
      "audio": ""
    },
    {
      "text": "A medical student doing a lab practical is rushed to the emergency room. She's unconscious, has a very high fever, a fast heartbeat, and quick breathing. She has a yellow mark on her arm and very low blood pressure. Some students said she spilled a chemical on herself while making a reagent. First, her vision got blurry, then she had a headache and shaky movements before fainting. What chemical did she most likely spill on herself?",
      "options": [
        {
          "label": "A",
          "text": "Carboxin",
          "correct": false
        },
        {
          "label": "B",
          "text": "Phenobarbital",
          "correct": false
        },
        {
          "label": "C",
          "text": "Dimercaprol",
          "correct": false
        },
        {
          "label": "D",
          "text": "Dinitrophenol",
          "correct": true
        }
      ],
      "correct_answer": "D. Dinitrophenol",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. D) Dinitrophenol</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation</li><li>\u2022 The correct answer is dinitrophenol (DNP), a chemical that uncouples oxidative phosphorylation in mitochondria.</li><li>\u2022 dinitrophenol</li><li>\u2022 Yellow Mark : Dinitrophenol is a yellow-colored powder , which explains the yellow mark on the student's arm. High Fever and Thermogenesis : DNP acts as an uncoupler of the electron transport chain (ETC) by dissipating the proton gradient across the mitochondrial membrane. Instead of ATP generation, energy is released as heat , leading to hyperthermia (high fever). Symptoms : Blurry Vision and Headache : These symptoms arise due to DNP toxicity affecting neural and metabolic functions. Fast Heartbeat and Breathing : A compensatory response to hyperthermia and decreased ATP levels. Shaky Movements and Unconsciousness : Indicate systemic toxicity and failure to produce sufficient ATP for normal cellular function.</li><li>\u2022 Yellow Mark : Dinitrophenol is a yellow-colored powder , which explains the yellow mark on the student's arm.</li><li>\u2022 Yellow Mark</li><li>\u2022 yellow-colored powder</li><li>\u2022 High Fever and Thermogenesis : DNP acts as an uncoupler of the electron transport chain (ETC) by dissipating the proton gradient across the mitochondrial membrane. Instead of ATP generation, energy is released as heat , leading to hyperthermia (high fever).</li><li>\u2022 High Fever and Thermogenesis</li><li>\u2022 uncoupler</li><li>\u2022 heat</li><li>\u2022 hyperthermia</li><li>\u2022 Symptoms : Blurry Vision and Headache : These symptoms arise due to DNP toxicity affecting neural and metabolic functions. Fast Heartbeat and Breathing : A compensatory response to hyperthermia and decreased ATP levels. Shaky Movements and Unconsciousness : Indicate systemic toxicity and failure to produce sufficient ATP for normal cellular function.</li><li>\u2022 Symptoms</li><li>\u2022 Blurry Vision and Headache : These symptoms arise due to DNP toxicity affecting neural and metabolic functions. Fast Heartbeat and Breathing : A compensatory response to hyperthermia and decreased ATP levels. Shaky Movements and Unconsciousness : Indicate systemic toxicity and failure to produce sufficient ATP for normal cellular function.</li><li>\u2022 Blurry Vision and Headache : These symptoms arise due to DNP toxicity affecting neural and metabolic functions.</li><li>\u2022 Blurry Vision</li><li>\u2022 Headache</li><li>\u2022 Fast Heartbeat and Breathing : A compensatory response to hyperthermia and decreased ATP levels.</li><li>\u2022 Fast Heartbeat and Breathing</li><li>\u2022 Shaky Movements and Unconsciousness : Indicate systemic toxicity and failure to produce sufficient ATP for normal cellular function.</li><li>\u2022 Shaky Movements</li><li>\u2022 Unconsciousness</li><li>\u2022 This aligns with the student's clinical presentation, particularly the high fever and yellow mark , which are characteristic of DNP exposure.</li><li>\u2022 high fever</li><li>\u2022 yellow mark</li><li>\u2022 Other Options:</li><li>\u2022 Other Options:</li><li>\u2022 Option A. Carboxin: Carboxin inhibits Complex II (succinate dehydrogenase) of the electron transport chain (ETC). It would impair ATP production but does not cause hyperthermia or yellow discoloration, which are key features in this case.</li><li>\u2022 Option A. Carboxin:</li><li>\u2022 Complex II</li><li>\u2022 hyperthermia</li><li>\u2022 Option B. Phenobarbital: Phenobarbital inhibits Complex I of the ETC. It is a barbiturate, typically causing CNS depression rather than hyperthermia and fast heartbeat. There is no association with yellow marks.</li><li>\u2022 Option B. Phenobarbital:</li><li>\u2022 Complex I</li><li>\u2022 CNS depression</li><li>\u2022 Option C. Dimercaprol: Dimercaprol is a chelating agent used to treat heavy metal poisoning. It does not affect the ETC or cause uncoupling, hyperthermia, or yellow marks.</li><li>\u2022 Option C. Dimercaprol:</li><li>\u2022 chelating agent</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 Dinitrophenol (DNP) is a yellow-colored chemical that acts as an uncoupler of oxidative phosphorylation, leading to thermogenesis (heat generation), hyperthermia, and systemic toxicity.</li><li>\u27a4 Dinitrophenol (DNP)</li><li>\u27a4 uncoupler</li><li>\u27a4 thermogenesis</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "d97f5cfe",
      "audio": ""
    },
    {
      "text": "A 7-year-old girl is brought to a pediatrician with complaints of intermittent muscle weakness. On physical examination, there is mild hepatomegaly. A liver biopsy is conducted which reveals abnormally structured glycogen with very long outer chains. The patient is most likely suffering from:",
      "options": [
        {
          "label": "A",
          "text": "Anderson disease",
          "correct": true
        },
        {
          "label": "B",
          "text": "Cori\u2019s disease",
          "correct": false
        },
        {
          "label": "C",
          "text": "Pompe\u2019s disease",
          "correct": false
        },
        {
          "label": "D",
          "text": "Limit dextrinosis",
          "correct": false
        }
      ],
      "correct_answer": "A. Anderson disease",
      "question_images": [],
      "explanation_images": [
        "https://cerebellum-web-static.s3.amazonaws.com/media/public/Screenshot%202024-12-18%20131450.jpg",
        "https://cerebellum-web-static.s3.amazonaws.com/media/public/Screenshot%202024-12-18%20131507.jpg"
      ],
      "explanation": "<p><strong>Ans. A) Anderson disease</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation</li><li>\u2022 The key findings in this patient\u2014 abnormally structured glycogen with very long outer chains \u2014are characteristic of Anderson disease , also known as Glycogen Storage Disease Type IV (Amylopectinosis) .</li><li>\u2022 abnormally structured glycogen with very long outer chains</li><li>\u2022 Anderson disease</li><li>\u2022 Glycogen Storage Disease Type IV (Amylopectinosis)</li><li>\u2022 Anderson Disease Overview : This condition is caused by a deficiency of the branching enzyme (amylo-\u03b1-1,4-\u03b1-1,6-transglucosidase). This enzyme is responsible for creating branch points in glycogen molecules. Without it, glycogen accumulates as abnormally long, unbranched chains , resembling amylopectin. The abnormal structure of glycogen cannot be broken down efficiently, leading to hepatomegaly (due to glycogen buildup) and muscle weakness . Clinical Features : Hepatomegaly : Due to accumulation of glycogen in the liver. Intermittent Muscle Weakness : Associated with glycogen storage defects affecting muscle metabolism. Progression : Over time, liver dysfunction and cirrhosis may occur as the abnormal glycogen damages liver tissue. Glycogen Structure : In Anderson disease, glycogen has very long, unbranched outer chains instead of the normal highly branched structure. This makes it less soluble and prone to accumulation.</li><li>\u2022 Anderson Disease Overview : This condition is caused by a deficiency of the branching enzyme (amylo-\u03b1-1,4-\u03b1-1,6-transglucosidase). This enzyme is responsible for creating branch points in glycogen molecules. Without it, glycogen accumulates as abnormally long, unbranched chains , resembling amylopectin. The abnormal structure of glycogen cannot be broken down efficiently, leading to hepatomegaly (due to glycogen buildup) and muscle weakness .</li><li>\u2022 Anderson Disease Overview</li><li>\u2022 This condition is caused by a deficiency of the branching enzyme (amylo-\u03b1-1,4-\u03b1-1,6-transglucosidase). This enzyme is responsible for creating branch points in glycogen molecules. Without it, glycogen accumulates as abnormally long, unbranched chains , resembling amylopectin. The abnormal structure of glycogen cannot be broken down efficiently, leading to hepatomegaly (due to glycogen buildup) and muscle weakness .</li><li>\u2022 This condition is caused by a deficiency of the branching enzyme (amylo-\u03b1-1,4-\u03b1-1,6-transglucosidase).</li><li>\u2022 branching enzyme</li><li>\u2022 This enzyme is responsible for creating branch points in glycogen molecules. Without it, glycogen accumulates as abnormally long, unbranched chains , resembling amylopectin.</li><li>\u2022 branch points</li><li>\u2022 abnormally long, unbranched chains</li><li>\u2022 The abnormal structure of glycogen cannot be broken down efficiently, leading to hepatomegaly (due to glycogen buildup) and muscle weakness .</li><li>\u2022 hepatomegaly</li><li>\u2022 muscle weakness</li><li>\u2022 Clinical Features : Hepatomegaly : Due to accumulation of glycogen in the liver. Intermittent Muscle Weakness : Associated with glycogen storage defects affecting muscle metabolism. Progression : Over time, liver dysfunction and cirrhosis may occur as the abnormal glycogen damages liver tissue.</li><li>\u2022 Clinical Features</li><li>\u2022 Hepatomegaly : Due to accumulation of glycogen in the liver. Intermittent Muscle Weakness : Associated with glycogen storage defects affecting muscle metabolism. Progression : Over time, liver dysfunction and cirrhosis may occur as the abnormal glycogen damages liver tissue.</li><li>\u2022 Hepatomegaly : Due to accumulation of glycogen in the liver.</li><li>\u2022 Hepatomegaly</li><li>\u2022 Intermittent Muscle Weakness : Associated with glycogen storage defects affecting muscle metabolism.</li><li>\u2022 Intermittent Muscle Weakness</li><li>\u2022 Progression : Over time, liver dysfunction and cirrhosis may occur as the abnormal glycogen damages liver tissue.</li><li>\u2022 Progression</li><li>\u2022 Glycogen Structure : In Anderson disease, glycogen has very long, unbranched outer chains instead of the normal highly branched structure. This makes it less soluble and prone to accumulation.</li><li>\u2022 Glycogen Structure</li><li>\u2022 In Anderson disease, glycogen has very long, unbranched outer chains instead of the normal highly branched structure. This makes it less soluble and prone to accumulation.</li><li>\u2022 In Anderson disease, glycogen has very long, unbranched outer chains instead of the normal highly branched structure. This makes it less soluble and prone to accumulation.</li><li>\u2022 very long, unbranched outer chains</li><li>\u2022 Other Options:</li><li>\u2022 Other Options:</li><li>\u2022 Option B. Cori\u2019s disease: Cori\u2019s disease (GSD Type III) is caused by a deficiency of the debranching enzyme . It leads to the accumulation of glycogen with short outer chains (limit dextrins), not long outer chains.</li><li>\u2022 Option B. Cori\u2019s disease:</li><li>\u2022 debranching enzyme</li><li>\u2022 short outer chains</li><li>\u2022 Option C. Pompe\u2019s disease: Pompe\u2019s disease (GSD Type II) is caused by a deficiency of acid maltase (\u03b1-1,4-glucosidase). It primarily affects the heart and muscles, causing cardiomyopathy and generalized muscle weakness. There is no abnormal glycogen structure.</li><li>\u2022 Option C. Pompe\u2019s disease:</li><li>\u2022 acid maltase</li><li>\u2022 cardiomyopathy</li><li>\u2022 Option D. Limit dextrinosis: This term refers to GSD Type III (Cori\u2019s disease) , where glycogen has short, branched outer chains . This does not match the description of long outer chains seen in Anderson disease.</li><li>\u2022 Option D. Limit dextrinosis:</li><li>\u2022 GSD Type III (Cori\u2019s disease)</li><li>\u2022 short, branched outer chains</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 Anderson disease (GSD Type IV) is caused by a deficiency of the branching enzyme , leading to glycogen with abnormally long outer chains . Key features include hepatomegaly , intermittent muscle weakness , and liver biopsy findings of structurally abnormal glycogen resembling amylopectin.</li><li>\u27a4 Anderson disease (GSD Type IV)</li><li>\u27a4 branching enzyme</li><li>\u27a4 abnormally long outer chains</li><li>\u27a4 hepatomegaly</li><li>\u27a4 muscle weakness</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "0e1677d4",
      "audio": ""
    },
    {
      "text": "An otherwise healthy 22-year-old man presents to the emergency department with acute onset jaundice and dark urine. He denies any recent illnesses but mentions that he took an over-the-counter medication for fever two days ago. His family history reveals that his maternal grandfather had a similar episode in the past. Peripheral smear shows the presence of Heinz bodies. Which enzyme deficiency is most consistent with this patient's presentation?",
      "options": [
        {
          "label": "A",
          "text": "Pyruvate kinase",
          "correct": false
        },
        {
          "label": "B",
          "text": "Hexokinase",
          "correct": false
        },
        {
          "label": "C",
          "text": "Glucose-6-phosphate dehydrogenase (G6PD)",
          "correct": true
        },
        {
          "label": "D",
          "text": "Aldolase A",
          "correct": false
        }
      ],
      "correct_answer": "C. Glucose-6-phosphate dehydrogenase (G6PD)",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. C) Glucose-6-phosphate dehydrogenase (G6PD)</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation</li><li>\u2022 The patient's presentation is consistent with Glucose-6-phosphate dehydrogenase (G6PD) deficiency , a common X-linked recessive disorder that causes acute hemolytic anemia following exposure to oxidative stress.</li><li>\u2022 Glucose-6-phosphate dehydrogenase (G6PD) deficiency</li><li>\u2022 acute hemolytic anemia</li><li>\u2022 Key Clinical Features : Acute Onset Jaundice and Dark Urine : Jaundice results from hemolysis of red blood cells, releasing bilirubin. Dark urine is caused by hemoglobinuria (presence of free hemoglobin in urine). Recent Medication Use : Over-the-counter medications like antimalarials (e.g., primaquine), sulfa drugs, or NSAIDs can trigger oxidative stress in G6PD-deficient individuals. Family History : X-linked inheritance explains the family history, particularly affecting male relatives (maternal grandfather). Heinz Bodies : These are aggregates of denatured hemoglobin caused by oxidative damage to red blood cells. They are seen on peripheral blood smears stained with supravital dyes. Role of G6PD : G6PD is an enzyme in the pentose phosphate pathway , which generates NADPH . NADPH is required to maintain glutathione in its reduced form, which protects red blood cells from oxidative stress. In G6PD deficiency, red blood cells are unable to neutralize reactive oxygen species, leading to hemoglobin denaturation, Heinz body formation, and hemolysis.</li><li>\u2022 Key Clinical Features : Acute Onset Jaundice and Dark Urine : Jaundice results from hemolysis of red blood cells, releasing bilirubin. Dark urine is caused by hemoglobinuria (presence of free hemoglobin in urine). Recent Medication Use : Over-the-counter medications like antimalarials (e.g., primaquine), sulfa drugs, or NSAIDs can trigger oxidative stress in G6PD-deficient individuals. Family History : X-linked inheritance explains the family history, particularly affecting male relatives (maternal grandfather). Heinz Bodies : These are aggregates of denatured hemoglobin caused by oxidative damage to red blood cells. They are seen on peripheral blood smears stained with supravital dyes.</li><li>\u2022 Key Clinical Features</li><li>\u2022 Acute Onset Jaundice and Dark Urine : Jaundice results from hemolysis of red blood cells, releasing bilirubin. Dark urine is caused by hemoglobinuria (presence of free hemoglobin in urine). Recent Medication Use : Over-the-counter medications like antimalarials (e.g., primaquine), sulfa drugs, or NSAIDs can trigger oxidative stress in G6PD-deficient individuals. Family History : X-linked inheritance explains the family history, particularly affecting male relatives (maternal grandfather). Heinz Bodies : These are aggregates of denatured hemoglobin caused by oxidative damage to red blood cells. They are seen on peripheral blood smears stained with supravital dyes.</li><li>\u2022 Acute Onset Jaundice and Dark Urine : Jaundice results from hemolysis of red blood cells, releasing bilirubin. Dark urine is caused by hemoglobinuria (presence of free hemoglobin in urine).</li><li>\u2022 Acute Onset Jaundice and Dark Urine</li><li>\u2022 hemoglobinuria</li><li>\u2022 Recent Medication Use : Over-the-counter medications like antimalarials (e.g., primaquine), sulfa drugs, or NSAIDs can trigger oxidative stress in G6PD-deficient individuals.</li><li>\u2022 Recent Medication Use</li><li>\u2022 antimalarials (e.g., primaquine), sulfa drugs, or NSAIDs</li><li>\u2022 Family History : X-linked inheritance explains the family history, particularly affecting male relatives (maternal grandfather).</li><li>\u2022 Family History</li><li>\u2022 Heinz Bodies : These are aggregates of denatured hemoglobin caused by oxidative damage to red blood cells. They are seen on peripheral blood smears stained with supravital dyes.</li><li>\u2022 Heinz Bodies</li><li>\u2022 denatured hemoglobin</li><li>\u2022 Role of G6PD : G6PD is an enzyme in the pentose phosphate pathway , which generates NADPH . NADPH is required to maintain glutathione in its reduced form, which protects red blood cells from oxidative stress. In G6PD deficiency, red blood cells are unable to neutralize reactive oxygen species, leading to hemoglobin denaturation, Heinz body formation, and hemolysis.</li><li>\u2022 Role of G6PD</li><li>\u2022 G6PD is an enzyme in the pentose phosphate pathway , which generates NADPH . NADPH is required to maintain glutathione in its reduced form, which protects red blood cells from oxidative stress. In G6PD deficiency, red blood cells are unable to neutralize reactive oxygen species, leading to hemoglobin denaturation, Heinz body formation, and hemolysis.</li><li>\u2022 G6PD is an enzyme in the pentose phosphate pathway , which generates NADPH .</li><li>\u2022 pentose phosphate pathway</li><li>\u2022 NADPH</li><li>\u2022 NADPH is required to maintain glutathione in its reduced form, which protects red blood cells from oxidative stress.</li><li>\u2022 glutathione</li><li>\u2022 In G6PD deficiency, red blood cells are unable to neutralize reactive oxygen species, leading to hemoglobin denaturation, Heinz body formation, and hemolysis.</li><li>\u2022 Other Options:</li><li>\u2022 Other Options:</li><li>\u2022 Option A. Pyruvate kinase: Pyruvate kinase deficiency also causes hemolytic anemia but does not lead to Heinz bodies . Instead, it is associated with echinocytes (burr cells) on the peripheral smear.</li><li>\u2022 Option A. Pyruvate kinase:</li><li>\u2022 Heinz bodies</li><li>\u2022 echinocytes</li><li>\u2022 Option B. Hexokinase: Hexokinase deficiency affects glycolysis and causes hemolytic anemia but does not involve oxidative stress or Heinz body formation.</li><li>\u2022 Option B. Hexokinase:</li><li>\u2022 Option D. Aldolase A: Aldolase A deficiency leads to hemolytic anemia and muscle weakness but is unrelated to oxidative stress or Heinz body formation.</li><li>\u2022 Option D. Aldolase A:</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 G6PD deficiency is an X-linked disorder characterized by hemolytic anemia triggered by oxidative stress (e.g., medications, infections, or fava beans). The presence of Heinz bodies on peripheral smear is diagnostic.</li><li>\u27a4 G6PD deficiency</li><li>\u27a4 hemolytic anemia</li><li>\u27a4 Heinz bodies</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "e8947805",
      "audio": ""
    },
    {
      "text": "In the TCA cycle, the enzyme Aconitase can be blocked by fluoroacetate. A graph below displays the activity of Aconitase both in the presence and absence of fluoroacetate, using a double reciprocal plot. The change in kinetic parameters of aconitase by this inhibitor is reflected as:",
      "options": [
        {
          "label": "A",
          "text": "Increase in Vmax",
          "correct": false
        },
        {
          "label": "B",
          "text": "Decrease in Vmax",
          "correct": true
        },
        {
          "label": "C",
          "text": "Decreases in Km",
          "correct": false
        },
        {
          "label": "D",
          "text": "Increase in both Km and Vmax",
          "correct": false
        }
      ],
      "correct_answer": "B. Decrease in Vmax",
      "question_images": [
        "https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2023/10/09/picture3_8crbkGu.jpg"
      ],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. B) Decrease in Vmax</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation</li><li>\u2022 Fluoroacetate as a Non-Competitive Inhibitor : Fluoroacetate gets converted to fluorocitrate , which inhibits aconitase . This inhibition is non-competitive , meaning it binds to both the enzyme and enzyme-substrate complex at an allosteric site, not at the active site. Effect of Non-Competitive Inhibition on Kinetic Parameters : In non-competitive inhibition : Vmax decreases : The inhibitor reduces the total number of active enzyme molecules, which lowers the maximum velocity (Vmax). Km remains unchanged : The substrate's affinity for the enzyme does not change since the inhibitor binds elsewhere. Interpreting the Lineweaver-Burk Plot : The y-axis represents 1/V1 (reciprocal of velocity). The x-axis represents 1/[S] (reciprocal of substrate concentration). In non-competitive inhibition: The Vmax decreases , so the y-intercept (where 1/V1 increases) shifts upwards . The Km remains constant , so the x-intercept (representing \u22121/Km) stays the same. In the Graph Provided : The plot with fluoroacetate has a steeper slope and a higher y-intercept , indicating a decrease in Vmax. The x-intercept is unchanged, confirming that Km remains constant .</li><li>\u2022 Fluoroacetate as a Non-Competitive Inhibitor : Fluoroacetate gets converted to fluorocitrate , which inhibits aconitase . This inhibition is non-competitive , meaning it binds to both the enzyme and enzyme-substrate complex at an allosteric site, not at the active site.</li><li>\u2022 Fluoroacetate as a Non-Competitive Inhibitor</li><li>\u2022 Fluoroacetate gets converted to fluorocitrate , which inhibits aconitase . This inhibition is non-competitive , meaning it binds to both the enzyme and enzyme-substrate complex at an allosteric site, not at the active site.</li><li>\u2022 Fluoroacetate gets converted to fluorocitrate , which inhibits aconitase . This inhibition is non-competitive , meaning it binds to both the enzyme and enzyme-substrate complex at an allosteric site, not at the active site.</li><li>\u2022 fluorocitrate</li><li>\u2022 aconitase</li><li>\u2022 non-competitive</li><li>\u2022 Effect of Non-Competitive Inhibition on Kinetic Parameters : In non-competitive inhibition : Vmax decreases : The inhibitor reduces the total number of active enzyme molecules, which lowers the maximum velocity (Vmax). Km remains unchanged : The substrate's affinity for the enzyme does not change since the inhibitor binds elsewhere.</li><li>\u2022 Effect of Non-Competitive Inhibition on Kinetic Parameters</li><li>\u2022 In non-competitive inhibition : Vmax decreases : The inhibitor reduces the total number of active enzyme molecules, which lowers the maximum velocity (Vmax). Km remains unchanged : The substrate's affinity for the enzyme does not change since the inhibitor binds elsewhere.</li><li>\u2022 In non-competitive inhibition : Vmax decreases : The inhibitor reduces the total number of active enzyme molecules, which lowers the maximum velocity (Vmax). Km remains unchanged : The substrate's affinity for the enzyme does not change since the inhibitor binds elsewhere.</li><li>\u2022 non-competitive inhibition</li><li>\u2022 Vmax decreases : The inhibitor reduces the total number of active enzyme molecules, which lowers the maximum velocity (Vmax). Km remains unchanged : The substrate's affinity for the enzyme does not change since the inhibitor binds elsewhere.</li><li>\u2022 Vmax decreases : The inhibitor reduces the total number of active enzyme molecules, which lowers the maximum velocity (Vmax).</li><li>\u2022 Vmax decreases</li><li>\u2022 Km remains unchanged : The substrate's affinity for the enzyme does not change since the inhibitor binds elsewhere.</li><li>\u2022 Km remains unchanged</li><li>\u2022 Interpreting the Lineweaver-Burk Plot : The y-axis represents 1/V1 (reciprocal of velocity). The x-axis represents 1/[S] (reciprocal of substrate concentration). In non-competitive inhibition: The Vmax decreases , so the y-intercept (where 1/V1 increases) shifts upwards . The Km remains constant , so the x-intercept (representing \u22121/Km) stays the same.</li><li>\u2022 Interpreting the Lineweaver-Burk Plot</li><li>\u2022 The y-axis represents 1/V1 (reciprocal of velocity). The x-axis represents 1/[S] (reciprocal of substrate concentration). In non-competitive inhibition: The Vmax decreases , so the y-intercept (where 1/V1 increases) shifts upwards . The Km remains constant , so the x-intercept (representing \u22121/Km) stays the same.</li><li>\u2022 The y-axis represents 1/V1 (reciprocal of velocity).</li><li>\u2022 y-axis</li><li>\u2022 The x-axis represents 1/[S] (reciprocal of substrate concentration).</li><li>\u2022 x-axis</li><li>\u2022 In non-competitive inhibition: The Vmax decreases , so the y-intercept (where 1/V1 increases) shifts upwards . The Km remains constant , so the x-intercept (representing \u22121/Km) stays the same.</li><li>\u2022 The Vmax decreases , so the y-intercept (where 1/V1 increases) shifts upwards . The Km remains constant , so the x-intercept (representing \u22121/Km) stays the same.</li><li>\u2022 The Vmax decreases , so the y-intercept (where 1/V1 increases) shifts upwards .</li><li>\u2022 Vmax decreases</li><li>\u2022 upwards</li><li>\u2022 The Km remains constant , so the x-intercept (representing \u22121/Km) stays the same.</li><li>\u2022 Km remains constant</li><li>\u2022 In the Graph Provided : The plot with fluoroacetate has a steeper slope and a higher y-intercept , indicating a decrease in Vmax. The x-intercept is unchanged, confirming that Km remains constant .</li><li>\u2022 In the Graph Provided</li><li>\u2022 The plot with fluoroacetate has a steeper slope and a higher y-intercept , indicating a decrease in Vmax. The x-intercept is unchanged, confirming that Km remains constant .</li><li>\u2022 The plot with fluoroacetate has a steeper slope and a higher y-intercept , indicating a decrease in Vmax.</li><li>\u2022 fluoroacetate</li><li>\u2022 higher y-intercept</li><li>\u2022 The x-intercept is unchanged, confirming that Km remains constant .</li><li>\u2022 Km remains constant</li><li>\u2022 Other Options:</li><li>\u2022 Other Options:</li><li>\u2022 Option A. Increase in Vmax: Incorrect. Vmax decreases in non-competitive inhibition.</li><li>\u2022 Option A. Increase in Vmax:</li><li>\u2022 Option C. Decrease in Km : Incorrect. Km remains unchanged because the inhibitor does not affect substrate binding affinity.</li><li>\u2022 Option C. Decrease in Km</li><li>\u2022 Option D. Increase in both Km and Vmax: Incorrect. Neither Km increases nor does Vmax increase in non-competitive inhibition.</li><li>\u2022 Option D. Increase in both Km and Vmax:</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 In the presence of fluoroacetate , aconitase undergoes non-competitive inhibition , resulting in a decrease in Vmax while Km remains unchanged , as demonstrated on the Lineweaver-Burk plot .</li><li>\u27a4 fluoroacetate</li><li>\u27a4 non-competitive inhibition</li><li>\u27a4 decrease in Vmax</li><li>\u27a4 unchanged</li><li>\u27a4 Lineweaver-Burk plot</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "09506432",
      "audio": ""
    },
    {
      "text": "A 3-month-old infant is brought to the pediatric clinic due to concerns about the musty odour emanating from the baby\u2019s sweat and urine. Newborn metabolic screening was conducted 1 day after birth and did not report any amino acid metabolic disorder. Given the scenario, which inherited metabolic disorder is most likely responsible for the infant\u2019s symptoms?",
      "options": [
        {
          "label": "A",
          "text": "Homocystinuria",
          "correct": false
        },
        {
          "label": "B",
          "text": "Primary hyperoxaluria",
          "correct": false
        },
        {
          "label": "C",
          "text": "Phenylketonuria (PKU)",
          "correct": true
        },
        {
          "label": "D",
          "text": "Glycinuria",
          "correct": false
        }
      ],
      "correct_answer": "C. Phenylketonuria (PKU)",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. C) Phenylketonuria (PKU)</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation</li><li>\u2022 The clinical presentation of a musty odor in sweat and urine, combined with the delayed onset of symptoms, is highly suggestive of Phenylketonuria (PKU) , an autosomal recessive metabolic disorder caused by a deficiency of phenylalanine hydroxylase (PAH) .</li><li>\u2022 musty odor</li><li>\u2022 Phenylketonuria (PKU)</li><li>\u2022 phenylalanine hydroxylase (PAH)</li><li>\u2022 Biochemical Basis of PKU :</li><li>\u2022 Biochemical Basis of PKU</li><li>\u2022 Phenylalanine hydroxylase normally converts phenylalanine to tyrosine using tetrahydrobiopterin (BH4) as a cofactor. In PKU, phenylalanine accumulates in the blood and is metabolized into phenylketones , which are excreted in sweat and urine, producing the characteristic musty or mousy odor .</li><li>\u2022 Phenylalanine hydroxylase normally converts phenylalanine to tyrosine using tetrahydrobiopterin (BH4) as a cofactor.</li><li>\u2022 phenylalanine to tyrosine</li><li>\u2022 tetrahydrobiopterin (BH4)</li><li>\u2022 In PKU, phenylalanine accumulates in the blood and is metabolized into phenylketones , which are excreted in sweat and urine, producing the characteristic musty or mousy odor .</li><li>\u2022 phenylketones</li><li>\u2022 musty or mousy odor</li><li>\u2022 Why Screening at 1 Day Missed the Diagnosis :</li><li>\u2022 Why Screening at 1 Day Missed the Diagnosis</li><li>\u2022 At 1 day of life , phenylalanine levels may not yet be significantly elevated because dietary intake is minimal, and enzyme activity may not be fully overwhelmed. Newborn screening for PKU is ideally performed 2-3 days after birth to ensure accurate detection of elevated phenylalanine levels. This delay explains why the initial screening did not detect PKU.</li><li>\u2022 At 1 day of life , phenylalanine levels may not yet be significantly elevated because dietary intake is minimal, and enzyme activity may not be fully overwhelmed.</li><li>\u2022 1 day of life</li><li>\u2022 Newborn screening for PKU is ideally performed 2-3 days after birth to ensure accurate detection of elevated phenylalanine levels.</li><li>\u2022 Newborn screening</li><li>\u2022 2-3 days after birth</li><li>\u2022 This delay explains why the initial screening did not detect PKU.</li><li>\u2022 Clinical Features of PKU :</li><li>\u2022 Clinical Features of PKU</li><li>\u2022 Musty Odor : Due to the accumulation of phenylacetate, a phenylketone. Mental Retardation : If untreated, phenylalanine and its metabolites are neurotoxic, leading to cognitive deficits. Hypopigmentation : Low tyrosine levels result in decreased melanin synthesis, causing fair skin, light hair, and blue eyes . Developmental Delay and Seizures : Associated with prolonged untreated PKU.</li><li>\u2022 Musty Odor : Due to the accumulation of phenylacetate, a phenylketone.</li><li>\u2022 Musty Odor</li><li>\u2022 Mental Retardation : If untreated, phenylalanine and its metabolites are neurotoxic, leading to cognitive deficits.</li><li>\u2022 Mental Retardation</li><li>\u2022 Hypopigmentation : Low tyrosine levels result in decreased melanin synthesis, causing fair skin, light hair, and blue eyes .</li><li>\u2022 Hypopigmentation</li><li>\u2022 fair skin, light hair, and blue eyes</li><li>\u2022 Developmental Delay and Seizures : Associated with prolonged untreated PKU.</li><li>\u2022 Developmental Delay and Seizures</li><li>\u2022 Other Options:</li><li>\u2022 Other Options:</li><li>\u2022 Option A. Homocystinuria: Homocystinuria is caused by defects in cystathionine \u03b2-synthase and presents with ectopia lentis (lens dislocation), intellectual disability, skeletal abnormalities, and thrombosis . It does not cause a musty odor.</li><li>\u2022 Option A. Homocystinuria:</li><li>\u2022 cystathionine \u03b2-synthase</li><li>\u2022 ectopia lentis (lens dislocation), intellectual disability, skeletal abnormalities, and thrombosis</li><li>\u2022 Option B. Primary Hyperoxaluria: This condition causes excess oxalate production , leading to calcium oxalate kidney stones and nephrocalcinosis. There is no musty odor associated with this condition.</li><li>\u2022 Option B. Primary Hyperoxaluria:</li><li>\u2022 oxalate production</li><li>\u2022 calcium oxalate kidney stones</li><li>\u2022 Option D. Glycinuria: Glycinuria is characterized by defective renal absorption of glycine, resulting in glycinuria. It does not cause abnormal odor or neurodevelopmental symptoms.</li><li>\u2022 Option D. Glycinuria:</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 Phenylketonuria (PKU) is an inherited metabolic disorder caused by a deficiency of phenylalanine hydroxylase , leading to musty odor , mental retardation, and hypopigmentation. Screening for PKU should be done 2-3 days after birth for accurate detection, as levels may not be elevated immediately at birth.</li><li>\u27a4 Phenylketonuria (PKU)</li><li>\u27a4 phenylalanine hydroxylase</li><li>\u27a4 musty odor</li><li>\u27a4 2-3 days after birth</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "a18dbc1c",
      "audio": ""
    },
    {
      "text": "A 5-year-old girl is brought to the pediatric clinic with concerns of frequent falls and visual problems. On examination, she displays a tall, thin stature with a high-arched palate, and lens dislocation downwards & inwards is noted in both eyes. Additionally, the child has a history of developmental delay and a predisposition to thromboembolic events. Given these clinical findings, which alteration in amino acid metabolism is most characteristic of the child's likely inherited metabolic disorder?",
      "options": [
        {
          "label": "A",
          "text": "Arginine becomes essential.",
          "correct": false
        },
        {
          "label": "B",
          "text": "Histidine becomes non-essential.",
          "correct": false
        },
        {
          "label": "C",
          "text": "Cysteine becomes essential.",
          "correct": true
        },
        {
          "label": "D",
          "text": "Tyrosine becomes non-essential.",
          "correct": false
        }
      ],
      "correct_answer": "C. Cysteine becomes essential.",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. C) Cysteine becomes essential.</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation</li><li>\u2022 The clinical findings described\u2014 lens dislocation downwards and inwards , tall stature, high-arched palate, frequent falls, developmental delay, and thromboembolic events \u2014are characteristic of Homocystinuria , an autosomal recessive disorder caused by defects in sulfur-containing amino acid metabolism.</li><li>\u2022 lens dislocation downwards and inwards</li><li>\u2022 tall stature, high-arched palate, frequent falls, developmental delay, and thromboembolic events</li><li>\u2022 Homocystinuria</li><li>\u2022 Homocystinuria Overview : Homocystinuria is most commonly caused by a deficiency of cystathionine \u03b2-synthase (CBS) , an enzyme that converts homocysteine to cystathionine , which is further converted to cysteine . As a result, homocysteine and methionine accumulate, while cysteine levels become low. Why Cysteine Becomes Essential : Under normal conditions, cysteine is synthesized from homocysteine via the CBS pathway. When CBS is deficient, the body cannot produce cysteine from homocysteine, so cysteine must now be obtained from the diet, making it essential . Clinical Features of Homocystinuria : Lens Dislocation : Downward and inward displacement of the lens (in contrast to Marfan syndrome , where the lens dislocates upwards). Tall, Thin Stature : Similar to Marfan syndrome but with additional features. Thromboembolic Events : Increased homocysteine levels predispose to vascular thrombosis, a major cause of morbidity. Developmental Delay : Neurodevelopmental problems are common. High-Arched Palate : A classic feature in connective tissue disorders like homocystinuria. Biochemical Pathway : Methionine \u2192 Homocysteine \u2192 Cystathionine \u2192 Cysteine In CBS deficiency, homocysteine accumulates, and cysteine cannot be produced, making cysteine essential .</li><li>\u2022 Homocystinuria Overview : Homocystinuria is most commonly caused by a deficiency of cystathionine \u03b2-synthase (CBS) , an enzyme that converts homocysteine to cystathionine , which is further converted to cysteine . As a result, homocysteine and methionine accumulate, while cysteine levels become low.</li><li>\u2022 Homocystinuria Overview</li><li>\u2022 Homocystinuria is most commonly caused by a deficiency of cystathionine \u03b2-synthase (CBS) , an enzyme that converts homocysteine to cystathionine , which is further converted to cysteine . As a result, homocysteine and methionine accumulate, while cysteine levels become low.</li><li>\u2022 Homocystinuria is most commonly caused by a deficiency of cystathionine \u03b2-synthase (CBS) , an enzyme that converts homocysteine to cystathionine , which is further converted to cysteine .</li><li>\u2022 cystathionine \u03b2-synthase (CBS)</li><li>\u2022 homocysteine</li><li>\u2022 cystathionine</li><li>\u2022 cysteine</li><li>\u2022 As a result, homocysteine and methionine accumulate, while cysteine levels become low.</li><li>\u2022 homocysteine</li><li>\u2022 methionine</li><li>\u2022 cysteine</li><li>\u2022 Why Cysteine Becomes Essential : Under normal conditions, cysteine is synthesized from homocysteine via the CBS pathway. When CBS is deficient, the body cannot produce cysteine from homocysteine, so cysteine must now be obtained from the diet, making it essential .</li><li>\u2022 Why Cysteine Becomes Essential</li><li>\u2022 Under normal conditions, cysteine is synthesized from homocysteine via the CBS pathway. When CBS is deficient, the body cannot produce cysteine from homocysteine, so cysteine must now be obtained from the diet, making it essential .</li><li>\u2022 Under normal conditions, cysteine is synthesized from homocysteine via the CBS pathway.</li><li>\u2022 cysteine</li><li>\u2022 homocysteine</li><li>\u2022 When CBS is deficient, the body cannot produce cysteine from homocysteine, so cysteine must now be obtained from the diet, making it essential .</li><li>\u2022 essential</li><li>\u2022 Clinical Features of Homocystinuria : Lens Dislocation : Downward and inward displacement of the lens (in contrast to Marfan syndrome , where the lens dislocates upwards). Tall, Thin Stature : Similar to Marfan syndrome but with additional features. Thromboembolic Events : Increased homocysteine levels predispose to vascular thrombosis, a major cause of morbidity. Developmental Delay : Neurodevelopmental problems are common. High-Arched Palate : A classic feature in connective tissue disorders like homocystinuria.</li><li>\u2022 Clinical Features of Homocystinuria</li><li>\u2022 Lens Dislocation : Downward and inward displacement of the lens (in contrast to Marfan syndrome , where the lens dislocates upwards). Tall, Thin Stature : Similar to Marfan syndrome but with additional features. Thromboembolic Events : Increased homocysteine levels predispose to vascular thrombosis, a major cause of morbidity. Developmental Delay : Neurodevelopmental problems are common. High-Arched Palate : A classic feature in connective tissue disorders like homocystinuria.</li><li>\u2022 Lens Dislocation : Downward and inward displacement of the lens (in contrast to Marfan syndrome , where the lens dislocates upwards).</li><li>\u2022 Lens Dislocation</li><li>\u2022 Marfan syndrome</li><li>\u2022 Tall, Thin Stature : Similar to Marfan syndrome but with additional features.</li><li>\u2022 Tall, Thin Stature</li><li>\u2022 Thromboembolic Events : Increased homocysteine levels predispose to vascular thrombosis, a major cause of morbidity.</li><li>\u2022 Thromboembolic Events</li><li>\u2022 Developmental Delay : Neurodevelopmental problems are common.</li><li>\u2022 Developmental Delay</li><li>\u2022 High-Arched Palate : A classic feature in connective tissue disorders like homocystinuria.</li><li>\u2022 High-Arched Palate</li><li>\u2022 Biochemical Pathway : Methionine \u2192 Homocysteine \u2192 Cystathionine \u2192 Cysteine In CBS deficiency, homocysteine accumulates, and cysteine cannot be produced, making cysteine essential .</li><li>\u2022 Biochemical Pathway</li><li>\u2022 Methionine \u2192 Homocysteine \u2192 Cystathionine \u2192 Cysteine In CBS deficiency, homocysteine accumulates, and cysteine cannot be produced, making cysteine essential .</li><li>\u2022 Methionine \u2192 Homocysteine \u2192 Cystathionine \u2192 Cysteine</li><li>\u2022 Homocysteine</li><li>\u2022 Cystathionine</li><li>\u2022 Cysteine</li><li>\u2022 In CBS deficiency, homocysteine accumulates, and cysteine cannot be produced, making cysteine essential .</li><li>\u2022 homocysteine</li><li>\u2022 cysteine essential</li><li>\u2022 Other Options:</li><li>\u2022 Other Options:</li><li>\u2022 Option A. Arginine becomes essential: Arginine becomes essential in urea cycle defects (e.g., ornithine transcarbamylase deficiency), not in homocystinuria.</li><li>\u2022 Option A. Arginine becomes essential:</li><li>\u2022 urea cycle defects</li><li>\u2022 Option B. Histidine becomes non-essential: Histidine is an essential amino acid under normal conditions and is not altered in homocystinuria.</li><li>\u2022 Option B. Histidine becomes non-essential:</li><li>\u2022 Option D. Tyrosine becomes non-essential: Tyrosine becomes non-essential in phenylketonuria (PKU) because it is synthesized from phenylalanine.</li><li>\u2022 Option D. Tyrosine becomes non-essential:</li><li>\u2022 phenylketonuria (PKU)</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 Homocystinuria , caused by a deficiency of cystathionine \u03b2-synthase (CBS) , results in cysteine becoming essential because it can no longer be synthesized from homocysteine. Key clinical features include lens dislocation (downward and inward) , tall stature , thromboembolic events , and developmental delay .</li><li>\u27a4 Homocystinuria</li><li>\u27a4 cystathionine \u03b2-synthase (CBS)</li><li>\u27a4 cysteine becoming essential</li><li>\u27a4 lens dislocation (downward and inward)</li><li>\u27a4 tall stature</li><li>\u27a4 thromboembolic events</li><li>\u27a4 developmental delay</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "c0896ea7",
      "audio": ""
    },
    {
      "text": "The quaternary structure of a protein refers to the spatial arrangement of multiple polypeptide chains that form a functional protein complex. Considering the structural organization of proteins. Based on this information, which of the following protein can\u2019t have quaternary structure?",
      "options": [
        {
          "label": "A",
          "text": "Myoglobin",
          "correct": true
        },
        {
          "label": "B",
          "text": "Immunoglobulin",
          "correct": false
        },
        {
          "label": "C",
          "text": "Hemoglobulin",
          "correct": false
        },
        {
          "label": "D",
          "text": "Collagen",
          "correct": false
        }
      ],
      "correct_answer": "A. Myoglobin",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. A) Myoglobin</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation</li><li>\u2022 Myoglobin consists of only one polypeptide chain . It serves as an oxygen-storage protein in muscles and has a tertiary structure . Since it does not have multiple chains, myoglobin does not have a quaternary structure . If a protein consists of only a single polypeptide chain , it will not have a quaternary structure and will instead stop at the tertiary structure .</li><li>\u2022 Myoglobin consists of only one polypeptide chain .</li><li>\u2022 only one polypeptide chain</li><li>\u2022 It serves as an oxygen-storage protein in muscles and has a tertiary structure .</li><li>\u2022 oxygen-storage protein</li><li>\u2022 tertiary structure</li><li>\u2022 Since it does not have multiple chains, myoglobin does not have a quaternary structure .</li><li>\u2022 myoglobin does not have a quaternary structure</li><li>\u2022 If a protein consists of only a single polypeptide chain , it will not have a quaternary structure and will instead stop at the tertiary structure .</li><li>\u2022 only a single polypeptide chain</li><li>\u2022 not have a quaternary structure</li><li>\u2022 tertiary structure</li><li>\u2022 Other Options:</li><li>\u2022 Other Options:</li><li>\u2022 The quaternary structure of a protein involves the interaction and arrangement of multiple polypeptide chains (subunits) to form a functional protein complex.</li><li>\u2022 quaternary structure</li><li>\u2022 multiple polypeptide chains (subunits)</li><li>\u2022 Option B. Immunoglobulin (Antibodies) :</li><li>\u2022 Option B. Immunoglobulin (Antibodies)</li><li>\u2022 Immunoglobulins consist of two heavy chains and two light chains , held together by disulfide bonds. This makes it a classic example of a protein with a quaternary structure .</li><li>\u2022 Immunoglobulins consist of two heavy chains and two light chains , held together by disulfide bonds.</li><li>\u2022 two heavy chains</li><li>\u2022 two light chains</li><li>\u2022 This makes it a classic example of a protein with a quaternary structure .</li><li>\u2022 This makes it a classic example of a protein with a quaternary structure .</li><li>\u2022 quaternary structure</li><li>\u2022 Option C. Hemoglobin :</li><li>\u2022 Option C. Hemoglobin</li><li>\u2022 Hemoglobin has four polypeptide chains (two alpha and two beta chains) and is responsible for oxygen transport in blood. Its quaternary structure allows for cooperative oxygen binding.</li><li>\u2022 Hemoglobin has four polypeptide chains (two alpha and two beta chains) and is responsible for oxygen transport in blood.</li><li>\u2022 four polypeptide chains</li><li>\u2022 Its quaternary structure allows for cooperative oxygen binding.</li><li>\u2022 Option D. Collagen :</li><li>\u2022 Option D. Collagen</li><li>\u2022 Collagen consists of three polypeptide chains arranged in a triple helix. This arrangement contributes to its strength and structural role in connective tissues.</li><li>\u2022 Collagen consists of three polypeptide chains arranged in a triple helix.</li><li>\u2022 three polypeptide chains</li><li>\u2022 This arrangement contributes to its strength and structural role in connective tissues.</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 Myoglobin lacks a quaternary structure because it consists of only one polypeptide chain and is organized at the tertiary structure level . Proteins like immunoglobulin, hemoglobin, and collagen have multiple chains, which gives them a quaternary structure.</li><li>\u27a4 Myoglobin</li><li>\u27a4 only one polypeptide chain</li><li>\u27a4 tertiary structure level</li><li>\u27a4 immunoglobulin, hemoglobin, and collagen</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "a3ea05d3",
      "audio": ""
    },
    {
      "text": "A 10-month-old infant presents to the pediatric clinic following a brief illness during which the child refused to eat. The parents report episodes of lethargy, and the child displays signs of hypoketotic hypoglycemia. Lab findings indicate the presence of dicarboxylic aciduria. Which inherited metabolic disorder is the most probable cause of these findings?",
      "options": [
        {
          "label": "A",
          "text": "Phenylketonuria (PKU)",
          "correct": false
        },
        {
          "label": "B",
          "text": "Glucose-6-phosphate dehydrogenase (G6PD) deficiency",
          "correct": false
        },
        {
          "label": "C",
          "text": "Medium-chain acyl-CoA dehydrogenase (MCAD) deficiency",
          "correct": true
        },
        {
          "label": "D",
          "text": "Maple syrup urine disease (MSUD)",
          "correct": false
        }
      ],
      "correct_answer": "C. Medium-chain acyl-CoA dehydrogenase (MCAD) deficiency",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. C) Medium-chain acyl-CoA dehydrogenase (MCAD) deficiency</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation</li><li>\u2022 Medium-chain acyl-CoA dehydrogenase (MCAD) deficiency is an inherited disorder of fatty acid \u03b2-oxidation. It is caused by a deficiency in the MCAD enzyme , which impairs the body\u2019s ability to break down medium-chain fatty acids for energy during periods of fasting or illness.</li><li>\u2022 Medium-chain acyl-CoA dehydrogenase (MCAD) deficiency</li><li>\u2022 MCAD enzyme</li><li>\u2022 Key Clinical Features:</li><li>\u2022 Key Clinical Features:</li><li>\u2022 Hypoketotic hypoglycemia \u2013 Fatty acids cannot be broken down to produce ketones and glucose, leading to hypoglycemia without appropriate ketone production. Dicarboxylic aciduria \u2013 When fatty acid oxidation is impaired, \u03c9-oxidation occurs instead, leading to the accumulation and excretion of dicarboxylic acids in the urine. Lethargy and vomiting \u2013 Occurs during fasting or illness due to energy deficiency. Refusal to eat \u2013 Illness precipitates the crisis, as fasting leads to an inability to generate energy from fatty acids. Sudden death \u2013 In severe cases, untreated MCAD deficiency can result in sudden death due to severe hypoglycemia and energy depletion.</li><li>\u2022 Hypoketotic hypoglycemia \u2013 Fatty acids cannot be broken down to produce ketones and glucose, leading to hypoglycemia without appropriate ketone production.</li><li>\u2022 Hypoketotic hypoglycemia</li><li>\u2022 Dicarboxylic aciduria \u2013 When fatty acid oxidation is impaired, \u03c9-oxidation occurs instead, leading to the accumulation and excretion of dicarboxylic acids in the urine.</li><li>\u2022 Dicarboxylic aciduria</li><li>\u2022 dicarboxylic acids</li><li>\u2022 Lethargy and vomiting \u2013 Occurs during fasting or illness due to energy deficiency.</li><li>\u2022 Lethargy and vomiting</li><li>\u2022 Refusal to eat \u2013 Illness precipitates the crisis, as fasting leads to an inability to generate energy from fatty acids.</li><li>\u2022 Refusal to eat</li><li>\u2022 Sudden death \u2013 In severe cases, untreated MCAD deficiency can result in sudden death due to severe hypoglycemia and energy depletion.</li><li>\u2022 Sudden death</li><li>\u2022 This combination of hypoketotic hypoglycemia and dicarboxylic aciduria is diagnostic for MCAD deficiency.</li><li>\u2022 hypoketotic hypoglycemia</li><li>\u2022 dicarboxylic aciduria</li><li>\u2022 Other Options:</li><li>\u2022 Other Options:</li><li>\u2022 Option A. Phenylketonuria (PKU): PKU results from a deficiency of phenylalanine hydroxylase , leading to elevated phenylalanine and neurological deficits. It does not cause hypoglycemia or dicarboxylic aciduria.</li><li>\u2022 Option A. Phenylketonuria (PKU):</li><li>\u2022 phenylalanine hydroxylase</li><li>\u2022 Option B. Glucose-6-phosphate dehydrogenase (G6PD) deficiency: G6PD deficiency causes hemolytic anemia following oxidative stress but does not result in hypoglycemia or dicarboxylic aciduria.</li><li>\u2022 Option B. Glucose-6-phosphate dehydrogenase (G6PD) deficiency:</li><li>\u2022 hemolytic anemia</li><li>\u2022 Option D. Maple syrup urine disease (MSUD): MSUD is caused by defects in branched-chain \u03b1-ketoacid dehydrogenase, leading to accumulation of branched-chain amino acids (leucine, isoleucine, and valine). It presents with a sweet odor of urine and neurological symptoms but does not cause hypoglycemia or dicarboxylic aciduria.</li><li>\u2022 Option D. Maple syrup urine disease (MSUD):</li><li>\u2022 sweet odor of urine</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 MCAD deficiency is characterized by:</li><li>\u27a4 MCAD deficiency</li><li>\u27a4 Hypoketotic hypoglycemia during fasting or illness Dicarboxylic aciduria Impaired fatty acid \u03b2-oxidation due to MCAD enzyme deficiency .</li><li>\u27a4 Hypoketotic hypoglycemia during fasting or illness</li><li>\u27a4 Hypoketotic hypoglycemia</li><li>\u27a4 Dicarboxylic aciduria</li><li>\u27a4 Dicarboxylic aciduria</li><li>\u27a4 Impaired fatty acid \u03b2-oxidation due to MCAD enzyme deficiency .</li><li>\u27a4 MCAD enzyme deficiency</li><li>\u27a4 Early diagnosis and prevention of fasting are critical to avoid metabolic crises.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "376428d2",
      "audio": ""
    },
    {
      "text": "A 3-year-old male child presents with self-mutilating behavior, including biting of fingers and lips. Laboratory findings indicate the presence of orange-colored crystals in the urine and elevated serum uric acid levels. Which of the following is responsible for the neurological features in this patient?",
      "options": [
        {
          "label": "A",
          "text": "Decreased de novo purine synthesis.",
          "correct": false
        },
        {
          "label": "B",
          "text": "Decreased de novo pyrimidine synthesis.",
          "correct": false
        },
        {
          "label": "C",
          "text": "Increased phosphoribosyl pyrophosphate (PRPP) levels",
          "correct": true
        },
        {
          "label": "D",
          "text": "Inhibition of xanthine oxidase",
          "correct": false
        }
      ],
      "correct_answer": "C. Increased phosphoribosyl pyrophosphate (PRPP) levels",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. C) Increased phosphoribosyl pyrophosphate (PRPP) levels</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation</li><li>\u2022 The clinical presentation of self-mutilating behavior (lip and finger biting), orange-colored crystals in urine (suggesting uric acid crystalluria), and elevated serum uric acid strongly suggests Lesch-Nyhan syndrome .</li><li>\u2022 self-mutilating behavior</li><li>\u2022 orange-colored crystals in urine</li><li>\u2022 elevated serum uric acid</li><li>\u2022 Lesch-Nyhan syndrome</li><li>\u2022 Lesch-Nyhan syndrome is caused by a deficiency of the enzyme hypoxanthine-guanine phosphoribosyl transferase (HGPRT) . HGPRT is critical for the purine salvage pathway , where it recycles hypoxanthine and guanine into purine nucleotides.</li><li>\u2022 Lesch-Nyhan syndrome is caused by a deficiency of the enzyme hypoxanthine-guanine phosphoribosyl transferase (HGPRT) .</li><li>\u2022 Lesch-Nyhan syndrome</li><li>\u2022 hypoxanthine-guanine phosphoribosyl transferase (HGPRT)</li><li>\u2022 HGPRT is critical for the purine salvage pathway , where it recycles hypoxanthine and guanine into purine nucleotides.</li><li>\u2022 purine salvage pathway</li><li>\u2022 hypoxanthine</li><li>\u2022 guanine</li><li>\u2022 Pathophysiology of Neurological Features:</li><li>\u2022 Pathophysiology of Neurological Features:</li><li>\u2022 HGPRT deficiency causes:</li><li>\u2022 HGPRT deficiency</li><li>\u2022 Failure of purine salvage \u2192 Increased breakdown of purines \u2192 Excess uric acid production (hyperuricemia). Accumulation of phosphoribosyl pyrophosphate (PRPP) , a substrate for de novo purine synthesis .</li><li>\u2022 Failure of purine salvage \u2192 Increased breakdown of purines \u2192 Excess uric acid production (hyperuricemia).</li><li>\u2022 Accumulation of phosphoribosyl pyrophosphate (PRPP) , a substrate for de novo purine synthesis .</li><li>\u2022 phosphoribosyl pyrophosphate (PRPP)</li><li>\u2022 de novo purine synthesis</li><li>\u2022 Increased PRPP levels :</li><li>\u2022 Increased PRPP levels</li><li>\u2022 PRPP stimulates de novo purine synthesis , leading to overproduction of purines and subsequent uric acid buildup. PRPP itself is neurotoxic and contributes to the neurological manifestations, including self-mutilating behavior and cognitive delays.</li><li>\u2022 PRPP stimulates de novo purine synthesis , leading to overproduction of purines and subsequent uric acid buildup.</li><li>\u2022 de novo purine synthesis</li><li>\u2022 PRPP itself is neurotoxic and contributes to the neurological manifestations, including self-mutilating behavior and cognitive delays.</li><li>\u2022 self-mutilating behavior</li><li>\u2022 Other Options:</li><li>\u2022 Other Options:</li><li>\u2022 Option A. Decreased de novo purine synthesis: Incorrect. De novo purine synthesis is increased in Lesch-Nyhan syndrome due to elevated PRPP levels.</li><li>\u2022 Option A. Decreased de novo purine synthesis:</li><li>\u2022 increased</li><li>\u2022 Option B. Decreased de novo pyrimidine synthesis: Incorrect. Pyrimidine synthesis is unaffected in Lesch-Nyhan syndrome.</li><li>\u2022 Option B. Decreased de novo pyrimidine synthesis:</li><li>\u2022 Option D. Inhibition of xanthine oxidase: Incorrect. Xanthine oxidase is responsible for converting xanthine and hypoxanthine to uric acid. While inhibition of this enzyme (e.g., by allopurinol) reduces uric acid levels, it is not the cause of neurological features.</li><li>\u2022 Option D. Inhibition of xanthine oxidase:</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 In Lesch-Nyhan syndrome , the deficiency of HGPRT leads to increased PRPP levels , which drives de novo purine synthesis and causes neurotoxic effects that result in self-mutilating behavior, hyperuricemia, and neurological dysfunction.</li><li>\u27a4 Lesch-Nyhan syndrome</li><li>\u27a4 HGPRT</li><li>\u27a4 PRPP levels</li><li>\u27a4 de novo purine synthesis</li><li>\u27a4 neurotoxic effects</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "4d9a8d9d",
      "audio": ""
    },
    {
      "text": "A patient presented with unusual genetic anomalies. Upon investigation, it was found that Uracil had been incorporated into the genetic code. This abnormality is linked to the deficiency of a specific vitamin. Which vitamin, when deficient, can lead to this occurrence?",
      "options": [
        {
          "label": "A",
          "text": "Vitamin B9",
          "correct": true
        },
        {
          "label": "B",
          "text": "Vitamin B12",
          "correct": false
        },
        {
          "label": "C",
          "text": "Vitamin B1",
          "correct": false
        },
        {
          "label": "D",
          "text": "Vitamin B2",
          "correct": false
        }
      ],
      "correct_answer": "A. Vitamin B9",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. A) Vitamin B9</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation</li><li>\u2022 The incorporation of uracil (U) into DNA instead of thymine (T) is a result of a deficiency of Vitamin B9 (folate) .</li><li>\u2022 uracil (U)</li><li>\u2022 thymine (T)</li><li>\u2022 deficiency of Vitamin B9 (folate)</li><li>\u2022 Mechanism:</li><li>\u2022 Mechanism:</li><li>\u2022 Thymine (T) is produced from uracil (U) through the action of thymidylate synthase . This enzyme converts dUMP (deoxyuridine monophosphate) to dTMP (deoxythymidine monophosphate) by adding a methyl group . The methyl group for this reaction is provided by N5, N10-methylene tetrahydrofolate , which is derived from folate (Vitamin B9) . In Vitamin B9 deficiency : The conversion of dUMP to dTMP is impaired due to the unavailability of the methyl group. As a result, uracil is incorporated into DNA in place of thymine, leading to genetic instability and abnormal DNA synthesis.</li><li>\u2022 Thymine (T) is produced from uracil (U) through the action of thymidylate synthase . This enzyme converts dUMP (deoxyuridine monophosphate) to dTMP (deoxythymidine monophosphate) by adding a methyl group .</li><li>\u2022 Thymine (T)</li><li>\u2022 uracil (U)</li><li>\u2022 thymidylate synthase</li><li>\u2022 This enzyme converts dUMP (deoxyuridine monophosphate) to dTMP (deoxythymidine monophosphate) by adding a methyl group .</li><li>\u2022 This enzyme converts dUMP (deoxyuridine monophosphate) to dTMP (deoxythymidine monophosphate) by adding a methyl group .</li><li>\u2022 dUMP (deoxyuridine monophosphate)</li><li>\u2022 dTMP (deoxythymidine monophosphate)</li><li>\u2022 methyl group</li><li>\u2022 The methyl group for this reaction is provided by N5, N10-methylene tetrahydrofolate , which is derived from folate (Vitamin B9) .</li><li>\u2022 N5, N10-methylene tetrahydrofolate</li><li>\u2022 folate (Vitamin B9)</li><li>\u2022 In Vitamin B9 deficiency : The conversion of dUMP to dTMP is impaired due to the unavailability of the methyl group. As a result, uracil is incorporated into DNA in place of thymine, leading to genetic instability and abnormal DNA synthesis.</li><li>\u2022 In Vitamin B9 deficiency</li><li>\u2022 The conversion of dUMP to dTMP is impaired due to the unavailability of the methyl group. As a result, uracil is incorporated into DNA in place of thymine, leading to genetic instability and abnormal DNA synthesis.</li><li>\u2022 The conversion of dUMP to dTMP is impaired due to the unavailability of the methyl group.</li><li>\u2022 dUMP to dTMP</li><li>\u2022 As a result, uracil is incorporated into DNA in place of thymine, leading to genetic instability and abnormal DNA synthesis.</li><li>\u2022 uracil</li><li>\u2022 genetic instability</li><li>\u2022 Consequences:</li><li>\u2022 Consequences:</li><li>\u2022 This abnormal incorporation causes DNA damage , mutations, and genetic anomalies, as uracil is not normally present in DNA. Folate deficiency leads to megaloblastic anemia due to impaired DNA synthesis and cell division.</li><li>\u2022 This abnormal incorporation causes DNA damage , mutations, and genetic anomalies, as uracil is not normally present in DNA.</li><li>\u2022 DNA damage</li><li>\u2022 Folate deficiency leads to megaloblastic anemia due to impaired DNA synthesis and cell division.</li><li>\u2022 Other Options:</li><li>\u2022 Other Options:</li><li>\u2022 Option B. Vitamin B12: B12 deficiency also leads to megaloblastic anemia but does not directly impair the conversion of dUMP to dTMP. Instead, it affects methionine synthesis and folate metabolism.</li><li>\u2022 Option B. Vitamin B12:</li><li>\u2022 methionine synthesis</li><li>\u2022 Option C. Vitamin B1: Vitamin B1 (thiamine) is involved in carbohydrate metabolism and does not play a role in thymine synthesis.</li><li>\u2022 Option C. Vitamin B1:</li><li>\u2022 Option D. Vitamin B2: Vitamin B2 (riboflavin) is involved in energy metabolism and as a coenzyme but is not related to uracil incorporation.</li><li>\u2022 Option D. Vitamin B2:</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 Vitamin B9 (folate) is required for the conversion of dUMP to dTMP via thymidylate synthase . In folate deficiency, uracil is incorporated into DNA instead of thymine, leading to genetic anomalies and DNA damage.</li><li>\u27a4 Vitamin B9 (folate)</li><li>\u27a4 dUMP to dTMP</li><li>\u27a4 thymidylate synthase</li><li>\u27a4 uracil</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "7b8b4eb4",
      "audio": ""
    },
    {
      "text": "A 60-year-old female presents with fatigue, pallor, and a tingling sensation in her feet. Lab investigations reveal megaloblastic anemia. Additionally, her blood tests show elevated levels of homocysteine and urine showed elevated Methyl malonic acid. Which vitamin deficiency best describe her condition?",
      "options": [
        {
          "label": "A",
          "text": "Vitamin B1 deficiency",
          "correct": false
        },
        {
          "label": "B",
          "text": "Vitamin B6 deficiency",
          "correct": false
        },
        {
          "label": "C",
          "text": "Vitamin B12 deficiency",
          "correct": true
        },
        {
          "label": "D",
          "text": "Vitamin C deficiency",
          "correct": false
        }
      ],
      "correct_answer": "C. Vitamin B12 deficiency",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. C) Vitamin B12 deficiency</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation</li><li>\u2022 The patient's symptoms and lab findings are classic for Vitamin B12 (cobalamin) deficiency .</li><li>\u2022 Vitamin B12 (cobalamin) deficiency</li><li>\u2022 Key Features of Vitamin B12 Deficiency:</li><li>\u2022 Key Features of Vitamin B12 Deficiency:</li><li>\u2022 Megaloblastic Anemia Impaired DNA synthesis due to reduced tetrahydrofolate levels. Neurological Symptoms Tingling sensation in the feet is due to subacute combined degeneration of the spinal cord . This occurs because methylmalonic acid accumulates and damages myelin sheaths. Elevated Homocysteine and Methylmalonic Acid Homocysteine increases because Vitamin B12 is a cofactor for methionine synthase , which converts homocysteine to methionine. Methylmalonic acid (MMA) increases because Vitamin B12 is needed for methylmalonyl-CoA mutase , which converts MMA to succinyl-CoA.</li><li>\u2022 Megaloblastic Anemia Impaired DNA synthesis due to reduced tetrahydrofolate levels.</li><li>\u2022 Megaloblastic Anemia</li><li>\u2022 Impaired DNA synthesis due to reduced tetrahydrofolate levels.</li><li>\u2022 Impaired DNA synthesis due to reduced tetrahydrofolate levels.</li><li>\u2022 Neurological Symptoms Tingling sensation in the feet is due to subacute combined degeneration of the spinal cord . This occurs because methylmalonic acid accumulates and damages myelin sheaths.</li><li>\u2022 Neurological Symptoms</li><li>\u2022 Tingling sensation in the feet is due to subacute combined degeneration of the spinal cord . This occurs because methylmalonic acid accumulates and damages myelin sheaths.</li><li>\u2022 Tingling sensation in the feet is due to subacute combined degeneration of the spinal cord .</li><li>\u2022 Tingling sensation</li><li>\u2022 subacute combined degeneration of the spinal cord</li><li>\u2022 This occurs because methylmalonic acid accumulates and damages myelin sheaths.</li><li>\u2022 methylmalonic acid</li><li>\u2022 Elevated Homocysteine and Methylmalonic Acid Homocysteine increases because Vitamin B12 is a cofactor for methionine synthase , which converts homocysteine to methionine. Methylmalonic acid (MMA) increases because Vitamin B12 is needed for methylmalonyl-CoA mutase , which converts MMA to succinyl-CoA.</li><li>\u2022 Elevated Homocysteine and Methylmalonic Acid</li><li>\u2022 Homocysteine increases because Vitamin B12 is a cofactor for methionine synthase , which converts homocysteine to methionine. Methylmalonic acid (MMA) increases because Vitamin B12 is needed for methylmalonyl-CoA mutase , which converts MMA to succinyl-CoA.</li><li>\u2022 Homocysteine increases because Vitamin B12 is a cofactor for methionine synthase , which converts homocysteine to methionine.</li><li>\u2022 Homocysteine</li><li>\u2022 methionine synthase</li><li>\u2022 Methylmalonic acid (MMA) increases because Vitamin B12 is needed for methylmalonyl-CoA mutase , which converts MMA to succinyl-CoA.</li><li>\u2022 Methylmalonic acid (MMA)</li><li>\u2022 methylmalonyl-CoA mutase</li><li>\u2022 Other Options:</li><li>\u2022 Other Options:</li><li>\u2022 Option  A. Vitamin B1 (Thiamine) Deficiency : Causes beriberi or Wernicke-Korsakoff syndrome but does not affect homocysteine or methylmalonic acid levels.</li><li>\u2022 Option  A. Vitamin B1 (Thiamine) Deficiency</li><li>\u2022 beriberi</li><li>\u2022 Wernicke-Korsakoff syndrome</li><li>\u2022 Option B. Vitamin B6 Deficiency : Elevates homocysteine but does not cause megaloblastic anemia or elevated methylmalonic acid.</li><li>\u2022 Option B. Vitamin B6 Deficiency</li><li>\u2022 Option D. Vitamin C Deficiency : Leads to scurvy with symptoms like bleeding gums and poor wound healing but no effect on homocysteine or methylmalonic acid.</li><li>\u2022 Option D. Vitamin C Deficiency</li><li>\u2022 scurvy</li><li>\u2022 Note :</li><li>\u2022 Note</li><li>\u2022 Vitamin B9 (Folate) Deficiency : Causes megaloblastic anemia and elevated homocysteine. However, methylmalonic acid is normal in folate deficiency.</li><li>\u2022 Vitamin B9 (Folate) Deficiency : Causes megaloblastic anemia and elevated homocysteine. However, methylmalonic acid is normal in folate deficiency.</li><li>\u2022 Vitamin B9 (Folate) Deficiency</li><li>\u2022 Causes megaloblastic anemia and elevated homocysteine. However, methylmalonic acid is normal in folate deficiency.</li><li>\u2022 Causes megaloblastic anemia and elevated homocysteine.</li><li>\u2022 megaloblastic anemia</li><li>\u2022 However, methylmalonic acid is normal in folate deficiency.</li><li>\u2022 methylmalonic acid is normal</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 Vitamin B12 deficiency leads to:</li><li>\u27a4 Vitamin B12 deficiency leads</li><li>\u27a4 Megaloblastic anemia Elevated homocysteine and methylmalonic acid Neurological symptoms (e.g., tingling, peripheral neuropathy).</li><li>\u27a4 Megaloblastic anemia</li><li>\u27a4 Elevated homocysteine and methylmalonic acid</li><li>\u27a4 Neurological symptoms (e.g., tingling, peripheral neuropathy).</li><li>\u27a4 This combination distinguishes B12 deficiency from folate or other vitamin deficiencies.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "9e3fd504",
      "audio": ""
    }
  ]
}